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To the Children with Neural Tube Defects 
 
 
 
A meeting was held quite far from Earth! 
It's time again for another birth. 
Said the Angels to the LORD above, 
This Special Child will need much love. 
 
His progress may be very slow, 
Accomplishments he may not show. 
And he'll require extra care 
From the folks he meets down there. 
 
He may not run or laugh or play, 
His thoughts may seem quite far away, 
In many ways he won't adapt, 
And he'll be known as handicapped. 
 
So let's be careful where he's sent, 
We want his life to be content. 
Please LORD, find the parents who 
Will do a special job for you. 
 
They will not realize right away 
The leading role they're asked to play, 
But with this child sent from above 
Comes stronger faith and richer love. 
 
And soon they'll know the privilege given 
In caring for their gift from Heaven. 
Their precious charge, so meek and mild, 
Is HEAVEN'S VERY SPECIAL CHILD. 
 
 
Edna Massionilla 
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GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is not the strongest of the species that survives,  
nor the most intelligent,  
but the one most responsive to change. 
 Charles Darwin (1809) 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
	 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
 
Introduction to neural tube defects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“nervorum propagines tam varie per tumorem dispersas” 
Nicolaas Tulp (1641) 
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1.1 The history of neural tube defects 
The first signs for Neural Tube Defects (NTDs) in humans are ancient. 
Anthropologists discovered spines with stigmata typical for infants born with 
meningomyeloceles. As these children were born in time periods where medical 
treatment was scarce, we can only suppose that most of them did not survive. But 
the large number of anthropological figures sculpted in stone and terracotta, makes 
us assume that persons survived with an otherwise devastating condition. The 
figures are often seated in the typical forward posture of a paraplegic individual with 
a thoraco-lumbar kyphotic spine [1].  
 
Figure 1. Figures from Meso-American cultures. From left to right: a terracotta figure from Colima, Mexico 
(circa 200 A.D.), a terracotta figure from Chancay, Peru (circa 1000 A.D.) and a child from the Olmec culture 
(circa 1500 B.C., Meso-America). The forward position with paraplegic legs and thoracolumbar kyphosis is 
indicative of individuals with a neural tube defect. 
 
The earliest definition of spina bifida is from the Dutch clinician Peter van 
Forest (1522-1597) [2]. Some years later, the Dutch surgeon Nicolaas Tulp (1593-
1674), famous as the main figure in Rembrandt’s painting “The Anatomy Lesson of 
Dr. Tulp”, introduced the term “spina bifida” as “nervorum propagines tam varie per 
tumorem dispersas” (the prolongations of the nerves scattered in different directions 
through the tumor). Tulp was in charge of the anatomy and dissection lessons for the 
Surgeons’ Guild in Amsterdam and was a friend of Rembrandt van Rijn. In his most 
famous work Observationes Medicae (1641) he described a number of cases with an 
excellent drawing of the condition, possibly by Rembrandt. He presented how the 
myelomeningocele sac should be dissected. But as his patients died, he 
recommended caution in the approach of patients, as consequences could be 
terrible. For more than 200 years, surgeons around the world tried various surgical 
procedures, but concluded that spina bifida was untreatable. Infections and 
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septicemia were almost invariably fatal. After the introduction of aseptic surgical 
techniques in the 1870s, discussions on the best surgical treatment recommenced 
and survival rates improved. In 1952, Nulsen, Spitz and Holter developed the first 
modern ventriculoperitoneal shunts. With all their problems, shunts transformed the 
future for patients with spina bifida and hydrocephalus. The medical revolution 
continued and in 2003, the National Institutes of Health began the “Management of 
Myelomeningocele Study (MOMS)” to investigate health consequences of pre- 
versus postnatal repair. Interestingly, fetal repair reduced the need for shunting and 
improved motor outcomes at 30 months but had higher maternal and fetal risks.  
We owe gratitude to our previous colleagues ameliorating the management of 
this devastating disorder. As a result, many children now live independently.   
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1.2 Clinical presentation of neural tube defects 
NTDs result from failure of spontaneous neural tube closure between the 3rd 
and 4th week of development. The most common NTDs are anencephaly and 
myelomeningocele (commonly named spina bifida), which are often referred to as 
‘open’ NTDs because the neural tube does not close completely. Craniorachischisis, 
which results from failure over the entire body axis, is an additional relatively rare 
form of open NTD. The ‘closed’ or skin-covered NTDs include encephalocele, 
meningocele and occult spinal dysraphisms (commonly called spina bifida occulta). 
 
 
Figure 2. Subtypes of mammalian neural tube defects related to stages of neural tube closure. The main 
‘open’ NTDs that result from a defective primary neurulation are presented in red. The main ‘closed’ NTD that 
resuls from a defective secondary neurulation is presented in green (Figure adapted from [3]).  
 
In spina bifida, the spinal cord (myelon), the coverings (meninges) and 
vertebral arches develop abnormally. Both the spinal cord and brain are affected. 
Sensory and motor functions at and below the level of the spinal cord defect are 
impaired, leading to paralysis (Table 1), bowel and bladder dysfunction. Nearly all 
infants have the Arnold-Chiari II malformation, which includes hindbrain herniation, 
brain-stem abnormalities, low-lying venous sinuses and a small posterior fossa.  
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Table 1: Rehabilitation needs for patients with NTDs according to their functional motor level.  
 
Functional motor 
level 
Expected muscle 
function 
Functional ability Equipment use Orthotic use 
Thoracic Abdominals, 
paraspinals, 
quadratus 
lumborum 
Nonfunctional 
ambulation/standing, 
early use of 
wheelchair  
Standing frame, 
wheelchair, 
parapodium 
Trunk-hip-knee-
ankle-foot orthosis 
High lumbar  
L1-L3 
Hip flexion, hip 
adduction 
Limited household 
ambulation, early 
use of wheelchair  
Wheelchair, 
walker, forearm 
crutches 
Reciprocating gait 
orthosis, hip-knee-
ankle-foot orthosis 
Midlumbar  
L3-L4 
Knee extension Household, limited 
community 
ambulation, 
wheelchair 
Wheelchair, 
walker, forearm 
crutches 
Knee-ankle-foot 
orthosis 
Low lumbar  
L4-L5 
Hip abduction, 
knee flexion, 
ankle dorsiflexion, 
ankle inversion, 
toe extension 
Household, 
community 
ambulation, 
wheelchair for long 
distances 
Wheelchair, 
forearm crutches 
Ankle-foot 
orthosis 
Sacral  
S1-S2 
Hip extension, 
ankle plantar 
flexion, ankle 
eversion, toe 
flexion 
Community 
ambulation 
- Supramalleolar-
foot orthosis, foot 
orthotic 
The severity of the neurologic disability in the lower limbs is correlated with the level of the injury to the spinal 
cord.  
 
 
Traditionally, postnatal surgery is performed within 48 hours after birth to 
minimize the risk of meningitis. Recently, a number of centres implemented prenatal 
surgery, with promising results on motor outcome [4]. As the Arnold-Chiari 
malformation obstructs the outflow of cerebrospinal fluid and causes hydrocephalus, 
almost all infants with lumbosacral spina bifida need ventriculoperitoneal shunting, 
which is often associated with surgical revisions to address failure or infection. 
Regular evaluation of neurological function by a specialized multidisciplinary team is 
essential for neurologic and physical function. Deterioration can occur very insidious 
and can be caused by undiagnosed shunt malfunction, hydromyelia, tethered cord, 
as well as orthopedic and urologic complications.   
 
In addition to surgery and regular clinical and neurological follow-up, patients 
need careful monitoring of urologic and bowel functions. The abnormal neurological 
control of the bladder may result in urinary retention with overflow and vesico-
ureteral reflux, recurrent urinary tract infections and deterioration of the renal 
function. Therefore, urodynamic studies and ultrasonography are performed to 
detect urological complications and the introduction of clean intermittent 
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catheterization dramatically reduced renal failure. As the innervation of the bowel 
and anus also often are affected, patients require bowel management treatment 
such as oral laxatives, suppositories and enemas. 
 
Overall, management of patients with NTDs is very complex and requires a 
multidisciplinary team to provide the best medical care. Integrated effort from many 
disciplines, including a specialized nurse, a pediatric neurologist and neurosurgeon, 
an orthopedic surgeon, an urologist, a physical therapist, a psychologist and a social 
worker, results in the best opportunity for coordinated and high-quality care.   
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1.3 Epidemiology of neural tube defects 
NTDs affect an average of one in 1000 pregnancies. The incidence varies by 
geographical location and ethnicity, and is obviously under influence of population-
specific risk alleles, dietary habits and environmental exposures [5]. Twin 
concordance rates, which are higher for monozygotic (7.7%) than dizygotic (4.0%) 
twins, attest for a genetic contribution. In addition, a lot of environmental factors are 
known to influence neural tube closure. It has been clear for forty years that maternal 
folic acid supplementation prevents both NTD recurrence [6] and occurrence [7], 
which quickly led to the recommendation of supplementation of 400 µg folic acid to 
women who are planning to become pregnant. Despite this recommendation, many 
NTDs are not prevented. As only a minority of women takes supplements and a lot of 
pregnancies are unplanned, mandatory fortification of cereal grains was introduced 
in the United States in 1998. The incidence in the US decreased from 2 per 1000 in 
the 1960s to 1 per 2000 nowadays. Mandatory fortification of folic acid resulted in a 
lower prevalence of NTDs than voluntary folic acid supplementation [8]. In Europe, 
mandatory folic acid fortification does not yet exist. A recent population based study 
in Europe showed a total prevalence of NTD of 9.1 per 10 000 births, which did not 
decrease after two decades of recommendations for folic acid supplementation [6,9]. 
Mandatory folic acid fortification should be considered more effective means for NTD 
prevention in Europe. Each year approximately 5000 fetuses are affected with a NTD 
in Europe and after prenatal diagnosis, termination of pregnancy is the most 
common outcome for fetuses with NTDs. Below are prevalence rates listed for 
Belgium, the Netherlands and all European member countries of Eurocat. 
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Table 2: Prevalence of neural tube defects and subtypes in Belgium, the Netherlands and all full member 
countries of Eurocat. 
 
Registry  Anomaly  Total N Prevalence LB FD TOPFA 
Belgium  Neural Tube Defects 648 8.74 31.0% 7.9% 61.1% 
 Anencephaly 245 3.31 4.9% 7.8% 87.3% 
 Encephalocele 53 0.72 34.0% 7.5% 58.5% 
 Spina Bifida 350 4.72 48.9% 8.0% 43.1% 
The Netherlands Neural Tube Defects 483 9.10 53.2% 14.3% 32.5% 
 Anencephaly 165 3.11 18.8% 27.3% 53.9% 
 Encephalocele 35 0.66 57.1% 20.0% 22.9% 
 Spina Bifida 283 5.33 72.8% 6.0% 21.2% 
Total Europe Neural Tube Defects 16973 9.67 32.2% 7.3% 60.5% 
 Anencephaly 6588 3.75 11.4% 12.0% 76.6% 
 Encephalocele 1813 1.03 37.5% 6.3% 56.3% 
 Spina Bifida 8572 4.88 47.1% 3.9% 49.0% 
Prevalence is stated per 10 000 births. LB: life births; FD: fetal deaths/still births from 20 weeks gestation; 
TOPFA: termination of pregnancy for fetal anomaly following prenatal diagnosis. Data are extracted from Eurocat 
from 1980 - 2012. Genetic conditions are excluded from the data.  
 
Every public intervention is characterized by concerns on benefits and risks. 
Folic acid has been used for more than forty years, and throughout its use, some old 
and new concerns exist [10]. The major concern is the possibility that a high dose of 
folic acid masks anemia caused vitamin B12 deficiency, but to date there is little 
evidence. Secondly, many studies investigated a link between folate, DNA 
methylation and cancer risk. It has been suggested that folic acid might prevent 
some cancers and might promote others, but currently there is no evidence that 
demonstrates a causal link between fortification and cancer.  
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1.4 Embryology of neural tube defects 
To gain insight into the embryological basis of NTDs, it is essential to understand the 
morphogenetic processes and molecular mechanisms that underlie neural tube 
closure.  
 
The human nervous system originates from the primitive ectoderm that also 
develops into epidermis [11]. The ectoderm, endoderm and mesoderm form the 
three primary germ layers that are developed by the 3rd week. The endoderm, 
particularly the notochordal plate and the intra-embryonic mesoderm, induces the 
overlying ectoderm to develop the neural plate in the 3rd week of development. The 
neural plate is converted into a tube by a two-stage process: primary and secondary 
neurulation. Primary neurulation initiates discontinuously at several discrete levels of 
the body axis (Figure 2). This process has been most intensively investigated in 
mice. Murine neural tube closure initiates at the hindbrain/cervical boundary (closure 
1), and spreads caudally and rostrally from this site. Separate closure initiation sites 
occur at the midbrain-forebrain (closure 2) and at the rostral limit of the forebrain 
(closure 3). Neural tube closure in humans is similar to mice, but closure 2 may be 
absent [11]. Interestingly, mouse embryos that lack closure 2 (described in the 
SELH/Bc inbred strain) achieve total cranial closure in around 80% of cases [12], 
indicating that closure 2 is not obligatory for brain formation. The process of primary 
neurulation generates the entire neural tube, with closure of the anterior neuropore 
on day 24 and the posterior neuropore on day 26. The posterior neuropore fuses 
with the process of secondary neurulation, a process in which the stem cells in the 
tail bud differentiate to form cells of neural fate. As the process of secondary 
neurulation does not require bending of the neural plate, defects are never open but 
involve tethering of the neural tube to surrounding tissues. On the other hand, failure 
of primary closure leads to exposure of the neuroepithelium to the environment, with 
degeneration of neural tissue and neuronal deficit. My study included patients with 
abnormalities in primary neurulation of the spinal cord, failures that result in ‘open’ 
spina bifida (myelomeningocele).  
 
 
 
	 13	
The following morphogenetic events are essential for successive neurulation:  
1) initiation of neural tube closure; 2) neural fold elevation and apposition; and 3) 
adhesion and fusion of the neural folds. As failure of these mechanisms may result in 
NTDs, insights in these processes are discussed below.  
 
1. Initiation of neural tube closure 
Immediately preceding neural tube closure, the initially elliptical neural plate 
becomes longer and narrower to form a keyhole-shaped structure with broad cranial 
and narrow spinal regions. Convergent extension is the driving force for this process. 
Cells move towards the midline and sequential intercalation of cells narrows and 
lengthens the neural plate along the anterior-posterior body-axis. The process of 
convergent extension depends on the Planar Cell Polarity Pathway (PCP) or non-
canonical Wnt signaling. Disruption of this pathway results in a wide neural plate, 
which makes neural fold fusion impossible. This results in craniorachischisis, the 
most severe NTD, with an open neural tube from the brain to the spinal cord. Mouse 
embryos with homozygous mutations in genes implicated in the PCP pathway 
(Dishevelled, Vangl2, Scribble, or Celsr1) exhibit failure of closure 1 (Figure 2), 
which results in craniorachischis. Interestingly, Vangl2, results in different 
phenotypes depending of its combination with other mutant genes: Vangl2 with Ptk7 
and Grhl3 results in open spina, whereas exencephaly occurs when Vangl2 is 
combined with a loss of the Cthrc1 gene [13]. These findings illustrate that a 
combination of related gene defects can produce different NTD phenotypes. In 
humans however, mutations of PCP genes are only associated with a few cases of 
NTDs [14]. Notably, also in humans, mutations in PCP genes are associated with 
different NTD phenotypes such as cranial, spinal and both open and closed NTD.  
 
2. Neural fold elevation and apposition 
Bending of the neuroepithelium of the spinal cord occurs at two sites: the median 
hinge point (MHP) and the paired dorsolateral hinge points (DLHPs). The MHP 
overlies the notochord and Sonic Hedgehog (Shh) has been implicated as the signal 
from the notochord that induces the floor plate of the neural tube. The paired DLHPs 
create longitudinal grooves that bring the neural fold tips face each other in the 
dorsal midline. Experiments with mice showed that Shh inhibits DLHP formation at 
the upper spinal cord, the strength of Shh signaling lessens down the neuraxis, 
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whereby DLHP formation occurs at lower spinal levels. This signal creates different 
combinations of bending points as closure progresses down the neural axis. At the 
upper levels bending occurs at the MHP, at intermediate spinal levels at both MHP 
and DLHP and at the lowest spinal levels solely at DLHPs. As Shh overexpression 
inhibits dorsolateral bending, this leads to NTDs [11]. Some mouse mutants such as 
Gli3, Ptc1, opb and Zic2 inhibit negative regulators of Shh signaling which results in 
severe NTDs [15].  
 
3. Adhesion and fusion of the neural folds 
Adhesion and fusion of apposed neural folds is essential for neural tube closure. The 
mechanisms of adhesion and fusion are poorly understood. It has been suggested 
that cellular protrusions consisting of extracellular carbohydrate material at the tips of 
the neural folds may be related to the adhesive properties of the cells. The 
protrusions seem to interdigitate when the folds appose, what provides an initial 
contact that facilitates subsequent cell adhesion [15]. In support of this idea, Efna5 
and Epha7 mice mutants with mutations in the ephrin family of cell-surface ligands, 
exhibit exencephaly due to a lack of fusion in apposed folds [15,16].  
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1.5 Genetic and environmental factors contribute to neural tube defects 
Both genetic and environmental factors are involved in the etiology of NTDs. The 
high recurrence risk for siblings (2-5%) indicates a strong genetic component, but the 
majority of NTDs are sporadic, with relatively few reports of multi-generational 
families, suggesting a multifactorial polygenic pattern of inheritance. Studies 
indicated numerous candidate genes and environmental factors, and introduced 
further complexity by potential gene-gene and gene-environment interactions. 
Although it is well established that there is a genetic component underlying NTDs, 
the genetic players still remain largely unknown. In order to unravel the underlying 
etiology, candidate genes for NTDs are mainly selected based on their biological 
plausibility from syndromes that include a NTD, but mostly from animal models with 
NTDs. In addition, environmental risk or preventive factors for NTDs point at genes 
that might influence neurulation such as genes involved in the folate metabolism or 
glucose homeostasis.  
 
Lessons from genetic syndromes that include a NTD 
The study of syndromes with NTDs and their associated anomalies contributes to 
our understanding of the potential pathogenic mechanisms underlying NTDs. NTDs 
are associated with genetic syndromes that include Meckel-Gruber syndrome, 
Joubert syndrome, Currarino syndrome, and Mohr syndrome [17]. They are also 
caused by various chromosomal abnormalities. Deletions and duplications of smaller 
chromosome segments and single-gene conditions are also important to identify 
human genes that contribute to NTDs. The proportion of patients with NTDs 
classified as isolated, multiple birth defects or syndromes varies widely among 
different studies. It has been estimated that 3-10% of NTDs are associated with 
chromosomal abnormalities [18-20]; this does not include single-gene conditions. 
Specific associated defects that occur with greatest frequency are facial clefting, 
cardiac defects, anotia/microtia, limb defects, anophtalmia/microphtalmia, abdominal 
wall defects, and renal anomalies. Less common associated defects include 
holoprosencephaly, amniotic bands and polydactyly. As midline anomalies are often 
associated defects, two hypotheses tried to explain the co-occurrence of structural 
anomalies with NTDs: the schisis associated and the midline developmental field 
concept. The schisis associated concept supposes that associated defects may be 
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considered defects of closure such as cleft lip, cleft palate, cardiac defects, 
omphalocele, and diaphragmatic hernia. The midline developmental field concept 
suggests a vulnerability of midline structures. However, none of both theories are 
supported by strong evidence.   
 
An example of how syndromal NTDs might help to unravel NTD etiology is Meckel-
Gruber syndrome (MGS). MGS is considered to be the most frequent syndromic 
NTD. It includes polycystic kidneys, postaxial polydactyly and central nervous 
system defects, usually microcephaly and encephalocele. The diseased genes are 
involved in the correct function of primary cilia. Primary cilia are hair-like extensions 
from the cell surface that have a fundamental role in extracellular signal transduction, 
cell fate control, tissue patterning and morphogenesis. Recently, it has become clear 
that cilia are involved in the Wnt and Shh signaling pathways. In MGS, disruption of 
these pathways results in hyperactivation of the PCP pathway and defects in 
convergent extension. In this way, research of MGS, provided an incredible insight 
into neural tube patterning during early embryogenesis [21].  
 
Lessons from animal models with NTDs 
Only higher vertebrates have a process of neurulation in which neural folding and 
fusion creates a closed neural tube. Therefore, embryos with NTDs are only seen in 
higher animals, including amphibians, birds, and mammals. The mouse is the most 
extensively studied mammalian experimental model. Multiple sources give rise to the 
mutant mouse strains: spontaneous, mutagen-induced and gene trap-induced 
mutations disrupted the function of an (un)known gene, thereby inducing NTDs. 
Various mouse mutants develop NTDs at different levels of the body-axis, covering 
the conditions observed in humans, and therefore provide a suitable model for 
human NTDs.   
 
Studies in mouse give evidence that more than 250 genes regulate successful 
neural tube closure in mice. This large number of mouse mutants demonstrates the 
genetic complexity that must underlie early development of the central nervous 
system (CNS). The genes are involved in diverse cellular functions (such as control 
of cell proliferation, cytoskeletal and transcriptional regulation) and multiple 
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molecular pathways. Hereby, we discuss the most valuable key points and lessons 
from mouse models of NTDs.  
 
 
 
 
 
 
 
 
 
 
 
1. Embryonic lethality and coexisting pathology 
Before concluding that a given mouse mutant exhibits NTDs, care must be taken to 
ensure that embryonic lethality and/or degeneration processes are not likely to be 
responsible for preventing normal development beyond neurulation. As the CNS is 
not necessary for in utero survival, embryonic/fetal lethality in a mouse mutant with 
NTDs must indicate a coexisting pathology. A particular problem of interpretation 
rises when embryos die in the period in which the neural tube closes around 
gestational day (GD) 8-10. Also in mouse embryos that die on GD10-11, the neural 
tube is open past the time that it should be closed, but the extreme body 
malformations suggest that the NTD is secondary to other developmental defects. 
Therefore, the discussion focuses mainly on the mutants that survive past GD12 
[16,22].  
2. Is there a link between genetic causation and NTD type? 
The majority of the mouse mutants present with exencephaly (80%), although a 
number also exhibit spinal defects. In humans, cranial and caudal NTDs have a 
comparable incidence. The intriguingly high proportion of mice with exencephaly 
compared to humans might be explained by the fact that the human embryo has a 
proportionally smaller brain than the mouse embryo at the corresponding 
neurulation-stage. The smaller brain poses less challenge for cranial neural tube 
closure, and might have made closure 2 unnecessary [23]. This however might also 
result in significant differences between mouse and human neural tube closure and 
many of the mouse candidate genes are not involved in NTDs of humans. 
1. Embryonic lethality and coexisting pathology 
2. Is there a link between gene and NTD type? 
3. Gene-gene interactions – a multifactorial concept? 
4. Gene-environment interactions – prevention possible? 
5. Role of folate pathway gene mutations in NTDs in mice? 
6. Most commonly affected biochemical pathways or cell functions?  
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3. Gene-gene interaction – a multifactorial concept? 
The mouse genes that produce NTDs mostly require homozygous effects. But for 
example PCP gene mutants are double heterozygotes that act additively in genetic 
combinatorial mechanisms [16,22]. In addition, it might be that homozygosity 
produces craniorachischis, whereas compound heterozygotes can produce both 
craniorachischisis and other NTD phenotypes. Another interesting finding comes 
from homozygous null mutants that die before GD10 or on GD10-12 with a highly 
penetrant syndromic NTD. Interestingly, heterozygotes or mutants with partial gene 
function at these genes have only a NTD, viable and non-syndromic. In this way also 
genes from mouse mutants that die before GD12 might be candidate genes for 
human NTDs [16]. In humans, the genetic risk for cranial or caudal NTDs is thought 
to be oligogenic [24]. The SELH/Bc mouse strain nicely illustrates this oligogenic, 
multifactorial inheritance pattern for NTDs. Four loci act additively: Exen1, Exen2, 
Exen3 and Exen4. In this model, the genes act approximately equal, additive and 
interchangeable. The curly tail model is an example of a more hierarchical model in 
which genetic variants at three “modifier” genes increase NTD risk in the mutant 
mice. In this situation, the modifier genes do not act on it’s own.  
 
All these findings support the multifactorial occurrence model for human NTDs, with 
a relatively sporadic occurrence and low recurrence risk, as the causative genetic 
variants segregate apart in subsequent generations [24]. The combination of two or 
more different genetic variants and environmental factors in a single individual would 
provide the interaction necessary to disturb neurulation.  
4. Gene-environment interactions – prevention possible? 
On the basis of findings that maternal folic acid supplementation prevented up to 
70% of human NTDs, the folate response has been investigated in mouse mutants 
[25]. Up to date, only a dozen mutant strains have been tested. Half of the tested 
strains responded well to folic acid and half did not. Dietary folic acid 
supplementation produced a wide range of responses, with prevention ranging 
between 35% and 85%, but also with an apparent exacerbation in some cases. 
Prevention was in no strain 100%. A reduction was seen for both cranial and caudal 
NTDs. Importantly, all the mutants had additional major developmental anomalies, 
insensitive for folic acid treatment. The variation in response might result from a wide 
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variety in dosing of folic acid, with sometimes a 100-fold higher dose used in mutants 
compared to humans [25]. Notably, the mouse mutants that are prevented by folic 
acid have no obvious connection to folate metabolism.  
In the light of the 30% human NTDs that do not respond at maternal folic acid 
supplementation, unresponsive mouse mutants and the research for other maternal 
supplements are of special interest. Three mouse mutants that are non-responders 
to folic acid, have a strong response to other maternal nutrients. In the Axd mutant, 
spina bifida was reduced by 50% by supplementation of methionine; in the ct mutant 
spina bifida reduced by 70-85% after inositol; and exencephaly in the SELH/Bc strain 
reduced by 55-85% when the mother was fed Purina 5001 instead of Purina 5015 
[25]. Surprisingly, given that human NTDs are mostly non-syndromal (85%) and 
responsive to folic acid, all the folic acid-responsive mouse mutants are syndromic 
whereas unresponsive mutants are mainly nonsyndromic.  
5. Role of folate pathway gene mutations in NTDs in mice? 
Mutations in folate-pathway genes do not cause a phenotype like that of the majority 
of human NTDs. Null mutants have been described for 10 genes involved in the folic 
acid metabolism. Only for the folate-receptor mutant Folr1 folic acid deficiency 
contributes to neurulation [25]. Untreated Folr1-mutants die by GD10, but survive 
after folic acid supplementation to GD18 and 5-30% have exencephaly. Null mutants 
for 6 genes (Cbs, Folr2, Mthfd1, Mthfd2, Mthfr, Shmt1) have normal neural tube 
closure. These findings do not exclude a possible role in combination with other 
genes. Three other null mutants (Mtr, Mtrr and Rfc1) die before GD9. For these 
genes, it might be interesting to investigate NTD phenotype in hypomorphs.  
 
In conclusion, mouse mutants suggest that folic acid supplementation does not 
simply compensate for a genetic lesion in the folate pathway or for dietary folic acid 
deficiency. A large number of genes can respond to folic acid. Mouse models 
support the importance of gene-environment interactions, whereby a genetic variant 
and suboptimal folate supply interact for an increased liability. 
6. Most commonly affected biochemical pathways or cell functions?  
The numerous mouse genes are involved in diverse biological classes and molecular 
pathways. As described previously, mouse mutants involved in apoptosis and cell-
cycle mutants give rise to cranial NTDs. Actin function is also essential for cranial 
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neural tube closure in mice. Mutations in PCP genes are linked to craniorachischis. 
Mutants are involved in both inter- as intracellular signaling, in a variety of pathways. 
Some are involved in gene transcription. Intriguingly, new affected biochemical 
pathways and cellular functions are still being identified. For example, mutations in 
protease-activated receptor cascade, inositol metabolism and defects in primary cilia 
are linked to NTDs. Also, several groups of genes are involved in epigenetic 
processes. There are 11 mouse mutants: Dnmt3b, Dnmt3l responsible for de novo 
methylation; Crebbp, Ep300, Cited2, Tcfap2a, Hdac4 and Sirt1 are involved in 
histone deacetylation and chromatin silencing; Cecr2, Kat2a, Smarca4 and Smarcc1 
also regulate chromatin remodeling.  
 
In the light of all these findings, it is unclear whether mouse genes offer good 
candidate genes for human NTDs. The majority of mouse NTDs are syndromic and 
highly penetrant. Human NTDs on the other hand are nonsyndromic and 
multifactorial. Attention focused on the human orthologues of the mouse mutants, 
with very few significant findings to date [26,27]. Therefore, if mouse NTD genes 
have a role in human NTDs, the mutations in humans might be partial or regulatory.  
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Lessons from studies that link NTDs with environmental factors 
Many non-genetic factors including hyperthermia, drugs, malnutrition, chemicals, 
maternal obesity and diabetes are associated with NTDs in humans (Table 3). 
 
Table 3: Non-genetic factors linked to the causation of NTDs in human pregnancy.  
 
Category Teratogenic agent Proposed teratogenic mechanism 
Folate antagonists Carbamazepine 
Fumonisin 
Trimethoprim 
Inhibition of cellular folate uptake 
Inhibition of cellular folate uptake 
Disturbance of folate metabolism 
Glycemic dysregulation Maternal diabetes 
mellitus 
Maternal gestational 
diabetes 
Maternal obesity 
Increased cell death in neuroepithelium 
 
Increased cell death in neuroepithelium 
 
Unknown 
Histone deacetylase inhibitors Valproic acid Disruption of key signaling pathways in 
neurulation 
Micronutrient deficiencies Folate 
Inositol 
 
Vitamin B12 
Zinc 
Disturbance of folate metabolism 
Disturbance of phosphorylation events 
downstream of protein kinase C 
Disturbance of folate metabolism 
Unknown 
Thermal dysregulation 
(hyperthermia in week 3-4 of 
pregnancy) 
Maternal fever 
Hot tubs 
Sauna use 
Unknown 
 
In addition to environmental factors, many sociodemographic factors are associated 
with NTD risk. For example a lower socioeconomic status and education, higher 
maternal and paternal age, parental occupation such as cooks, cleaners, farm 
workers and gardeners are linked to a higher NTD risk [28].  
 
As inositol supplementation reduced NTD incidence in the ct mouse mutant, recently 
the Prevention of Neural Tube Defects by Inositol (PONTI) study investigated inositol 
usage in human pregnancy for NTD prevention [29]. There were no adverse effects 
of inositol supplementation during pregnancy. This pilot study encourages further 
evaluating of inositol supplementation for primary prevention of NTDs [29].  
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1.6 Epigenetics: the missing links for neural tube defects? 
Neural tube closure is influenced by a complex multifactorial etiology including 
both genetic and environmental factors. Although more than 250 genes are known to 
cause NTDs in mice and many candidate genes are investigated in patient cohorts, 
the molecular basis underlying most human NTDs is still unknown [30]. Up to 70% of 
NTDs can be prevented by an optimal maternal red blood cell folate concentration 
[31]. 
 
Several lines of evidence support the link between NTDs and epigenetics; 
especially with an impaired methylation cycle [32]. The basis of the epigenetic 
control layer is complex; DNA methylation, histone modifications and non-coding 
RNA are the main investigated mechanisms that do alter gene expression 
independently of nucleotide sequence [33]. The methylation hypothesis suggests 
that folate prevents NTDs by stimulating cellular methylation reactions. Folate is 
central to the one-carbon metabolism that produces pyrimidines and purines for DNA 
synthesis and for the generation of the methyldonor S-adenosyl-methionine. 
Disturbances in the one-carbon metabolism, like maternal hyperhomocysteinemia 
and the homocysteine remethylation MTHFR 677C>T variant are known risk factors 
for NTDs [31]. Folate deficiency may increase NTD risk by decreasing DNA 
methylation, but to date, human studies vary widely in study design in terms of 
analyzing different clinical subtypes of NTDs, using different methylation 
quantification assays and using DNA isolated from diverse types of tissues. Some 
studies have focused mainly on global DNA methylation differences while others 
have quantified specific methylation differences for imprinted genes, transposable 
elements and DNA repair enzymes. Findings of global DNA hypomethylation and 
LINE-1 hypomethylation suggest that epigenetic alterations may disrupt neural tube 
closure.  
 
Epigenetic mechanisms serve as key regulatory elements during vertebrate 
embryogenesis. DNA methyltransferases (DNMT) play a central role in mammalian 
development. They are inherent to DNA-reprogramming, the genome-wide erasure 
of epigenetic footprints with resetting of the methylation signature that is essential for 
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vertebrate embryogenesis. This process takes place in the same time window as 
neural tube folding [32].  
 
Multiple model systems support the hypothesis that abnormal methylation 
contributes to NTDs. Mice deficient for DNMT3B or treated with methyl cycle 
inhibitors have cranial NTDs [34,35], which underscores the necessity of proper 
remethylation for neural tube closure. In addition, mutations in several epigenetic 
regulators in mice have been shown to result in NTDs [16,22]. Histone deacetylation 
inhibitors (e.g. valproate) influence neural crest development and neural tube closure 
in humans, zebrafish and chick embryos [36-39]. All these findings suggest an 
underlying disturbed methylation cycle in NTDs.  
 
It is clear that epigenetic regulators play key roles in neural tube closure [32]. 
However, it is still unclear which DNA regions are more sensitive to methylation 
changes during embryogenesis and can lead to NTDs. Chapter 2 provides a 
literature review on the relation between folate, DNA methylation changes and NTDs 
[40].  
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1.7 Zebrafish as a model for neural tube defects 
Similarities between zebrafish and human embryonic neurulation provide 
evidence that the zebrafish could be a useful model system for analyzing neural tube 
development [41]. Zebrafish form a neural tube that does not require bending and 
fusion of the neural plate, but the genetic programs of notochord formation and 
development are shared. Advantages like external fertilization, large clutch size, 
rapid development and optical transparency, render zebrafish as a good model to 
characterize novel candidate genes. The neural plate is present by 6-7 hours post 
fertilization (hpf) and the first neurons form by 16 hpf.  
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Figure 3: Comparison of mammalian and zebrafish neurulation. Mammalian neurulation involves both 
primary and secondary neurulation. In primary neurulation, epithelial cells columnarize to form the neural plate. 
The neural plate rolls and folds the lateral edges into a dorsal position. In secondary neurulation the 
mesenchymal cells (brown) form a rod, which undergoes epithelial transition to form the neural tube. Zebrafish 
neurulation has many similarities to mammalian primary neurulation. Both begin with an epithelial sheet that 
columnarizes to form the neural plate. In the zebrafish, the lateral edges of the neural plate thicken and undergo 
subsequently a sinking movement forming the neural keel, which is a solid mass of cells. The two sides of 
mammalian neural folds fuse to close the tube, while in zebrafish the two sides of the neural keel come together 
and form the neural rod, which lumen opens subsequently. Adapted from [41] with permission. 
 
For example, in humans, mutations in the PCP gene VANGL1 were identified 
in few patients with NTDs [42] and were next characterized as loss of function 
variants in Vangl2 depleted zebrafish [43]. In addition, other members of the PCP 
pathway were analyzed in zebrafish and were shown to cause severe gastrulation 
defects or shortening of the trunk as well as mediolateral expansion of somites [44]. 
Valproic acid, an anti-epileptic drug, is an important risk factor for spina bifida in 
humans and the drug also induces developmental defects in neurulation in zebrafish 
and Xenopus [36]. Valproic acid is an inhibitor of histone deacetylases (HDACs). 
HDAC inhibitors elevate histone acetylation, which is associated with “open” 
chromatin structure and active gene transcription. On the other hand, histone 
deacetylation is associated with “closed” and transcriptionally silent chromatin. 
Especially HDAC inhibitors increase the transcription of certain genes involved in 
cessation of cell proliferation and differentiation of tissues or apoptosis.  
Based on all these findings, zebrafish provide a model system for the study of 
potential mutations and drugs associated with human NTDs.  
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Folate, DNA methylation and neural tube defects 
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Abstract  
Neural tube defects (NTDs), affecting 1-2 per 1000 pregnancies, are severe 
congenital malformations that arise from the failure of neurulation during early 
embryonic development. The methylation hypothesis suggests that folate prevents 
NTDs by stimulating cellular methylation reactions. Folate is central to the one-
carbon metabolism that produces pyrimidines and purines for DNA synthesis and for 
the generation of the methyldonor S-adenosyl-methionine. This review focuses on 
the relation between the folate-mediated one-carbon metabolism, DNA methylation 
and NTDs. Studies will be discussed that investigated global or locus-specific DNA 
methylation differences in patients with NTDs. Folate deficiency may increase NTD 
risk by decreasing DNA methylation, but to date, human studies vary widely in study 
design in terms of analyzing different clinical subtypes of NTDs, using different 
methylation quantification assays and using DNA isolated from diverse types of 
tissues. Some studies have focused mainly on global DNA methylation differences 
while others have quantified specific methylation differences for imprinted genes, 
transposable elements and DNA repair enzymes. Findings of global DNA 
hypomethylation and LINE-1 hypomethylation suggest that epigenetic alterations 
may disrupt neural tube closure. However, current research does not support a linear 
relation between red blood cell folate concentration and DNA methylation. Further 
studies are required to better understand the interaction between folate, DNA 
methylation changes and NTDs.  
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2.1 Nutri-epigenomics: epigenetic changes induced via diets 
Epigenetics is the study of mitotically or meiotically heritable changes in gene 
expression that do not result from changes in the underlying DNA sequence. DNA 
methylation changes, histone modifications and alteration in expression patterns of 
non-coding RNAs are the main investigated mechanisms that modulate chromatin 
structure and contribute to the regulation of the major molecular processes in the cell 
nucleus, including transcription, replication, repair and RNA processing. Epigenetic 
modifications are dynamic throughout life and can be heavily influenced by external 
factors such as food nutrients, drugs, alcohol and many more. DNA methylation 
patterns strongly control gene expression. As they are dynamic during cellular 
differentiation and can be changed in disease, they offer a particular potential as a 
biomarker. Moreover, as they can be inherited mitotically in somatic cells, they 
provide the link between changes induced by the environment and alterations in 
gene expression that eventually might lead to a disease phenotype [45]. This review 
will only focus on epigenetic modifications induced by DNA methylation that is 
proven to be essential for normal development, tissue differentiation and tissue 
homeostasis. 
 
DNA methylation is a covalent modification of genomic DNA, which adds a 
methyl group to the base cytosine (Figure 1). In eukaryotes it mostly occurs at 
cytosines next to guanine, termed CpG dinucleotides. The symmetry of CpG 
dinucleotides provides a 
mechanism for transmitting 
epigenetic information through 
DNA replication and cell 
division. Once established by 
the de novo DNA 
methyltransferases DNMT3A 
and DNMT3B, the 
maintenance methyltransferase DNMT1 enables propagation through cell division 
[46]. Epigenetic memory implies stability of the modified base. The stability and 
instructive potential of DNA methylation varies dependent on sequence context and 
CpG density [46]. Almost all mammalian CpG dinucleotides (99%), including those 
Figure 1. DNA methylation at C5 of the cytosine pyrimidine 
ring, converting them to 5-methylcytosine. SAM: S-adenosyl-
methionine, SAH: S-adenosyl-homocysteine. 
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located in gene bodies, repetitive elements and the majority of inactive or repressed 
regulatory elements, are fully methylated [47]. Methylation is generally associated 
with transcriptional silencing [48]. Conversely, unmethylated CpGs reside either in 
CpG rich regions, termed CpG islands (CGI), or are located at active promoters, 
enhancers and boundary elements. CGIs overlap with about 60% of human 
promoters that are typically unmethylated. Methylation of CGIs is generally 
associated with gene repression. Loss of methylation occurs both passively as 
actively. Active demethylation occurs in the germline and early embryo and also 
during somatic differentiation. The ten-eleven-translocation (TET) proteins are 
implicated in active DNA de-methylation, by their ability to oxidize 5-methylcytosine 
to 5-hydroxymethylcytosine and further to formyl- and carboxylmethylcytosine. These 
products can be removed by DNA repair processes or via replication [46]. The 
identification and quantification of DNA methylation turnover is critical for interpreting 
DNA methylation marks but also for concepts of epigenetic memory, as the stability 
of the modified base could be impaired by pathways of active demethylation. 
Epigenetic marks appear to be controlled by the genetic sequence [49]. Epigenome-
wide methylation studies revealed that both DNA methylation and gene expression 
mainly follow genetic sequence, providing evidence for shared genetic and 
epigenetic mechanisms. Epigenetic modifications are informative indicators of 
underlying regulatory activity. However, the establishment, turnover and recognition 
of DNA methylation by transcription factors and how defects in these mechanisms 
contribute to disease, still remain largely unknown. 
 
Nutri-epigenomics is an emerging discipline that examines the role of dietary 
influences on gene expression. Nutrition can influence DNA methylation because the 
mammalian one-carbon metabolism is highly dependent on dietary methyl donors 
and cofactors. Diet-DNA methylation interactions have been associated with the 
development of cancer and diverse complex diseases. The ‘developmental origins of 
health and disease’ hypothesis suggests that increased susceptibility to disease is 
partly shaped during fetal programming [50]. This developmental time period, 
including gametogenesis and early embryogenesis, is especially prone to 
environmental influences as genomic DNA from the pre-implantation embryo 
undergoes extensive demethylation, with lineage-specific remethylation after 
implantation. Methylation patterns need to be maintained over many rounds of rapid 
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cellular proliferation during fetal and early postnatal development. S-
adenosylmethionine (SAM) supplies methyl groups used for DNA methylation. 
Therefore, early malnutrition could affect these embryonic methylation patterns 
resulting in gene expression changes or genome instability, thereby contributing to 
disease susceptibility, even if these changes in methylation only occur in a subset of 
cells of a single tissue. The viable yellow allele of murine Agouti (Avy) has been one 
of the most thoroughly characterized mice models for such diet-induced DNA 
methylation interactions. This model perfectly illustrates the influence of a mother’s 
diet during pregnancy on the adult phenotype of her offspring, directly linked to 
changes in DNA-methylation [51].  
 
2.2 Folate influences DNA methylation via the one-carbon metabolism 
Folate is a water soluble B-vitamin (vitamin B9) that is essential for DNA and 
RNA synthesis and different methylation reactions. Natural diet contains folate 
monoglutamates and polyglutamates that need to be hydrolyzed to monoglutamates 
for intestinal absorption. The monoglutamate form, 5-methyltetrahydrofolate (5-
methyl THF), is the predominant folate in blood circulation. 5-methyl THF is taken up 
into cells by tissue-specific folate receptors and is sequestered after 
polyglutamylation. Polyglutamated folates do not cross cellular membranes and are 
thus retained within the cell [31,52,53]. Inside the cell, folate functions both as an 
acceptor and a donor of one-carbon units in several critical pathways. These 
pathways include synthesis or catabolism of amino acids (serine, glycine, histidine, 
and methionine) and synthesis of nucleotides (thymidine and purines). Folates are 
also critical in the methylation cycle through their role in methionine synthesis, the 
precursor of SAM. This is the major methyl donor for many important methylation 
reactions including DNA methylation and synthesis of creatine, phospholipids and 
neurotransmitters. The folate and homocysteine pathways are shown in Figure 2 
(chemical structures are illustrated in Figure 3). The interaction between these 
biochemical pathways eventually results in the methylation of DNA, proteins and 
lipids for which folate is an essential intermediate compound.  
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2.3 Relation between folate, DNA methylation and neural tube defects 
Neural tube defects (NTDs), affecting 1-2 per 1000 pregnancies, are severe 
congenital malformations that arise from the failure of neurulation during early 
embryonic development. Neural tube closure takes place between the 3rd and 4th 
week of in utero development and is influenced by a complex multifactorial etiology 
including both genetic and environmental factors [28]. Multiple environmental factors 
such as parental occupation, maternal obesity and maternal nutrition have been 
related to NTDs. The maternal folate status was associated with NTD risk as early as 
40 years ago [54]. Two studies in the early 1990s provided unequivocal evidence 
that maternal supplementation with folic acid, the more stable synthetic form of 
folate, during pregnancy prevented both NTD recurrence [6] and occurrence [7], 
which led to the recommendation of supplementation of 400 µg folic acid in women 
of child-bearing age. Up to 70% of NTDs can be prevented by an optimal maternal 
red blood cell folate concentration. However, the exact mechanism how folate can 
prevent NTDs is not understood [31]. More and more studies suggest that not only 
folate but also its associated methylation metabolism are involved in the etiology of 
NTDs. Indeed, a low red blood cell folate concentration results in reduced 
remethylation of homocysteine to methionine with subsequent lower levels of SAM 
and hyperhomocysteinemia. Studies have shown that this type of metabolic profile 
with decreased methylation capacity is reflected in the maternal blood of NTD-
affected pregnancies. The only well-characterized genetic risk factor for human 
NTDs is the 677C>T (rs1801133) change in the 5,10-methylene tetrahydrofolate 
reductase gene (MTHFR). The MTHFR 677C>T variant leads to 
hyperhomocysteinemia and global DNA hypomethylation, which is more pronounced 
under low folate conditions [31,55-58]. However, the exact mechanism by which the 
MTHFR variant would affect neural tube closure is not known, although several 
hypotheses are possible [59]: 1) increased homocysteine may be toxic for the 
embryo, 2) homocysteine accumulation that leads to increased oxidative stress or 
endoplasmic reticulum stress, 3) altered distribution of folates that interfere with DNA 
synthesis and 4) decreased availability of SAM that disrupts methylation reactions.  
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An altered folate metabolism affects both DNA biosynthesis and DNA methylation. 
Therefore, the MTHFR variant has also been investigated in several cancers [60] 
though results are complex and inconsistent. Interestingly, a hypomorphic mutation 
of the murine methionine synthase reductase (Mtrr) gene results in intrauterine 
growth restriction, developmental delay and congenital malformations, including 
NTDs [61]. Moreover, the Mtrr genotype of either maternal grandparent determined 
the developmental potential of their wild-type progeny via an altered DNA 
methylation pattern, intrauterine growth defects and congenital malformations. 
Several other lines of evidence suggest that maternal relatives compared to paternal 
relatives are more likely to have one or more genotypes associated with decreased 
folate metabolism [62]. Neural tube closure requires precise coordination of cell 
proliferation, survival, differentiation and migration. Therefore, it is expected that 
impairment in folate levels with subsequent altered one-carbon metabolism could 
Figure 2. Folate dependent homocysteine remethylation and its interaction with S-adenosyl-methionine 
transmethylation reactions. The folate-mediated one-carbon-metabolism is required for the synthesis of 
purines, thymidylate, and the remethylation of homocysteine to methionine. The monoglutamate form 5-methyl 
tetrahydrofolate is the predominant folate in the blood circulation and is taken up into cells by tissue specific folate 
receptors or carriers. The more stable synthetic folic acid enters the remethylation cycle after reduction to 
dihydrofolate and then tetrahydrofolate. DHF: dihydrofolate; MTHFD: methenyltetrahydrofolate dehydrogenase; 
MTHFR: methylenetetrahydro-folate reductase; MTR: methionine synthase; SAH: S-adenosylhomocysteine; 
SAM: S-adenosyl-methionine; THF: tetrahydrofolate.   
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easily disrupt any of these processes. Instead of folate or vitamin B12 deficiency, 
several studies reported hyperhomocysteinemia as a biomarker for NTDs [63,64]. 
 
2.4 DNA methylation studies related to neural tube defects 
The methylation hypothesis suggests that folate prevents NTDs by stimulating 
cellular methylation reactions. It is expected that changes in cytosine methylation are 
not randomly distributed in the DNA but are preferentially located at loci that are 
more sensitive to these processes.  Imprinted genes and transposable DNA 
elements are both associated with high CpG density and, therefore, recent studies 
have quantified the methylation of such CpGs [51,65]. Neural tube closure depends 
on highly coordinated morphologic events and multiple biologic interactions that 
include proteins that regulate cytoskeletal organization, cell cycle, neurogenesis, cell 
viability and cell surface-extracellular matrix interactions. A tight regulation of DNA 
repair is critical for normal embryogenesis and therefore, DNA methylation 
disturbances and genomic instability are believed to result in neural tube closure 
defects. 
  
Imprinted genes are expressed in a parent-of-origin specific manner, 
controlled by epigenetic marks. To date, more than 70 imprinted genes have been 
identified in the human genome [66]. Their parental-specific ‘marks’ or imprints are 
established during germ cell development, mainly via allele-specific methylation. 
Imprint marks resist the first wave of demethylation that occurs in the pre-
implantation embryo following fertilization [67]. CpG methylation of imprinted genes 
is necessary for their monoallelic (parent-specific) gene expression. The allele-
specific methylation of imprinted genes typically occurs at the differentially 
methylated regions (DMRs). DMRs can differ in size between one single CpG to an 
entire gene locus [68].  
 
Transposable elements are repetitive mobile elements that can move along 
chromosomal DNA and can be classified as DNA transposons (that transpose by a 
direct DNA “cut-and-paste” mechanism) or retrotransposons (that transpose via an 
RNA intermediate). Non-long terminal repeat (non-LTR) retrotransposons that 
include long interspersed nuclear element 1 (LINE-1) and short interspersed 
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elements (SINEs, including Alu sequences) constitute the main class of transposable 
elements, which accounts for approximately one-third of the human genome. The 
extremely high density of transposable elements, in comparison to our exon coding 
genome (2%), results in their ability to affect genomic stability and influence genome 
evolution. There are > 500 000 LINE-1 copies and > 1 million Alu copies in the 
human genome, integrated into the ancestral genome more than 150 and 80 million 
years ago, respectively. About 12% of all CpGs fall within LINE-1 and about 25% fall 
within Alu sequences. It is hypothesized that the host genome methylates 
retrotransposon DNA as a defense mechanism to limit detrimental transcription. 
Their CpG methylation is necessary for transcriptional silencing and there is 
evidence that they are sensitive to nutrient exposures [69].  
 
DNA repair mechanisms prevent chromosome instability and DNA 
mutagenesis during time periods of rapid embryonic proliferation and differentiation. 
Silencing of DNA repair genes has been linked to altered promoter methylation in 
different tumor cell types. Especially for neurons, repair mechanisms are important 
for non-replicating DNA. In addition to DNA mismatch repair mechanisms, the adult 
brain contains high levels of DNA methyltransferase to restore the original pattern of 
methylation after deamination of 5-methylcytosine to thymine and cytosine to uracil 
[70]. Microsatellite instability (MSI) is a signal of genomic instability and reflects the 
status of DNA mismatch repair mechanisms [71].  
 
2.5 Are changes in DNA methylation modifying risk factors for neural tube 
defects? 
A literature search in PubMed until June 2014 was performed for the meta-
analysis using a search strategy designed to identify studies evaluating DNA 
methylation alterations related to NTDs. PubMed search parameters ("DNA 
Methylation") AND ("Neural Tube Defects”) resulted in only 18 studies. For inclusion 
in this review, studies also had to meet the following criteria: 1) being a randomized 
control trial, cohort, case-control or cross-sectional study using human tissues and 2) 
investigating global DNA methylation or specific methylation differences of candidate 
genes for NTDs in patient samples with a NTD. This selection further resulted in 9 
	 37	
studies that investigated DNA methylation in relation to NTDs using human samples 
(overview in Table 1). These studies will next be discussed in more detail. 
 
Methylation is the key regulator of imprinted gene expression and the 
methylation patterns of imprinted genes are sensitive to malnutrition in early 
development. Several studies quantified the methylation of imprinted genes in 
patients with NTDs. They focused mainly on the insulin-like growth factor 2 (IGF2), a 
maternally imprinted gene that has a key role in fetal and placental development. By 
binding to the insulin-like growth factor receptor, IGF2 activates intracellular signaling 
cascades that promote cell growth and survival. Liu et al [72] investigated H19 and 
IGF2 methylation in brain tissue of patients with NTDs by methylation-specific PCR 
(MSP) and bisulfite sequencing PCR (BSP). Methylation of the H19 differentially 
methylated region 1 (DMR1) was higher for patients with NTDs compared to controls 
(73.3% vs 58.3%; P<0.05). There was no significant difference for IGF2 DMR0 
methylation between patients with NTDs and controls. In addition to IGF2 
methylation in brain, Wu et al [73] investigated IGF2 methylation in placental and 
lung tissue of patients with NTDs. But only in neural tissue the IGF2 DMR0 was 
significantly hypermethylated in patients (19.3% vs 16.7% in controls; P=0.001). 
DMR0 methylation was not significantly different in placental or lung tissue and 
DMR2 was not differentially methylated in brain, placental or lung tissue. The 
average methylation level of DMR0 was much higher in lung and placental tissues 
(54.6% and 55.7%, respectively), representing tissue-specific methylation 
differences. IGF2 mRNA expression was negatively correlated with the methylation 
level of DMR0 (R²=0.893) in HCT15 cells. Stolk et al [74] investigated H19, IGF2 and 
KCNQ1OT1 methylation in peripheral white blood cells of patients with NTDs but 
found no significant differences.  
 
Changes in the methylation pattern of transposable elements affect genomic 
stability. Therefore, Wang et al [75] investigated and found LINE-1 hypomethylation 
in neural tissues from patients with NTDs and this difference was more pronounced 
for cranial compared to caudal NTDs (52.43%, 57.32% and 59.03% for anencephaly, 
spina bifida and control samples, respectively; P<0.001). LINE-1 promotor 
hypomethylation might result in decreased chromosomal instability in NTDs due to 
increased retrotransposition. There was no correlation between LINE-1 
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hypomethylation and the maternal nutrition status of folate, vitamin B12 or 
homocysteine levels. The underlying mechanism might be explained by: 1) the 
induction of an imbalance in DNA synthesis and repair or 2) the alteration of DNA 
methylation. However, more studies are needed to provide further insights in these 
hypotheses.  
 
Global DNA hypomethylation and chromosomal aberrations have been 
linked in several cancers, implying that global DNA hypomethylation may play an 
important role in inducing chromosomal instability [76]. Global DNA methylation 
studies related to complex diseases such as NTDs are still limited. Wang et al [75] 
were the first to investigate global DNA methylation in neural tissue of patients with 
NTDs. They found significant methylation differences between anencephaly, spina 
bifida and control samples (4.79%, 5.26% and 5.95%, respectively). 
Hypomethylation was most pronounced in patients with a cranial NTD. This study 
also found a significantly reduced maternal plasma vitamin-B12 concentration, lower 
plasma concentrations of folate and higher concentrations of homocysteine, 
supporting the link between an impaired one-carbon-metabolism and increased risk 
for NTDs. However, no significant correlation was found between global methylation 
levels and maternal plasma concentrations of folate, vitamin B-12 or homocysteine. 
A second study performed by Chang et al [77], investigated tissue-specific global 
DNA methylation in multiple tissues of second-trimester NTD and control human 
fetuses. The distribution of DNA methylation in NTD fetuses was significantly 
different from that in controls. The alteration of DNA methylation in brain tissue was 
more significant than that in other tissues (3.19% vs 3.57 % in controls; P<0.001) but 
there were no significant differences between the different subgroups of patients with 
NTDs (anencephaly, encephalocoele, spina bifida). In this study, the maternal folate 
concentration was significantly lower in NTD fetuses and correlated with brain-tissue 
DNA methylation. Chen et al [78] correlated global DNA methylation levels with the 
complexity of NTDs and MTHFR genotype. Global DNA methylation levels were 
significantly decreased in brain tissue of NTD-affected fetuses (4.12 vs. 4.99% in 
controls; P<0.001). Stratification for the MTHFR genotype revealed a skewed 
distribution of global DNA methylation levels with no differences in methylation status 
for genotype C/C (P=0.687), lower DNA methylation in patients with NTDs and 
genotype C/T (P=0.059) and significantly lower methylation values in patients with 
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genotype T/T (3.79% vs. 5.23%; P < 0.001). This skewed distribution implied that the 
T/T genotype contributed to reduced DNA methylation levels in NTD fetuses. The 
NTD group had a higher proportion of the T/T homozygous mutant but the difference 
was non-significant (P=0.15).  
 
Impaired expression of DNA repair genes leads to chromosome instability 
and DNA mutations. Tran et al [79] combined methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) and mass spectrometry to investigate the 
promoter methylation status of seven DNA repair genes (TP73, MSH6, MGMT, 
BRCA1, BRCA2, ATM, TP53). Two genes, MSH6 and MGMT, had a different 
methylation pattern detected by MS-MLPA but only MGMT remained significantly 
different after adjusting for multiple testing. The mean level of MGMT methylation 
using mass spectrometry was 41.04 % for the NTD case group and 42.71% for the 
control group (P=0.034) but subgroup analysis showed only significant differences 
for patients with anencephaly (39.83%). The mean methylation level of the MGMT 
promotor was lower in female patients with NTDs (41.19% vs 44.20%  
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Table 1: List of human studies focusing on DNA methylation in NTD patients. 
 
 
 
Ref Assay Subjects Methylation 
status 
Tissue Outcome 
Liu  
[72] 
- MSP and BSP 
- MSI 
- 17 NTD 
patients; 7 
controls 
(Imprinted 
genes)  
- 22 NTD 
patients; 7 
controls 
(Mismatch 
repair genes) 
- Imprinted genes 
(H19 DMR1 and 
IGF2 DMR0) 
- Mismatch repair 
genes (hMLH1 
and hMSH2) 
 
Brain  Higher DNA methylation of H19 DMR in 
NTD patients (73.3 vs 58.3 % in controls; 
P<0.05). MSI in 23/50 NTD tissues. Non-
significant higher incidence of MSI in 
patients with H19 DMR1 
hypermethylation.  
Wu  
[73] 
- Mass 
spectrometry 
- IGF2 
expression in 
HCT15 cells 
treated with 5-
Aza-CdR 
55 NTD 
patients; 46 
controls 
- Imprinted genes 
(IGF2 DMR0 and 
DMR2) 
Brain, lung, 
placenta 
Hypermethylation of IGF2 DMR0 in brain 
tissue of NTD patients (19.3% vs 16.7% 
in controls; P=0.001). Higher average 
methylation of IGF2 DMR0 in lung and 
placental tissue versus brain tissue. IGF2 
mRNA expression was negatively 
correlated with methylation of DMR0 
(R²=0.893). 
Stolk 
[74] 
- Mass 
spectrometry 
- 48 NTD 
patients; 62 
controls 
(Dutch study) 
- 34 NTD 
patients; 78 
controls 
(Texan study) 
- Imprinted genes 
(IGF2-DMR, 
H19, 
KCNQ10T1);  
- Non-imprinted 
genes 
(LEKR/CCNL, 
MTHFR, 
VANGL1) 
Peripheral 
white blood 
cells 
Only for Dutch study cohort: DNA 
methylation changes for MTHFR (-0.33% 
absolute decrease in patients; P=0.001) 
and for LEKR/CCNL (+1.36% absolute 
increase in patients; P=0.048), borderline 
significance for VANGL (+0.17% absolute 
increase in patients; P=0.063).  
Wang 
[75] 
- Mass 
spectrometry 
- Global DNA 
Methylation  
- Folic acid, 
vitamin B-12, 
and tHcy in 
maternal 
plasma 
 
48 NTD 
patients; 49 
controls 
- Global DNA  
- Transposable 
elements (LINE-
1) 
Brain Lower DNA methylation in NTD patients 
(5.01% vs 5.95% for controls; P=0.047). 
Lower LINE-1 methylation in NTD patients 
(for anencephaly, spina bifida and control 
samples respectively 52.43%, 57.32%, 
and 59.03%; P<0.001). Lower plasma 
vitamin B-12 in NTD patients (P<0.05).  
Chang 
[77] 
- HLPC 
- Global DNA 
methylation 
- Maternal 
serum folate 
status 
 
45 NTD 
patients; 45 
controls 
- Global DNA Brain, skin, 
heart, 
kidney, 
liver, lung  
Lower DNA methylation in brain tissue of 
NTD patients (3.19% vs 3.57 % in 
controls; P<0.001). Lower mean maternal 
folate concentration in NTD fetuses, in 
correlation with brain tissue methylation 
status.  
Chen 
[78] 
- MTHFR 
genotype  
- Global DNA 
methylation  
65 NTD 
patients; 65 
controls 
- Global DNA Brain, skin  Lower DNA methylation in brain tissue of 
NTD patients (4.12% vs 4.99% in 
controls; P<0.001). Skewed distribution of 
DNA methylation after stratification for 
MTHFR genotype with significantly lower 
levels for NTD patients with genotype T/T 
(3.79% vs 5.23% in controls; P < 0.001).  
Tran 
[79] 
- MS-MLPA 
- Mass 
spectrometry 
50 NTD 
patients; 58 
controls 
- DNA repair 
genes (TP73, 
MSH6, MGMT, 
BRCA1, BRCA2, 
ATM, TP53) 
Brain  Lower DNA methylation of MGMT in NTD 
patients (41.04% vs 42.71%; P=0.034). 
Lower MGMT promotor methylation in 
female NTDs. 
Farkas 
[80] 
- Pyro-
sequencing 
- RFC1 
genotype 
68 NTD 
patients; 38 
controls 
- Folate transport 
genes (FOLR1, 
PCFT, RFC1) 
Placenta No significant differences for FOLR1, 
PCFT or RFC1 methylation, but 
methylation fractions differed according to 
RFC1 80G>A genotype in NTD patients.  
Wang 
[81] 
- Mass 
spectrometry  
- PTCH1 
genotype  
187 NTD 
patients; 212 
controls 
- SHH regulator 
(PTCH1) 
Brain  Increased risk for spina bifida with the G 
allele of c.3944C>T (only in females) and 
the T allele of c.1729-2350G>A. Lower 
DNA methylation for CpG sites around 
c.3944C>T GG genotype in patients (75% 
vs 86% in controls; P=NA).   
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Abbreviations: Bisulfite sequencing PCR (BSP); Methylation specific-multiplex ligation-dependent probe 
amplification (MS-MLPA); Methylation Specific PCR (MSP); Microsatellite Instability (MSI); Neural Tube Defect 
(NTD); Quantitative high-performance liquid chromatography (HLPC); total Homocysteine (tHcy); Whole genome 
array competitive genomic hybridization (CGH). 
 
in controls, P=0.009). Liu et al [72] studied the methylation status of the mismatch 
repair genes hMLH1 and hMSH2 and MSI in NTD tissues. MSI was observed in 23 
of the 50 NTD tissues. MSP and BSP were used to determine the methylation 
patterns of the hMLH1 and hMSH2 promoters but these promoters were not 
significantly hypermethylated in NTDs compared to controls. 
 
Some methylation studies focused on candidate genes that are already 
known to be associated with NTD risk. Stolk et al [74] found a significant 
association for MTHFR and LEKR/CCNL DNA methylation in a Dutch case-control 
cohort. However, absolute methylation differences did not exceed 1.36%. Farkas et 
al [80] investigated whether aberrant DNA methylation of folate transport genes in 
the placenta could compromise folate supplies to the embryo. There were no 
significant differences in FOLR1, PCFT or RFC1 methylation between placentas 
from controls and patients with NTDs but there was an inverse relation between DNA 
methylation in the DMRs of FOLR1 and RFC1 and mRNA levels. The mean RFC1 
methylation fraction was lower in NTD patients with RFC1 80G>A genotype and high 
homocysteine levels, suggesting a gene-nutrition interaction between folate intake 
and RFC1 genotype, DNA methylation status and mRNA transcription. Sonic 
hedgehog (SHH) signaling plays a crucial role in neurulation. Therefore, Wang et al 
[81] investigated PTCH1, a negative regulator of SHH signaling. They determined 
the genotype of 18 SNPs of PTCH1 and combined these results with their 
surrounding methylation status. They found an increased risk of spina bifida with the 
G allele of c.3944C>T (only in females) and the T allele of c.1729-2350G>A. The 
CpG sites near the c.3944C>T allele were analyzed to better understand the 
possible roles of this SNP. Patients had lower DNA methylation for CpG sites near 
the c.3944C>T GG genotype compared to controls (75% vs 86% in controls; P=NA). 
Therefore, it was suggested that methylation modifications associated with the 
c.3944C>T polymorphism may be preventive for NTDs.  
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2.6 Conclusion: can folate affect neural tube closure via changes in DNA 
methylation? 
Nutrition can influence DNA methylation because the mammalian one-carbon 
metabolism is highly dependent on dietary methyl donors and cofactors. DNA 
methylation is essential for normal mammalian development and regulation. The 
long-standing beneficial evidence of folate raises the question whether improved 
nutrition may further prevent NTDs, not only during embryogenesis but also in the 
developing nervous system after birth. To date, human studies vary widely in study 
design, choice of DNA methylation assay and the type of tissues used for DNA 
extraction. Studies mainly focused on genomic DNA methylation differences and 
specific methylation differences in imprinted genes, transposable elements and DNA 
repair enzymes. Findings of global DNA hypomethylation and LINE-1 
hypomethylation suggest that disruption of genomic stability may disrupt neural tube 
closure but current research does not support a linear relation between red blood cell 
folate and DNA methylation. It is still unclear how specific regions of the genome 
respond to folate intake. Further studies are required to investigate this relation. 
Nutri-epigenomics may represent a mechanistic link between nutrition and NTD risk. 
However, epigenetic marks appear to be controlled by genetic sequence. Hence, 
research should include genome-wide epigenetic and genetic studies to understand 
the relative role of genes versus environment in epigenetic variability in patients with 
NTDs.  
 
 
 
 
 
 
 
 
 
 
	 43	
Fi
gu
re
 3
. C
he
m
ic
al
 s
tr
uc
tu
re
s 
of
 th
e 
m
ai
n 
pl
ay
er
s 
in
 th
e 
fo
la
te
 d
ep
en
de
nt
 h
om
oc
ys
te
in
e 
re
m
et
hy
la
tio
n 
cy
cl
e.
 T
he
 m
on
og
lu
ta
m
at
e 
fo
rm
 5
-m
et
hy
l t
et
ra
hy
dr
of
ol
at
e 
is
 th
e 
pr
ed
om
in
an
t f
ol
at
e 
in
 th
e 
bl
oo
d 
ci
rc
ul
at
io
n 
an
d 
is
 ta
ke
n 
up
 in
to
 c
el
ls
 b
y 
tis
su
e 
sp
ec
ifi
c 
fo
la
te
 re
ce
pt
or
s 
or
 c
ar
rie
rs
. M
TR
: m
et
hi
on
in
e 
sy
nt
ha
se
. 
 
	
	 
 
 
THESIS OBJECTIVES & OVERVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Science never solves a problem without creating ten more. 
 George Bernard Shaw (1856-1950)
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OBJECTIVES & METHODS 
 
The overall aim of this doctoral thesis is to determine gene regions and biological 
pathways that are more sensitive to changes in DNA methylation during 
embryogenesis and are associated with neural tube defects (NTDs). In addition to a 
genome-wide DNA methylation analysis, we performed locus-specific and functional 
validation studies of candidate genes, as well as functional gene enrichment 
analyses. 
 
Aim 1: Genome-wide analysis of DNA methylation  
Evidence from literature supports the link between an impaired methylation cycle 
and NTDs. DNA methylation, the most studied form of epigenetic modification, 
results from the addition of a methyl group to cytosine (5-mC) in the context of CpG 
dinucleotides. We have applied the Illumina Human Methylation 450K BeadChip 
(HM450k), using leukocyte DNA from 10 patients with a myelomeningocele (MMC), 
to identify candidate gene regions that are significantly hypo- or hypermethylated 
compared to 6 healthy control subjects. The HM450k allows genome-wide 
methylation analysis: more than 485.000 methylation sites per sample are 
interrogated at single-nucleotide resolution. It covers 99% of RefSeq genes, 96% of 
CpG islands (CGI) as well as multiple CGI shores and isolated CpGs. The 
interrogated cytosines cross promoter regions, 5’ and 3’ UTRs, gene bodies and 
intergenic regions. The HM450k represents so far the most standardized 
methodology to assess DNA methylation at genome-wide level [82,83].  
 
The HM450k array data are analyzed using both a candidate-gene specific approach 
whereby single gene information is extracted from the genome-wide analysis 
(Chapter 3 for HOX gene cluster as known genes involved in embryogenesis) as 
well as using a genome-wide approach to identify novel genes that are differentially 
methylated between patients and controls (Chapter 4).  
 
Analyzing HM450k data is complex and data filtering, processing and interpretation 
are not well standardized [83]. In order to acquire knowledge in the technical and 
analytical aspects of HM450k arrays, I received a Short-Term Scientific Mission 
grant (supported by COST–BM1209: European Network of congenital imprinting 
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disorders) to visit the lab of Prof. D. Monk (laboratory of Genomic Imprinting and 
Cancer at IDIBELL, Barcelona) for training in analyzing HM450k data. During this 
research stay, I analyzed the HM450k data performed to study overall genome 
methylation for patients with the imprinting disease pseudohypoparathyroidism 
(PHP) (Chapter 5). Patient samples and their clinical data were already available for 
this study from the EuroPHP consortium. Next, locus-specific validation studies were 
performed with the Sequenom EpiTYPER.  
 
Aim 2: Locus-specific validation of candidate gene loci  
We performed validation studies for the identified gene loci from the HOX-specific 
(Chapter 3) and genome-wide methylation (Chapter 4) analysis using the 
Sequenom EpiTYPER for 83 MMC patients, 12 unaffected healthy siblings, 30 age- 
and gender matched unrelated young adults without a family history of NTDs and 5 
families of patients with MMC. The Sequenom EpiTYPER assay is based on 
bisulfite-conversion followed by PCR target amplification and a base-specific 
cleavage process. The resulting cleavage pattern is further analyzed by a mass 
spectrometry-based method for both qualitative and quantitative methylation 
information. This methodology allows the simultaneous analysis of a larger sample 
set of patients with NTDs and informs on both the magnitude and the population 
variability of the differentially methylated locus of interest.  
 
Aim 3: Functional analysis of candidate genes 
Zebrafish are a useful model system for analyzing the effects of gene depletion and 
overexpression on neural tube development as important similarities in embryonic 
neurulation between humans and vertebrates have been observed [11]. DNA hyper- 
or hypomethylation is usually associated with respectively gene silencing and 
overexpression. Therefore, the effects of candidate genes in zebrafish are studied by 
the morpholino-induced knock down strategy or via overexpression of mRNA and a 
detailed morphological analysis of neural tube development during embryogenesis is 
performed. Whole mount In Situ Hybridization (WISH) using a probe for the paired 
box gene 2a (pax2a) is used to analyze neural tube development. Functional 
analysis in zebrafish is used for Chapters 3 and 4. 
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Aim 4: Building biological pathways 
In addition to identifying individual genes and their regulatory regions as risk factors 
for NTDs, the next challenge is to define the developmental requirement for those 
genes that are obligatory for neurulation and whose disruption or differential 
expression leads to NTDs. The development of the nervous system is a complex and 
dynamic process, under influence of many genetic and non-genetic factors, with 
candidate genes in diverse functional classes. Building well-established cell 
biological and/or molecular functions into specific signaling pathways is essential to 
understand their contribution to neurulation and their potential interactions. 
Reactome and the Ingenuity Pathway Analysis (IPA) programs are used to 
investigate whether the identified candidate genes are part of a similar biological 
network. In addition, gene enrichment analysis based on ontologies of gene function 
is used to identify relevant biological mechanisms. Functional pathway analyses and 
gene prioritization studies are performed in collaboration with Prof. Y. Moreau for 
Chapter 4 (Department of Electrical Engineering ESAT-SCD, University of Leuven, 
Belgium).  
 
Ethical approval was obtained for this study (S55277).
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The important thing is not to stop questioning.  
Curiosity has its own reason for existing. 
 Albert Einstein (1879-1955) 
	 
 
 
 
 
 
	 
 
 
 
 
 
 
CHAPTER 3 
 
 
DNA methylation of Homeobox genes  
in patients with Spina Bifida 
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3.1 Abstract 
Neural tube defects (NTDs) are common birth defects of complex etiology. 
Though family- and population-based studies have confirmed a genetic component, 
the responsible genes for NTDs are still largely unknown. Based on the hypothesis 
that folic acid prevents NTDs by stimulating methylation reactions, also epigenetic 
factors as DNA methylation are predicted to be involved in NTDs. Homeobox (HOX) 
genes play a role in spinal cord development and are tightly regulated in a 
spatiotemporal and collinear manner, partly by epigenetic modifications. We have 
quantified DNA methylation for the different HOX genes by subtracting values from a 
genome-wide methylation analysis using leukocyte DNA from 10 myelomeningocele 
(MMC) patients and 6 healthy controls. From the 1575 CpGs profiled for the 4 HOX 
clusters, 26 CpGs were differentially methylated (p-value < 0.05 and β-difference > 
0.05) between MMC patients and controls. 77% of these CpGs were located in the 
HOXA and HOXB clusters, with the most profound difference for 3 CpGs within the 
HOXB7 gene body. A validation case-control study including 83 MMC patients and 
30 unrelated healthy controls confirmed a significant association between MMC and 
HOXB7 hypomethylation (-14.4%; 95% CI 11.9-16.9%; p-value <0.0001) 
independent of the MTFHR 667C>T genotype. Significant HOXB7 hypomethylation 
was also present in 12 unaffected siblings, each related to a MMC patient, 
suggestive of an epigenetic change induced by the mother. The inclusion of a neural 
tube formation model using zebrafish showed that Hoxb7a overexpression but not 
depletion resulted in deformed body axes with dysmorphic neural tube formation. 
Our results implicate HOXB7 hypomethylation as risk factor for NTDs and highlight 
the importance for future genome-wide DNA methylation analyses without 
preselecting candidate pathways. 
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3.2 Introduction 
Neural tube defects (NTDs), affecting 0.5-2 per 1000 pregnancies, arise as a 
failure of the neural tube to close in the cranial (anencephaly) or the caudal 
(myelomeningocele) region [28,84,85]. The nature and severity of NTDs is 
determined by the stage and axial level at which closure fails. Cranial NTDs are 
mostly not compatible with life while caudal NTDs give rise to lifelong disabilities. 
Although more than 250 genes are known to cause NTDs in mice [16,22] and many 
candidate genes have been studied in patient cohorts, the molecular basis 
underlying NTDs still remains largely unknown. Folic acid reduced the incidence of 
NTDs by 50-75% [31]. However, in most NTD-affected pregnancies maternal folic 
acid levels are within the normal range [86] and despite optimal supplementation a 
significant proportion of NTDs are even unresponsive to folic acid [31,87]. This would 
suggest the existence of folic acid resistance in mothers at risk for NTD-affected 
pregnancies but this hypothesis is not supported by genetic and/or environmental 
risk factors. Folic acid is central to the one-carbon metabolism that produces 
pyrimidines and purines for DNA synthesis and for the generation of S-adenosyl-
methionine that is a methyl donor for DNA, RNA and protein methylation. The only 
well-characterized genetic risk factor for NTDs is the 677C>T variant in the 5,10-
methylene tetrahydrofolate reductase gene (MTHFR), causing thermolability of the 
enzyme and predicted to divert the available methyl groups from the DNA 
methylation towards the DNA synthesis pathway [31]. Interestingly, the MTHFR 
677C>T variant is associated with global DNA hypomethylation in both controls and 
NTDs [31,78], and this seems to be more pronounced under low folic acid conditions 
[88]. Most DNA methylation studies in patients with NTDs were performed 
independent of the presence of the MTHFR 677C>T variant. Findings of global DNA 
and LINE-1 hypomethylation were found in fetal neural tissue DNA from NTD 
patients, suggesting that disruption of genomic stability may lead to abnormal neural 
tube closure [75,77].    
 
The methylation hypothesis suggests that folic acid prevents NTDs by 
enhancing cellular methylation reactions. It is known that a tight regulation of 
genome-wide erasure of epigenetic footprints with resetting of the methylation 
signature is critical for normal embryogenesis and therefore, it is believed that DNA 
methylation changes and genomic instability may disturb neural tube folding [32]. 
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Immediately post fertilization, rapid de-methylation takes place, followed by re-
methylation in the blastocyst and early embryo. It is expected that changes in 
cytosine methylation are not randomly distributed in the genome but are 
preferentially located at loci that are more sensitive to these processes. Methylome 
analysis during early embryonic differentiation showed changes in the methylation 
patterns for developmental regulatory genes, such as Homeobox (HOX) genes [89]. 
The HOX gene clusters comprise a family of genes assembled in four clusters (HOX 
A, B, C, D located on chromosomes 7, 17, 12 and 2, respectively). HOX genes 
encode highly conserved transcription factors expressed in the brain and spinal cord 
that play a central role in establishing the anterior-posterior body axis during 
embryogenesis (Figure 1) [90,91]. Their expression is tightly regulated in a 
spatiotemporal and collinear manner, partly by chromatin structure and epigenetic 
modifications [92-94]. Though genetic studies could not show an association 
between variants in HOX genes and NTDs [90], DNA methylation studies for the 
HOX cluster genes have not yet been performed.  
 
 
Figure 1: Genomic organization and expression patterns of HOX genes for humans and zebrafish. HOX 
genes are evolutionary highly conserved, it appears that an ancestral HOX gene cluster was duplicated twice 
within the 2R genome duplication events, and was important to allow the emergence of vertebrates. Mammals 
have 39 HOX genes distributed in 4 clusters; they pattern the embryo along the rostro-caudal axis. Based on 
sequence similarities and position within the cluster, genes can be classified in 13 paralog groups (HOX1-13). 
They become activated during early embryogenesis in a time sequence that reflects their physical order within 
the clusters, referred to as ‘temporo-spatial collinearity’. Genes at the 3’ end of the clusters are activated first, and 
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genes located at more 5’ genomic positions are activated subsequently. The 3’ paralog groups HOX1-5 have 
restricted expression borders in general in the hindbrain, while HOX4-11 genes are detected in the spinal cord. 
The overall number of hox genes in zebrafish (48) is close to that in mammals (39), despite the existence of 
seven clusters. This is due to a massive elimination of Hox genes after the additional duplication. Genes 
indicated in blue refer to the HOX genes that are differentially methylated. [Figure adapted with permission from 
Veraksa A, Del Campo M, McGinnis W (2000) Developmental patterning genes and their conserved functions: 
from model organisms to humans. Mol Genet Metab 69: 85-100.] 
 
We hypothesize that children born from mothers with folic acid resistance and 
a disturbed methylation cycle can present with an abnormal DNA methylation profile 
for HOX genes, resulting in increased risk for abnormal embryonic development and 
NTDs. Therefore, the aim of this study was to investigate DNA methylation of HOX 
genes as mediator of NTD risk using data extracted from a genome-wide DNA 
methylation analysis study performed for 10 patients with lumbosacral MMC and 6 
healthy unrelated controls. A validation study was performed to quantify locus-
specific methylation differences in larger cohorts. The functional characterization of 
the candidate HOX gene was finally analyzed using a zebrafish model of neural tube 
formation.  
 
	 59	
3.3 Materials and Methods 
Ethics statement 
Written informed consent to collect blood samples for (epi)genetic studies was 
obtained from all participants and/or their legal representatives. This study was 
approved by the Medical Ethics Committee of the University of Leuven (ML9193).  
 
Description of MMC patients, related healthy siblings and unrelated controls 
A total of 85 MMC patients and 12 healthy related siblings enrolled in this study are 
followed at the pediatric neurology department of the University Hospital Leuven (all 
<18 years). Detailed clinical and general characteristics for all these subjects are 
reported in Table 1.  As sensory and motor functions at and below the level of the 
spinal cord defect are impaired; paralysis, bowel and bladder dysfunction is present 
in most of the patients. Folic acid supplementation was recommended, but red blood 
cell folate was not measured during pregnancy. Table 1 also indicates which MMC 
patients were included in the 450K array and/or the Sequenom validation study. In 
addition, we have recruited 30 age- and gender-matched non-related healthy control 
subjects with no family history of NTDs (15 males and 15 females).  
 
Table 1: Background information of MMC patients included in the HumanMethylation 450K BeadChip and 
Sequenom EpiTYPER. 
 
Patient Type 
MMC 
Hy/VP ACM Scoliosis ADL UI Ethnicity Age 
mother 
Patient  
MTHFR  M/F 
 
Sibling 
MTHFR   M/F 
Δ  Age 
1*+ S yes 1 yes 2 yes Belgian 36 CC F   
2*+ LS yes 2 yes 3 yes Belgian 29 CT F   
3*+ LS yes 2 yes 3 yes Moroccan 32 CT M   
4*+ LS yes 1 yes 3 yes Indonesian 26 CC F   
5*+ LS yes 2 no 2 yes Belgian  CC M CC F 5 
6*+ LS yes 2 yes 3 yes Belgian 27 CC F   
7*+ LS yes 1 yes 3 yes Belgian  CC M   
8*+ S yes 2 no 1 yes Belgian 27 CC F   
9* S no 0 no 1 yes Belgian  TT M   
10* LS yes 2 no 2 yes Belgian 25 CC M   
11+ LS yes 2 yes 3 yes Belgian 27 CC M   
12+ LS yes 2 yes 3 yes Turkish 28 CC F   
13+ S yes 0 no 1 yes Belgian 33 CT M   
14+ LS yes 2 yes 3 yes Belgian  CC F   
15+ LS yes 2 yes 3 yes Turkish 20 CT F   
16+ S yes 2 yes 3 yes Belgian  TT M   
17+ LS yes 2 yes 3 yes Belgian 25 CT F   
18+ S yes 2 yes 2 yes Belgian 28 CC M   
19+ LS yes 2 no 1 yes Belgian 36 CT M   
20+ LS yes 2 yes 1 yes Belgian  CT M   
21+ LS yes 2 yes 3 yes Belgian 36 CT F   
22+ TL & LS yes 2 yes 3 yes Belgian 23 CC M   
23+ S no 0 yes 1 yes Belgian 30 CT M   
24+ LS yes 2 yes 2 yes Belgian 25 CT F   
25+ LS yes 2 no 2 yes Belgian 34 CC F   
26+ LS no 0 no 1 yes Belgian  CC F   
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27+ LS yes 2 yes 3 yes Belgian  CT M CC F -20 
28+ LS yes 2 yes 3 yes Moroccan  CT F   
29+ LS yes 2 yes 3 yes Belgian 31 CC M CC M -19 
30+ LS yes 0 no 1 yes Mongolian  CC F   
31+ LS no 0 no 1 no Belgian 20 TT M CC M -20 
32+ LS yes 2 no 1 yes Belgian 22 CC M   
33+ LS yes 2 yes 2 yes Belgian 28 CT M   
34+ LS yes 2 yes 3 yes Belgian  CT F   
35+ S yes 2 no 1 yes Belgian 33 CT M   
36+ LS yes 2 no 3 yes Belgian 27 CC M   
37+ LS yes NA yes 2 yes Belgian 26 CT F   
38+ LS yes 2 yes 2 yes Belgian  CT F   
39+ LS yes 2 yes 3 yes Belgian 28 CT F   
40+ LS yes 2 no 1 yes Belgian 32 CC M   
41+ LS no NA no 3 yes Belgian 36 CC M CT M -26 
42+ L yes 2 yes 3 yes Ukrainian 20 CC F   
43+ LS yes 2 no 1 yes Belgian 25 CC F TT M 20 
44+ LS yes 2 yes 3 yes Belgian  CC M   
45+ LS yes 2 yes 3 yes Belgian 29 CT F   
46+ LS yes 2 yes 3 yes Belgian  CC F   
47+ S yes 2 no 1 yes Moroccan 31 CT F   
48+ LS yes 2 yes 2 yes Belgian 27 CT F   
49+ S yes 2 yes 3 yes Belgian 34 CC F   
50+ S no NA no 1 yes Belgian 36 CT F CC F 17 
51+ LS yes 2 no 3 yes Belgian 30 CC F   
52+ LS yes 2 no 1 yes Moroccan 24 CC F   
53+ S yes 2 no 1 yes Belgian 28 CC F   
54+ S no NA no 1 yes Belgian  CT F   
55+ LS yes 2 no 2 yes Bosnian 31 CT F CC M 53 
56+ S no 0 no 1 yes Belgian 30 CC F   
57+ LS yes 2 no 1 yes Belgian 24 CC F   
58+ S no 2 no  yes Moroccan 26 CC F   
59+ LS yes 2 yes 3 yes Belgian 27 CC F   
60+ LS yes 2 no 1 yes Turkish 35 CT F CC F -101 
61+ LS yes 2 yes 3 yes Belgian  CT F   
62+ LS yes 2 no 1 yes Turkish 29 CT F   
63+ LS yes 2 yes 3 yes Belgian 35 CT F   
64+ L & CP yes 2 no 2 yes Belgian 40 CT F CT F -27 
65+ LS yes 2 yes 2 yes Belgian  CT F   
66+ LS yes 2 yes 2 yes Belgian 24 CT F   
67+ LS yes 2 yes 2 yes Belgian  CT F   
68+ S yes 2 no 1 no Belgian  CT M   
69+ LS yes 2 yes 3 yes Belgian 24 CT M   
70+ LS yes 2 yes 3 yes Belgian 29 CC M   
71+ LS yes 2 yes 3 yes Belgian 33 CC F   
72+ LS yes 2 yes 2 yes Belgian 29 CC M   
73+ LS yes 2 yes 3 yes Belgian 29 CT F CT F -24 
74+ LS yes 2 yes 2 yes Belgian  CT M   
75+ LS yes 2 no 1 yes Belgian  CC F   
76+ LS yes 2 yes 2 yes Belgian 31 CT F   
77+ LS yes 2 yes 3 yes Belgian 26 CC M   
78+ LS yes 2 yes 3 yes Belgian 30 CT M   
79+ S no 0 no 1 yes Belgian  CT M   
80+ LS yes 2 no 1 yes Belgian 30 CC F   
81+ LS yes NA no 2 yes Turkish  CT M   
82+ TL yes 2 yes 3 yes Belgian  TT F   
83+ TL yes 2 yes 1 yes Belgian 24 TT F   
84+ TL yes 1 yes 3 yes Belgian 37 CC F   
85+ TL yes 2 no 1 no Belgian  TT F   
 
*Inclusion in HumanMethylation 450K BeadChip (10 MMC patients) and +Sequenom EpiTYPER (83 MMC 
patients); MMC: myelomeningocele; M: male; F: female; S: Sacral; LS: Lumbosacral; TL: Thoracolumbal; CP: 
Cheilopalatoschisis; Hy/VP: presence of hydrocephaly and ventriculoperitoneal drain; ACM: Arnold Chiari 
Malformation: 1 = type 1, 2 = type 2; NA: Not Available; ADL: Activities of daily life: 1 = ambulatory, 2 = 
household ambulatory with wheelchair for longer distances, 3 = wheelchair dependent; UI: urinary incontinence; 
MTHFR 677C>T genotype (CC/CT/TT) in 85 MMC patients: 47% CC - 53% CT/TT versus 40% CC - 60% CT/TT 
in 30 healthy unrelated controls (P-value = ns).  
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Genome-wide DNA methylation analysis using the HM450k 
Genome-wide DNA methylation analysis was assessed using Illumina Infinium 
HumanMethylation 450K BeadChip (Illumina, Inc., California, USA) that provides a 
genome-wide coverage of CpG sites (99% of RefSeq genes, covering the promoter 
region, 5’UTR, first exon, gene body and 3’UTR, Figure 2) [95]. Bisulfite conversion 
of leukocyte DNA (1 µg) was performed using the EZ DNA methylation kit (Zymo 
Research, Irvine CA, USA). Control nested PCR reactions were done on both 
unconverted and converted DNA to verify DNA conversion. Arrays were processed 
according to the manufacturer’s protocol. Samples were randomly distributed to 
control for batch effects. Before analyzing the data, possible sources of technical 
bias were excluded. Probes were excluded from further analysis if >95% of samples 
had a detection value >0.01 [83]. The software GenomeStudio (Illumina) was used to 
convert on-chip fluorescent methylation values into numerical values (β-value). 
Methylation, described as a β-value, is a continuous variable ranging between 0 (no 
methylation) and 1 (full methylation) for each CpG site. From this genome-wide 
analysis, we extracted the methylation levels for the different CpGs that cover all 
regions within the HOX clusters (for overview see Table 2). We discarded the 
following probes (608 in total): i) probes with absent signals in one or more of the 
DNA samples analyzed, ii) non-CpG probes, iii) probes containing SNPs and iv) 
leukocyte-specific probes [83]. The signal processing was conducted using the 
Illumina Methylation Analyzer (IMA) package implicated in the open source statistical 
environment R [96]. Two filters were applied to identify differentially methylated 
CpGs between MMC patients and controls: i) absolute β-value difference >0.05 and 
ii) p-value <0.05 as calculated with the Wilcoxon rank-sum test.  
 
Table 2: Number of probes for the 4 HOX clusters included in the HM450k. 
Cluster Gene UCSC RefSeq Gene region including 
shores/shelves 
Total Filtered 
A HOX A1 Chr7:27132614-27135625 Chr7:27131625-27240499 481 298 
HOX A13 Chr7:27236499-27239725 
B HOX B1 Chr17:46606807-46608272 Chr17:46602807-46810111 409 236 
HOX B13 Chr17:46802127-46806111 
C HOX C4 Chr12:54410636-54449814 Chr12:54328576-54453814 360 232 
HOX C13 Chr12:54332576-54340328 
D HOX D1 Chr2:177053307-177055635 Chr2:176953532-177059635 325 201 
HOX D13 Chr2:176957532-176960666 
     1575 967 
Nucleotide positions accord to the NCBI build 37/hg19.  
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Figure 2. Genomic context of CpG methylation by HumanMethylation 450k Beadchip.  
A. Schematic diagram of CpGs depicts their genomic context relative to the nearest CpG island (top) or gene 
(bottom). Island context is defined as being within an “island” (dark grey), in a 4kb “shore” (grey) flanking the 
island, or in an “open sea” (light grey) more than 4kb from an island. Gene context is defined relative to the 
nearest open reading frame: within 1500 (TSS1500) or 200 bp (TSS200) of a transcription start site, in the 5’ 
UTR, the 1st exon of a transcript, in the body of gene or the 3’ UTR. B. Pie charts show the distribution of the 
CpGs examined based upon their genomic context for all probes retained from the array (left column) and for 
all the differentially methylated probes (right column). Distribution within the HOX clusters and gene and island 
context after analysis with the IMA R package is presented.  
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Methylation of CpGs within the HOXB7 gene body using the Sequenom 
EpiTYPER 
Leukocyte DNA (1 µg) was subjected to bisulfite treatment using the 
MethylDetectorTM bisulfite modification kit (Active Motif, Carlsbad CA, USA) as we 
described [97,98]. The Sequenom MassARRAY (Sequenom, San Diego, CA, USA) 
was used for quantitative DNA methylation analysis of the CpG island within the 
HOXB7 gene body using conditions described. [97] Long cycling incubation was 
applied to further optimize the conversion reaction. [99] Primers were designed using 
the Sequenom EpiDesigner BETA software (www.epidesigner.com), taking into 
account amplicon coverage, number of CpGs, fragment size and number of 
nucleotide repeats in the primer sequence. The primers were: 5’-
aggaagagagGTGTTGGGATTATAGGTTTGAGTTT-3’ and 5’-
cagtaatacgactcactatagggagaaggctACTAAACTTCTCTTCCTCTCCCTTTC-3’. This 
395 bp long amplicon covers 26 CpGs but the EpiTYPER analysis only detected 10 
separate analytical units that comprise single, duplicate or triplicate CpGs as shown 
in Figure 3A. The Illumina probe cg07547765 is similar as CpG6. The 2 other 
Illumina probes cg11041817 and cg22622477 are located within the studied CpG 
Sequenom amplicon but were not detected by the EpiTYPER. PCR steps were 
performed in triplicate for each DNA sample and a standard deviation between 
replicates was mostly <10%. When triplicate measurements had a SD >10% or when 
only one of the triplicates was available, data for that sample were excluded. The 
mean of 3 values was used for further analyses. The EpiTYPER analysis method 
reports CpG methylation values as percentage. Statistical analyses to quantify DNA 
methylation differences were performed using the Prism 6 software (GraphPad 
Software Inc., San Diego, CA, USA). A two-tailed T-test was used to assess 
differences in mean DNA methylation levels between cohorts for the overall HOXB7 
amplicon considered as methylation average and for each CpG unit within this 
amplicon separately.  
 
MTHRF 677C>T genotyping 
Leukocyte DNA from MMC patients, related healthy siblings and unrelated healthy 
controls was screened for the presence of the MTHFR 677C>T variant by PCR and 
restriction digestion as described [100].  
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Functional in silico analysis of HOXB7 methylation versus expression  
A correlation between HOXB7 CpG promoter methylation and gene expression was 
studied by data mining using the open source database MENT (Methylation and 
Expression database of Normal and Tumor tissues) [101]. The database only 
included Illumina 27K BeadChip CpG probes (cg09357097 and cg06493080 as 
shown in Figure 4A) that are located in the HOXB7 promoter and not in the gene 
body.  
 
Hoxb7a overexpression and depletion in zebrafish 
Wild-type AB zebrafish strains were maintained according to standard protocols 
[102]. Embryos were produced by natural mating and collected and fixed at different 
stages based on standard morphological criteria [103]. To produce Hoxb7a mRNA, 
the full coding Hoxb7a transcript (NM_001115091.2) was PCR amplified and cloned 
in the pGEM T Easy vector (Promega, Madison, WI, USA). Forward and reverse 
primers were 5’-ATGAGTTCATTGTATTATGCGA-3’ and 5’-
GTAGTTTATACATCTATATTAA-3’. Next, capped and polyadenylated Hoxb7a 
mRNAs were synthesized using mMESSAGE mMACHINE® High Yield Capped 
RNA Transcription Kit and Poly(A) Tailing Kit (both from Ambion, Austin, TX, USA) 
according to the manufacturer’s protocol. The synthesized mRNA was diluted in 
phenol red to different concentrations as indicated in the figure legends. Morpholino 
(MO) injection was performed with a splice Hoxb7a-MO (5’-
AGCACCTGTGAAAAGCGCAGAATGA-3’). This MO was designed against Chr17: 
46,685,144-46,685,550. Off-target effects were assessed by injecting with a 
standard control MO against beta-globin (5'-CCT CTT ACC TCA GTT ACA ATT TAT 
A 3'). MOs were designed by Gene Tools, LLC (Philomath, OR, USA). All injected 
embryos were life-screened at 24, 48 and 72 hours post-fertilization (hpf) using a 
Zeiss Lumar V12 (Carl Zeiss Microscopy, Thornwood, NY, USA) and images were 
captured with a Leica DFC310 FX digital color camera (Leica Microsystems, Wetzlar, 
Germany). Overexpression and depletion experiments were performed in duplicate. 
Ethical approval was obtained for these studies.  
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Pax2a whole mount in situ hybridization 
Whole mount In Situ Hybridization (WISH) with a probe for the paired box gene 2a 
(pax2a) was performed 24h after injection of MOs or Hoxb7a mRNA. Pax2a cDNA 
obtained from Dr. W. Driever (University of Freiburg, Germany) was cloned in the 
pGEM-3zf+ for the synthesis of a digoxygenin (DIG) labeled antisense RNA probe as 
described [104]. The Pax2a probe was subsequently used to analyze the influence 
of Hoxb7a overexpression and inhibition on spinal cord and notochord formation 
using standard morphological criteria [103]. WISH experiments were performed in 
duplicate. Embryos were screened using a Zeiss Lumar V12 (Carl Zeiss Microscopy, 
Thornwood, NY, USA) and images were captured with a Leica DFC310 FX digital 
color camera (Leica Microsystems, Wetzlar, Germany). 
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Figure 3. HOXB7 methylation studies by Sequenom EpiTYPER in MMC patients. A: Localization of the 
studied amplicon (Chr17:46,685,144-46,685,550) within HOXB7 Exon 2. The amplicon covers 26 single CpGs 
and our assay provides data 10 analytical CpG units. Nucleotide positions accord to the NCBI build 37/hg19. 
The CpG units studied by the HM450k (cg11041817, cg22622477 and cg07547765) and the in silico analysis 
(cg06493080, cg09357097) are also indicated. B: Boxplot representing the methylation pattern of MMC patients 
and controls with box = 25th and 75th percentiles; bars = min and max values. The mean methylation level of 
each group is shown below the plot. C: Methylation pattern for each CpG unit within the amplicon. Wilcoxon 
Rank-Sum test was performed. D. Boxplot representing the methylation pattern of MMC patients and controls 
divided according to MTHFR 677C>T genotype with box = 25th and 75th percentiles; bars = min and max 
values. The mean methylation level of each group is shown below the plot. 
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3.4 Results 
DNA methylation analysis of the different HOX genes in MMC case-control 
study 
Methylation values for all CpGs located within the 4 HOX clusters were extracted 
from data obtained from a 450K array-based genome-wide methylation analysis, 
using leukocyte DNA from 10 MMC cases and 6 unrelated age- and gender-matched 
healthy controls. Detailed clinical characteristics of these MMC patients are reported 
in Table 1. Pie charts were made to show the equal distribution of the filtered CpG 
probes (n=967) based on i) location within the 4 different HOX clusters, ii) location 
with respect to gene transcripts and iii) location with respect to the CpG Island 
(Figure 2). From the 967 filtered CpGs profiled on the HM450k (Table 2), only 26 
CpGs were found to be differentially methylated between MMC patients and controls 
(Table 3). Interestingly, 25 of these 26 CpGs were hypomethylated for the MMC 
patients and 20 of the 26 CpGs were located within the HOXA or HOXB clusters. 
Only for the HOXB7 gene, 3 different CpG probes (cg11041817, cg22622477 and 
cg07547765) were significantly hypomethylated in MMC patients (β-differences of -
0.29; -0.16 and -0.26, respectively with all p-values of 0.007). These 3 probes are 
located within a single CpG island at chr17:46,685,244-46,685,449 within the 
HOXB7 gene body (Figure 3A).  
 
HOXB7 methylation analysis in MMC case-control study 
A validation study using larger cohorts (83 MMC patients described in Table 1) was 
performed with the Sequenom EpiTYPER technology to quantify methylation of the 
above selected CpG island located in the HOXB7 gene body. A Sequenom amplicon 
was developed that covers 26 CpGs  (Figure 3A) including the 3 significant CpGs 
detected in the 450K array. Within this amplicon, the EpiTYPER detected 10 
analytical CpG units for which CpG6 is similar to cg07547765. DNA methylation 
values for the amplicon for 83 MMC patients and 30 unrelated healthy controls were 
normally distributed (Shapiro-Wilk test, P>0.05). A significant HOXB7 
hypomethylation (p-value < 0,0001) was detected for MMC patients versus controls 
with mean methylation values of 41% (95% CI: 38-45%) versus 56% (95% CI: 50-
61%), respectively (Figure 3B). The mean level of methylation for each CpG unit 
within the amplicon was also significantly different between MMC patients and 
controls (Figure 3C). To exclude an effect of changes in methylation due to 
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differences in ethnicity, the HOXB7 methylation pattern between 70 Belgian MMC 
patients was compared to 10 Non-Caucasian MMC patients without significant 
differences.  
 
Table 3: Methylation of the HOX genes using the HumanMethylation 450K BeadChip and analysis. 
Cluster Gene Chr Illumina ID P-value β-diff Ctrls (n=6) MMC (n=10) 
    < 0.05 > 0.05 Mean SD Mean SD 
A: Chr.7p14 HOXA2 7 cg06055873 0.016 -0.06 0.32 0.03 0.26 0.04 
 HOXA2 7 cg19432993 0.031 -0.12 0.69 0.05 0.57 0.12 
 HOXA2 7 cg06166490 0.016 -0.12 0.70 0.06 0.58 0.11 
 HOXA2 7 cg04027736 0.022 -0.11 0.61 0.06 0.50 0.11 
 HOXA2 7 cg00445443 0.042 -0.10 0.41 0.08 0.31 0.11 
  7 cg15037137 0.007 -0.05 0.85 0.02 0.80 0.07 
 HOXA4 7 cg25952581 0.042 -0.09 0.45 0.06 0.37 0.11 
 HOXA4 7 cg17591595 0.042 -0.08 0.73 0.05 0.65 0.09 
 HOXA11 7 cg24709033 0.011 -0.06 0.27 0.03 0.21 0.04 
B: Chr.17q21 HOXB5 17 cg01405107 0.042 0.09 0.49 0.05 0.58 0.08 
 HOXB6 17 cg09983216 0.016 -0.13 0.55 0.08 0.42 0.10 
 HOXB7 17 cg11041817 0.007 -0.29 0.70 0.08 0.41 0.20 
 HOXB7 17 cg22622477 0.007 -0.16 0.36 0.06 0.20 0.09 
 HOXB7 17 cg07547765 0.007 -0.26 0.71 0.10 0.44 0.18 
  17 cg19051015 0.022 -0.09 0.72 0.05 0.63 0.07 
 HOXB9 17 cg15117739 0.007 -0.10 0.68 0.04 0.57 0.07 
 HOXB9 17 cg12057127 0.042 -0.06 0.72 0.01 0.67 0.07 
  17 cg20454400 0.031 -0.06 0.37 0.04 0.31 0.05 
  17 cg16654603 0.011 -0.09 0.67 0.02 0.58 0.08 
  17 cg02052915 0.016 -0.05 0.36 0.03 0.31 0.04 
C: Chr.12q13  12 cg08299265 0.016 -0.06 0.39 0.04 0.33 0.03 
  12 cg26643142 0.031 -0.06 0.35 0.03 0.30 0.05 
 HOXC4 12 cg18473521 0.011 -0.12 0.43 0.08 0.31 0.07 
D: Chr.2q31 HOXD9 2 cg04730882 0.005 -0.07 0.35 0.03 0.28 0.05 
  2 cg07783843 0.011 -0.06 0.24 0.02 0.18 0.04 
  2 cg05525812 0.007 -0.07 0.25 0.02 0.18 0.05 
Nucleotide positions accord to NCBI build 37/hg19. Selection is performed along both β-value > 0.05 difference 
and p-value < 0.05; calculated with Wilcoxon Rank-Sum test. The 3 probes in bold are located within the same 
CpG island at Chr17:46,685,244-46,685,449 within the HOXB7 gene body. This region was selected for the 
validation study using Sequenom EpiTYPER. β-diff: β-difference; Chr: chromosome; Ctrls: controls; MMC: 
myelomeningocele.    
 
 
As findings of global DNA hypomethylation and LINE-1 hypomethylation suggest that 
disruption of genomic stability may disrupt neural tube closure and the MTHFR 
677C>T variant is associated with global DNA hypomethylation, we determined the 
MTHFR 677C>T variant for MMC patients and healthy controls (Table 1). 
Interestingly, an intrinsic defect in the folic acid pathway related to MTHFR activity 
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seems not to be involved as no association was found between MTHFR 677 CC 
versus CT+TT carriers and HOXB7 methylation (Figure 3D). 
 
HOXB7 methylation analysis in unaffected siblings of MMC patients 
For 12 out of 83 MMC patients, DNA was also collected from their healthy siblings 
(Table 1). Remarkably, the mean methylation level of the HOXB7 amplicon was not 
different between MMC patients and their unaffected siblings with values of 37% 
(95% CI: 33-40%) versus 40% (95% CI: 37-42%) (Figure 4A). Multiple T-testing for 
each CpG within the HOXB7 amplicon also showed no significant differences 
between patients and healthy siblings (Figure 4B).  
 
 
Figure 4. HOXB7 methylation studies by Sequenom EpiTYPER in pairs of unaffected siblings versus 
MMC patients. A: Boxplot representing the methylation pattern of affected siblings and unaffected siblings with 
box = 25th and 75th percentiles; bars = min and max values. The mean methylation level of each group is shown 
below the plot. B: Methylation pattern for each CpG unit within the amplicon. Wilcoxon Rank-Sum test was 
performed.  
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HOXB7 methylation versus expression 
Since leukocyte RNA was not collected for our cohorts, we used the MENT database 
to estimate a correlation between HOXB7 methylation and gene expression. The 2 
CpGs (cg09357097 and cg06493080) located in the HOXB7 promoter (Figure 3A) 
showed no correlation with gene expression in normal brain and blood tissues. 
However, there is evidence that lower HOXB7 methylation values in brain tightly 
regulate higher and stable gene expession levels compared to the higher 
methylation levels in blood that are associated with a variable gene expression 
(Figure 5). Interestingly, cg06493080 showed a strong negative correlation with gene 
expression in different cancer tissues, especially for brain (correlation -0.15, P-value 
0.008).  
 
 
Figure 5. HOXB7 cg06493080 methylation versus expression in normal tissue extracted from brain and 
blood. HOXB7 methylation versus expression in A: brain and B: blood. A low degree of methylation and high 
expression is observed for brain tissue. In blood HOXB7 has a higher methylation compared to brain tissue and 
the expression pattern is highly variable for similar methylation levels. Data are extracted from the MENT 
database (Methylation and Expression database of Normal and Tumor tissues 
(http://mgrc.kribb.re.kr:8080/MENT/). Cg06493080 is located in the promotor region of HOXB7 on position 
Chr17:46688310. Datasets GSE15745 (brain) and GSE26212 (blood) contain respectively 492 and 96 samples.  
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Hoxb7a overexpression and depletion in zebrafish   
Functional genetics was performed in zebrafish to study alterations in Hoxb7a 
expression during embryogenesis and neural tube formation. The regulation of the 
HOX clusters is highly conserved between humans and zebrafish (Figure 1). Hoxb7a 
has an anterior expression limit adjacent to the somite 3-4 boundary at the 20 somite 
stage [105]. We analyzed embryos with Hoxb7a depletion and overexpression using 
microinjection of a splice morpholino (MO) and synthetic Hoxb7a mRNA, 
respectively. MO-induced Hoxb7a depletion resulted in hypopigmentation and 
developmental delay with dysmorphy in 83-94 % of the embryos at 24 hours post 
fertilization (hpf) (Figure 6). However, pax2a staining to visualize neural tube 
formation at 24 hpf was not different between Hoxb7a- or control-MO injected 
embryos, even for the severely affected Hoxb7a depleted embryos (Figure 6). 
Embryos injected with different concentrations of Hoxb7a mRNA also present with 
severe to mild malformations in about 48-71 % of the embryos at 24 hpf (Figure 7B). 
These embryos had shorter anterior/posterior axes as well as crooked or bent tails 
(Figure 7A). Interestingly, pax2a staining after overexpression of Hoxb7a for different 
concentrations showed a neural tube was that was absent or completely 
disorganized (Figure 7C).  
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Figure 6. Phenotype analysis of Hoxb7a depletion in zebrafish embryos. A: Phenotype analysis at 72hpf of 
600 µM Hoxb7a MO injected zebrafish resulted in a developmental delay with hypopigmentation, shortening and 
bending of the tail. B: Phenotype analysis after pax2a staining at 24 hpf resulted in about 88% embryos with a 
developmental delay. C1-2: Pax2a WISH at 24hpf in control AB zebrafish; D1-2: Pax2a staining in 24hpf 
zebrafish after microinjection of 600 µM Hoxb7a MO is normal; E1-2: Pax2a staining in 24hpf zebrafish after 
microinjection of 400 µM Hoxb7a MO is normal.   
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Figure 7. Phenotype analysis of Hoxb7a-overexpression in zebrafish embryos. A: Phenotype analysis at 72 
hpf of Hoxb7a mRNA injected zebrafish resulted in significant hypopigmentation and malformation in 66% of the 
injected zebrafish. These embryos had shorter anterior/posterior axes as well as crooked or bent tails. B: 
Phenotype analysis after pax2a at 24 hpf resulted in about 63% embryos with a mild or severe affected 
phenotype after Hoxb7a overexpression compared to 13% in injected controls. C: Pax2a staining after 
microinjection of different concentrations of mRNA. From left to right severe, mild affected and wild type (WT) 
embryos at 24 hpf. WT zebrafish show expression in the hindbrain, hindbrain-midbrain boundary, neural tube, 
mesoderm, optic stalk, otic vesicle and pronephric duct. Microinjection 62.5 µM mRNA, 125 µM mRNA and 250 
µM mRNA resulted in respectively 48%, 71% and 61% malformed zebrafish. There was no correlation between 
mRNA dosage and severity of malformation. 
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3.5 Discussion 
As HOX genes play key roles in neural tube closure and many studies have 
shown that folic acid prevents NTDs by stimulating cellular methylation reactions, we 
extracted methylation data for the different HOX genes from a genome-wide DNA 
methylation analysis performed for 10 MMC patients and 6 unrelated healthy 
controls. Interestingly, 25 of the 26 CpGs were hypomethylated for the MMC patients 
with the HOXB7 gene body as most significant locus. Interestingly, HOXB7 
hypomethylation was not only confirmed in a larger MMC cohort but was also 
detected in 12 healthy siblings each related to a MMC patient. These results are 
suggestive for a maternal effect that contributes to HOXB7 hypomethylation. 
Additional healthy siblings must be recruited but gender, age, MTHFR 677C>T 
genotype or MMC being the firstborn or not, seem no predictive risk factors for NTDs 
based on data for these sibling pairs (Table 1). HOXB7 hypomethylation by itself is 
likely not to be causative for NTDs but rather be part of a complex combination of 
environmental and (epi)genetic risk factors. We found no association between 
MTHFR CC versus CT+TT carriers and HOXB7 methylation suggesting that an 
intrinsic defect in the folic acid pathway related to MTHFR activity is not involved. 
Though we had no measurements of maternal folic acid levels or uptake, it is known 
that folic acid levels in most affected pregnancies are within the normal range [86] 
and despite optimal supplementation a significant proportion of NTDs are 
unresponsive to folic acid [31,87]. We therefore hypothesize that these mothers have 
folic acid resistance leading to a disturbed methylation cycle with alterations in DNA 
methylation and an increased risk for abnormal embryonic development. Additional 
studies must be undertaken to study the association between maternal folic acid 
intake and HOXB7 methylation in DNA from the mother and her offspring.  
 
HOX genes encode for evolutionary highly conserved transcription factors 
expressed in the central nervous system (Figure 1). They are tightly regulated in a 
spatiotemporal and collinear manner [92-94], patterning the embryo along the rostro-
caudal axis. The HOXA and HOXB clusters have a closer phylogenetic relationship 
and hence share more functionality than with either the HOXC or HOXD cluster 
[106]. Their cooperative functioning is necessary for the generation of the cranial 
neural crest and craniofacial diversity [107-109]. The spinal cord is a caudal 
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structure, but the neural cells from which it derives initially express rostral, forebrain-
like characteristics. The caudal character emerges soon after neural induction, 
through different extrinsic signals [110,111]. According to our study, differential HOX 
gene methylation in MMC patients occurs in both anterior and posterior HOX genes. 
Moreover, failure in establishing correct HOX gene methylation in the HOXA and 
HOXB clusters may result in disturbances in neural cell identity that ultimately leads 
to neural malformations. HOX gene clusters are evolutionary highly conserved 
between human and zebrafish and a neural tube formation zebrafish model was 
previously used to study VANGL1 [43]. HOX7 has two paralog members in humans 
and only one in zebrafish (Figure S1) but the zebrafish Hoxb7a gene shares 60% 
homology with the human HOXB7 sequence. As HOXB7 hypomethylation is 
suggestive for HOXB7 overexpression, Hoxb7a overexpression experiments were 
performed in zebrafish. Overexpression of Hoxb7a in zebrafish resulted in 
developmental abnormalities and pax2a staining showed abnormal neural tube 
formation in about 60% of the embryos. 
 
In the present study, we were of course not able to use patients DNA samples 
from brain or spinal cord tissue. Concordant DNA methylation profiles in brain and 
blood samples from the same individuals suggest that blood might hold promise as 
surrogate for brain tissue to detect DNA methylation [112-114]. Genome-wide 
methylation arrays revealed similar methylation patterns for the HOX genes in breast 
cancers and white blood cells, which suggests that methylation is more likely to be a 
normal developmental and tissue-specific process that does not directly relate to the 
malignant mechanism [115]. Interestingly, functional in silico analysis using the 
MENT database showed no correlation with gene expression in normal brain and 
blood tissues for the methylation of two HOXB7 promoter CpGs but there is evidence 
that lower HOXB7 methylation values in brain tighly regulate higher and stable gene 
expession levels compared to the higher methylation levels in blood that are 
associated with a variable HOXB7 gene expression. These data would suggest that 
HOXB7 hypomethylation is associated with higher gene expression. A limitation of 
our study was the lack of HOXB7 gene expression studies using leukocyte RNA from 
MMC cases and unrelated healthy controls but RNA samples were not collected. 
Additional studies are needed to correlate the methylation levels of the HOXB7 gene 
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body CpGs with HOXB7 gene or protein expression values. Furthermore, it would be 
interesting to compare our findings in leukocytes with neural tissue.  
 
3.6 Conclusion 
 This is the first study that uses genome-wide DNA methylation data for the 
locus-specific analysis of the different HOX genes in patients with NTDs. We found 
evidence that HOXB7 hypomethylation is a potential risk factor for MMC but also that 
the underlying methylation defect is present in both affected and non-affected 
offspring. This could confirm the hypothesis that children born from mothers with folic 
acid resistance and a disturbed methylation cycle, can present with alterations in 
DNA methylation with high risk for abnormal embryonic development. Investigating 
the complex etiology of NTDs requires consideration of more DNA methylation 
studies; therefore genome-wide DNA methylation analysis without focusing on 
candidate pathways could reveal more epigenomic changes associated with NTDs. 
The challenge ahead is to determine which DNA regions are more sensitive to 
methylation changes during embryogenesis and lead to NTDs.  
	 
 
 
 
 
CHAPTER 4 
 
 
Genome-wide DNA methylation  
in patients with Spina Bifida 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Review 
Anne Rochtus, Raf Winand, Griet Laenen, Elise Vangeel, Benedetta Izzi, Christine 
Wittevrongel, Yves Moreau, Carla Verpoorten, Katrien Jansen, Chris Van Geet, 
Kathleen Freson. Methylome analysis for spina bifida shows SOX18 
hypomethylation as risk factor with evidence for a complex (epi)genetic interplay to 
affect neural tube development. 
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4.1 Abstract 
Background: Neural tube defects (NTDs) are severe congenital malformations 
that arise from failure of neurulation during early embryonic development. The 
molecular basis underlying most human NTDs remains still largely unknown. Based 
on the hypothesis that folic acid prevents NTDs by stimulating methylation reactions, 
DNA methylation changes could play a role in NTDs. Indeed, we performed a 
methylome analysis for patients with myelomeningocele (MMC) and using a 
candidate CpG analysis for HOX genes, a significant association between HOXB7 
hypomethylation and MMC was found.  
Methods: In the current study, we analysed leukocyte methylome data of 10 
patients with MMC and 6 controls using IMA and WateRmelon R-packages and 
performed validation studies using larger MMC and control cohorts with Sequenom 
EpiTYPER.  
Results: The methylome analysis showed 75 CpGs in 45 genes that are 
significantly differentially methylated in MMC patients. CpG-specific methylation 
differences could be replicated for the top 6 candidate genes ABAT, CNTNAP1, 
SLC1A6, SNED1, SOX18 and TEPP, though SOX18 was the only locus with an 
overall methylation difference (p-value = 0.0003). Chemically-induced DNA 
demethylation in HEK cells resulted in SOX18 hypomethylation and increased 
expression. Injection of sox18 mRNA in zebrafish resulted in NTDs that could not be 
rescued by addition of folic acid. Quantification of DNA methylation for the SOX18 
locus was also determined for 5 families where parents had normal methylation 
values compared to significant lower values for both the MMC as their non-affected 
child. Interestingly, SOX18 methylation studies for a boy with MMC and a paternally 
inherited chromosomal deletion that includes BMP4 showed extremely low 
methylation values that are also present in his healthy mother while his father had 
normal values.  
Conclusion: This is the first genome-wide methylation study in leukocytes for 
patients with NTDs. We report SOX18 as a novel MMC risk gene but our findings 
also suggest that SOX18 hypomethylation must interplay with environmental and 
(epi)genetic factors to cause NTDs. Further studies are needed that combine 
methylome data with next generation sequencing approaches to support such 
additive effect of (epi)genetics as cause for spina bifida. 
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4.2 Introduction 
Neural tube defects (NTDs) are severe congenital malformations with a 
frequency of 1-2 per 1000 pregnancies [28]. Despite its high prevalence and severe 
consequences, the underlying molecular basis of most human NTDs remains largely 
unknown. Folic acid supplementation is known to reduce the incidence of NTDs, 
though its mode of action for NTD prevention is poorly understood. The only well-
characterized genetic risk factor for human NTDs is the 677C>T change in the 5,10-
methylene tetrahydrofolate reductase (MTHFR) gene. This variant is known to lead 
to hyperhomocysteinemia and global DNA hypomethylation [31,55,56]. This 
association led to the hypothesis that folic acid prevents NTDs by stimulating DNA 
methylation. Therefore, changes in DNA methylation are predicted to be involved in 
NTDs [31,40]. Different research groups have quantified global (e.g. via LINE-1 
elements) or locus-specific (e.g. imprinted genes, transposable elements, DNA 
repair enzymes) DNA methylation for patients with NTDs using DNA from diverse 
types of tissues [40]. Methylation studies of imprinted genes showed significant 
hypermethylation of the IGF2 and H19 differentially methylated regions (DMRs) 
using brain tissue of NTD patients [72,73]. Some methylation studies focused on 
DNA methylation of DNA repair genes but only for MGMT a slightly lower DNA 
methylation in brain was found for NTD patients [79]. Investigation of DNA 
methylation of the candidate genes folate receptor α (FOLR1), proton-coupled folate 
transporter (PCFT) and reduced folate carrier 1 (RFC1) genes did not show 
significantly differences between patients and controls.though some minor 
differences were observed according to RFC1 80G>A genotype [80]. This suggests 
a gene-nutrition interaction between folate intake and the RFC1 genotype in NTD-
affected births. The most robust finding of all DNA methylation studies for NTDs was 
found for LINE-1 and global DNA methylation. Lower levels of LINE-1 and global 
DNA methylation were found for NTD patients and the hypomethylation was more 
pronounced for cranial compared to caudal NTDs [75]. We previously performed a 
genome-wide DNA methylation study using the HumanMethylation 450K BeadChip 
(HM450k) and leukocyte DNA from 10 patients with myelomeningocele (MMC) and 6 
unrelated healthy controls. DNA methylation profiles for the Homeobox (HOX) genes 
were subtracted from the overall methylome data as these genes are known to play 
a central role in neural tube development and are tightly regulated by epigenetic 
modifications [116]. We found evidence that HOXB7 hypomethylation is a potential 
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risk factor for MMC. Interestingly, a study by Kok et al. found that DNA methylation of 
HOXB7 in particular but also the majority of the other HOX genes tend to be 
increased after folic acid and vitamin B12 supplementation [117]. A recent meta-
analysis investigated the impact of maternal plasma folate during pregnancy on DNA 
methylation in cord blood [118]. They found that multiple developmental processes 
are influenced by maternal folate, including neural tube development.  
 
For this study, we analysed the data of the genome-wide DNA methylation 
study without focusing on candidate genes or pathways to discover novel 
methylation changes associated with MMC. The analysis was performed using 
Illumina Methylation Analyzer (IMA) [96] and WateRmelon [119] R-packages. 
Findings were confirmed using a locus-specific validation study with the Sequenom 
EpiTYPER and in larger MMC and control cohorts. The most significant overall 
hypomethylation was found for the SOX18 locus in MMC patients. Furthermore, 
SOX18 expression studies were performed in chemically-induced hypomethylated 
DNA from HEK cells and neural tube development was studied in sox18 mRNA 
injected zebrafish embryos. Additionally, we quantified SOX18 methylation in 5 
families that include parents, the MMC patient and its non-affected sibling and in 1 
family with a MMC patient that has a paternally inherited BMP4 deletion.  
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4.3 Materials and methods 
Ethics statement 
Written informed consent to collect blood samples for (epi)genetic studies was 
obtained from all participants and/or their legal representatives. This study was 
approved by the Medical Ethics Committee of the University of Leuven (study 
ML9193).  
 
Description of MMC patients, related healthy siblings and unrelated healthy 
controls 
A total of 85 MMC patients, 12 healthy related siblings and 30 age- and gender 
matched non-related healthy control subjects enrolled in this study. The MMC 
patients are followed at the pediatric neurology department of the University Hospital 
Leuven (all <18 years). Detailed clinical and general characteristics for all these 
subjects are previously reported in Table 1 of Chapter 3 [116].  As sensory and 
motor functions at and below the level of the spinal cord defect are impaired; 
paralysis, bowel and bladder dysfunction is present in most of the patients. Folic acid 
supplementation was recommended, but red blood cell folate was not measured 
during pregnancy. For the family study we included the parents of 5 sibling pairs 
(pairs 5,27,29,41,60 from Table 1 in Chapter 3 [116]). 
 
Description of case of Caucasian boy with BMP4 deletion 
The male patient was born at full term to a G2P1 Caucasian mother by a lower 
segment caesarean section after an uncomplicated pregnancy with normal prenatal 
ultrasounds. At birth, he presented an open lumbosacral myelomeningocoele and 
bilateral talipes equinovarus. The anterior fontanelle was full and bulging. Bilateral 
lower limb weakness was evident, and initially he did not have neurogenic bladder or 
bowel dysfunction. Cranial ultrasound revealed hydrocephaly and Arnold-Chiari II 
malformation. External ventriculoperitoneal drainage and surgical repair of the spinal 
defect were performed at the day of birth. Renal ultrasound showed a multicystic 
dysplastic kidney on the right side.  
Comparative genomic hybridization using an 180k oligo array platform (180K 
Cytosure ISCA v2, OGT, Oxford, UK) showed a 1.665 kb deletion on chromosome 
14q22.1q22.2 (14:53,267 987-54,933 219; NCBI/hg19, February 2009) and a 
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microdeletion on chromosome 2p11.2 (2:83,380 184-83,915 440; NCBI/hg19, 
February 2009). The deleted region on chromosome 14 spans the genes FERMT2, 
DDHD1, BMP4, DKN3 and CNIH (Figure 1), the microdeletion on chromosome 2 
does not cover any known gene. The father of the patient has postaxial polydactyly, 
severe myopia and pro-optosis. He carries both deletions. The mother of the patient 
has a 45X/46XX mosaicism. She consumed periconceptional synthetic folic acid 
supplementation. The DECIPHER ID of the patient is 288171 
(hhtps://decipher.sanger.ac.uk). 
 
 
Figure 1. Genetic deletion on Chr 14q22 of Caucasian boy with lumbosacral myelomeningocele. Bar indicates 
1.665 kb deletion on chromosome 14q22.1q22.2 (53,267,987-54,933,219) encompassing the genes FERMT2, 
DDHD1, BMP4, DKN3 and CNIH. Nucleotide positions accord to NCBI build 37/hg19. 
 
MTHRF 677C>T genotyping 
Leukocyte DNA from MMC patients, related healthy siblings and unrelated healthy 
controls was screened for the presence of the MTHFR 677C>T variant by PCR and 
restriction digestion as described [100]. The MTHFR genotype of the 85 MMC 
patients and 12 unaffected siblings is previously reported in [116]. Genotyping for the 
10 parents of the family study revealed six parents (3M/3F) with a CT genotype and 
four parents (2M/2F) with a CC genotype.  
 
Genome-wide DNA methylation analysis using the HM450K  
Leukocyte DNA (1 µg) was subjected to bisulfite treatment using the EZ DNA 
methylation kit (Zymo Research, Irvine CA, USA). Subsequently, genome-wide DNA 
methylation was assessed using Illumina Infinium HumanMethylation 450K 
BeadChip (Illumina, Inc., California, USA). The HM450k experiment and data 
preprocessing were performed as described previously [116]. The analysis was 
conducted using both the Illumina Methylation Analyzer (IMA) package implicated in 
the open source statistical environment R [96] and the WateRmelon R-package 
[119]. The following three filters were applied on the data for the two pipelines to 
identify the most significant differentially methylated regions between MMC patients 
Scale
chr14:
RefSeq Genes
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53,500,000 54,000,000 54,500,000 55,000,000
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and controls: i) absolute β-value difference > 0.10; ii) P-value < 0.01 and iii) 
presence of multiple CpGs per locus. The data discussed in this publication have 
been deposited in NCBI's Gene Expression Omnibus [120] and are accessible 
through GEO Series accession number GSE81846.  
 
Functional enrichment analysis 
Based on the results from the genome-wide DNA methylation analysis a list of CpGs 
corresponding to differentially methylated CpG sites was generated and tested for 
enrichment of known gene ontology pathways. This is performed by means of a 
hypergeometric test and an FDR-based multiple testing correction of the obtained P-
values. The cut-off threshold was set at P<0.001. The enrichment analysis was 
visualized using the open-source plugin Enrichment Map [121] in Cytoscape 3.2.1.  
 
Methylation of CpGs for 6 genes using the Sequenom EpiTYPER 
Leukocyte DNA (1 µg) was subjected to bisulfite treatment using the 
MethylDetectorTM bisulfite modification kit (Active Motif, Carlsbad CA, USA). 
Subsequently, DNA methylation analysis of the top 6 differentially methylated genes 
was analyzed by Sequenom EpiTYPER (Sequenom, San Diego, CA, USA) as we 
described in previous research [97,98,116]. The primers are described in Table 1. 
Statistical analyses to quantify DNA methylation differences were performed using 
the Prism 6 software (GraphPad Software Inc., San Diego, CA, USA). Not all DNA 
methylation values are normally distributed (D’Agostino and Pearson normality test). 
A two-tailed t-test with Welch’s correction was used to assess differences in mean 
DNA methylation levels between cohorts for the amplicons considered as 
methylation average and for each CpG unit within this amplicon separately.  
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Table 1: Primers for the validation studies with Sequenom EpiTYPER. 
Gene Primers Size No of 
CpGs 
Cove- 
rage 
Amplicon 
ABAT_L aggaagagagTTTAGAATGGAGGTTGTAGGAGAG
A 
304 12 12 Chr16: 8806432 - 
8806735 
ABAT_R cagtaatacgactcactatagggagaaggctCTTCCAAATT
CCCAATCTATAACAT 
    
CNTNAP1_L aggaagagagAAAATTTTATTTGGTATTTGGGAAA 384 29 29 Chr17: 40838821-
40839204 
CNTNAP1_R cagtaatacgactcactatagggagaaggctCCCTCCCAAC
TTAAACATCTAACTA 
    
SLC1A6_L aggaagagagATGGGAGTATTTTATTTGTGGGAA
T 
435 13 13 Chr19: 15121145-
15121580 
SLC1A6_R cagtaatacgactcactatagggagaaggctAAAAACACAC
AACTCTTTCCTAACCTA 
    
SNED1_L aggaagagagTGAAGTTTATTTTTAGAAGAGTAA
GGTAA 
470 30 29 Chr2: 241989125-
241989592 
SNED1_R cagtaatacgactcactatagggagaaggctTCCAAACAAA
ATATCAAAATAACCC 
    
SOX18_L aggaagagagTGTTTTGTTTAGAGGAGAGTAGTT
TGA 
284 29 19 Chr20: 62679321-
62679605 
SOX18_R cagtaatacgactcactatagggagaaggctACAAATAACC
CAAAAACCCAAAA 
    
TEPP_L aggaagagagTTTTAGTTAAATTTGGTGGGATGT
G 
460 27 25 Chr16: 58019630-
58020090 
TEPP_R cagtaatacgactcactatagggagaaggctAAACACCTTA
CCCTCCCTAACAAC 
    
Primers used for the validation studies with Sequenom EpiTYPER. Nucleotide positions accord to NCBI build 
37/hg19. Chr: chromosome; No of CpGs: number of CpG sites in the amplicon; coverage: number of CpG sites that 
are analysed with Sequenom EpiTYPER. 
 
 
Gene overexpression in zebrafish 
Wild-type AB zebrafish strains were maintained according to standard protocols 
[102]. Embryos were produced by natural mating and collected and fixed at different 
stages based on standard morphological criteria [103]. Zebrafish embryos were 
injected with abat, slc1a6 and sox18 mRNA. The production of mRNA was 
performed as previously reported [116]. Details of transcripts and primers are 
described in Table 2. Off-target effects were assessed by injecting with a standard 
control MO against beta-globin (5'-CCT CTT ACC TCA GTT ACA ATT TAT A 3'). All 
injected embryos were life-screened at 24 hours post-fertilization (hpf) using a Zeiss 
Lumar V12 (Carl Zeiss Microscopy, Thornwood, NY, USA) and images were 
captured with a Leica DFC310 FX digital color camera (Leica Microsystems, Wetzlar, 
Germany). Experiments were performed in triplicate. Ethical approval was obtained 
for these studies. 
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Table 2: Primers for the functional validation studies in zebrafish. 
Gene Primers Refseq Ensembl 
Abat  5'-CTG TCT GTG TCT CGG TGA GTG CTA CAC 
ATG-3' 
NM_201498.2 ENSDARG00000006031 
 5'-AGG CCA GAC ACT ACT CTA TTT ATG CTC-3'   
Sox18  5'-CGT GTT GGT CTT GCT GGA ATG AAT-3' XM_001337666.1 ENSDARG00000058598 
 5'-TTA TCC TGT AAT GCA GGC GCT GTA ATA 
GA-3' 
  
Nucleotide positions accord to NCBI build 37/hg19. 
 
Pax2a whole mount in situ hybridization 
Whole mount In Situ Hybridization (WISH) for the paired box gene 2a (pax2a) was 
performed with digoxigenin-labeled antisense riboprobes as previously described 
[104,116]. The influence of gene overexpression on spinal cord and notochord 
formation was studied using standard morphological criteria [103]. WISH 
experiments were performed in duplicate.  
 
Gene expression analysis in HEK293 cells  
The human embryonic kidney (HEK) cell line were cultured under standard 
conditions or pretreated with 5 µM 5-aza-2'-deoxycytidine (Sigma Aldrich, Belgium) 
for demethylation studies. All cells were maintained at 37°C in a humidified 
environment with 5% CO2.  
Leukocyte DNA (1 µg) was extracted and subjected to bisulfite treatment using the 
MethylDetectorTM bisulfite modification kit (Active Motif, Carlsbad CA, USA) as we 
described [97,98]. The primers from the validation study were used for amplification 
of the amplicons (Table 1). Subsequently, Sanger sequencing was performed and 
the methylation ratio were compared before and after 5-aza-2’-deoxycytidine 
treatment.  
Total RNA was extracted from cells using TRIzol (Invitrogen) reagent, according to 
the manufacturer’s protocol. cDNA was synthesized using reverse transcriptase 
(Invitrogen, Ghent, Belgium). Human gene expression was measured using Sybr 
Green PCR. qRT-PCR reactions were analysed using an ABI 7000 real-time PCR 
machine (Life Technologies). Expression was quantified via the ΔΔCt method [122] 
and expressed in arbitrary units. Primer sequences are listed in Table 3. 
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Table 3: Primers for the real-time quantitative PCR. 
Gene Refseq Sequence 
ABAT Hs.PT.58.21416182  5'- TTT CGG AAG CTG AGA GAC ATC -3'  
  5'- GCT GAA GGT CAT CAC GTC TG -3'  
SOX18 NM_018419 5'- GTGGCACTGGCCAAACT-3'  
  5'- GTGTTACCTCTCATTGTCTCCAG -3'  
SLC1A6 Hs.PT.58.50488526.g 5'- CCT TCT AGT GTT CCC AGT TTC TAC -3'  
  5'-CAT CTC ATC AGA TCT AAG TGT CTA GAG-
3' CNTNAP1 Hs.PT.58.25634554  5'- GTA CCA GCT AAC CAC TCG AC -3'  
  5'- GAG AAC TTC TGC TCT GTC AGT G -3'  
TEPP Hs.PT.58.19812321.g  5'- GTA CTT GAA GCC CGA CGT G -3'  
  5'- ACT GTA GCT GGA GCC GAA -3'  
SNED1 Hs.PT.58.26360591  5'- CTA CCG AGT TCA CCA AGA CAT -3'  
  5'- GTG GAG TGT AAC AAG AAC GTC T -3'  
Nucleotide positions accord to NCBI build 37/hg19. 
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4.4 Results 
DNA methylation of LINE elements and folic acid regulatory genes  
Findings of global DNA and LINE-1 hypomethylation in patients with NTDs [69,75] 
suggest that genomic instability might interfere with neural tube closure. We 
extracted the methylation values for all LINE-1 and LINE-2 probes from our HM450k 
study. About 20158 CpG probes correspond to 1498690 LINE-1 and LINE-2 
elements. The mean methylation of these LINE probes was not significantly different 
between MMC patients and controls (mean β-value was 77,6% versus 77,7%; 
respectively) though unsupervised hierarchical clustering analysis grouped almost all 
MMC patients separately from the controls (Figure 2).   
 
 We next extracted methylation values for 43 genes (including 698 CpG 
probes) involved in the folic acid and the one carbon metabolism [26]. There are no 
methylation differences for the folic acid genes between MMC patients and controls 
(Figure 3). According to unsupervised hierarchical clustering analysis, samples are 
clustered irrespective of the subgroup. 
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Methylome analysis for gene identification 
The HM450k data were analysed and the 6 highest ranked genes were ABAT, 
CNTNAP1, SLC1A6, SNED1, SOX18, and TEPP (Table 4). Ranking genes based 
on having a β-value > 0.10 and p-value < 0.01 resulted in a total of 45 genes that 
include 75 CpG sites (Table 5) with a significant differential methylation value in 
MMC patients. Among these 75 CpGs, 54 CpGs (72%) are associated with 
decreased methylation in MMC patients. To evaluate if certain biological functions 
would be enriched in this gene list, we performed a functional enrichment analysis, 
that showed an overrepresentation of gene ontology classes mainly related to 
cytoplasm, transcription, neuron projection, synaptic processes, cell projection and 
some minor others (Figure 4). Interestingly, the genes seem to act together through 
various pathways, as they are often involved in divergent gene ontology categories. 
The gene ontology enrichment analysis favours the hypothesis that NTDs are the 
result of a complex multifactorial combination.  
 
 
Table 4: Top 6 differentially methylated genes investigated by HM450k and selected for validation with 
Sequenom EpiTYPER. 
 
Gene Illumina ID WateRmelon IMA R-package Gene group 
  P-value β-diff P-value β-diff  
ABAT 
Chr16p13 
cg01881182 0,0017 -0,20 0,0047 -0,15 5' UTR 
cg16586594 0,0005 -0,18 0,0005 -0,19 5' UTR 
cg08834902 0,0047 -0,23 0,0047 -0,16 5' UTR 
SLC1A6 
Chr19p13 
cg12695707 0,0002 -0,27 0,0005 -0,16 TSS1500 
cg09470638 0,0010 -0,25 0,0048 -0,14 TSS200 
cg02489552 0,0002 -0,14 0,0002 -0,21 TSS200 
SOX18 
Chr20q13 
cg02231404 0,0010 -0,20 0,0010 -0,21 Body 
cg22138735 0,0005 -0,17 0,0005 -0,17 Body 
TEPP 
Chr16q21 
cg04370442 0,0047 -0,15 0,0075 -0,16 Body 
cg12499872 0,0005 -0,31 0,0005 -0,15 Body 
CNTNAP1 
Chr17q21 
cg16308533 0,0005 -0,17 0,0010 -0,19 Body 
cg11629889 0,0002 -0,14 0,0010 -0,16 Body 
SNED1 
Chr2q37 
cg23491743 0,0017 -0,16 0,0030 -0,17 Body 
cg25241559 0,0005 -0,15 0,0005 -0,17 Body 
Nucleotide positions accord to NCBI build 37/hg19. β-diff: β-difference; Chr: chromosome; MMC: 
myelomeningocele. These 6 genes were selected for the validation study using Sequenom EpiTYPER. 
 
 
 
 
	 91	
Table 5: Top 75 differentially methylated CpGs investigated by HM450k and top 45 genes selected for functional gene 
enrichment. 
 
    WateRmelon IMA R-package MMC (n=10) Controls (n=6) Gene 
group Gene Chr mapinfo Illumina ID P-value β-diff P-value β-diff Mean SD Mean SD 
CAPZB 1 19732786 cg16694480 0,0047 -0,24 0,0047 -0,16 0,51 0,08 0,67 0,05 Body 
HEYL 1 40098811 cg12634306 0,0030 -0,21 0,0075 -0,22 0,44 0,16 0,66 0,03 Body 
ROR1 1 64602654 cg07797372 0,0010 0,14 0,0010 0,12 0,61 0,05 0,49 0,05 Body 
MTMR11 1 149908313 cg13476072 0,0010 0,16 0,0005 0,10 0,81 0,03 0,70 0,06 Body 
PEAR1 1 156883745 cg13224583 0,0017 -0,26 0,0017 -0,20 0,51 0,16 0,72 0,03 Body 
ENAH 1 225838196 cg13305444 0,0010 -0,12 0,0017 -0,10 0,71 0,06 0,82 0,03 Body 
GALNT2 1 230415343 cg00589617 0,0047 -0,32 0,0030 -0,23 0,62 0,18 0,85 0,07 3'UTR 
  2 795935 cg21032567 0,0017 -0,11 0,0030 -0,12 0,72 0,07 0,84 0,03  
  2 9324127 cg06153448 0,0010 0,20 0,0030 0,14 0,63 0,05 0,48 0,10  
UCN 2 27530884 cg06536868 0,0005 -0,13 0,0030 -0,12 0,46 0,09 0,59 0,03 5'UTR 
  2 45397874 cg20201270 0,0005 0,15 0,0030 0,12 0,43 0,11 0,31 0,03  
  2 131094827 cg01331772 0,0017 -0,35 0,0017 -0,32 0,37 0,18 0,69 0,08  
  2 202929157 cg10590964 0,0030 0,19 0,0030 0,12 0,80 0,06 0,68 0,03  
NRP2 2 206628625 cg05348875 0,0075 -0,26 0,0075 -0,17 0,58 0,13 0,75 0,09 Body 
PLCD4 2 219472607 cg17980119 0,0030 -0,17 0,0030 -0,11 0,57 0,10 0,68 0,03 TSS200 
ECEL1P2 2 233251770 cg13138089 0,0017 -0,15 0,0017 -0,15 0,55 0,20 0,70 0,02 TSS200 
SNED1 2 241989271 cg23491743 0,0017 -0,16 0,0030 -0,17 0,67 0,15 0,84 0,04 Body 
SNED1 2 241989379 cg25241559 0,0005 -0,15 0,0005 -0,17 0,70 0,17 0,87 0,01 Body 
CC2D2A 4 15480643 cg18797590 0,0075 0,12 0,0075 0,11 0,77 0,07 0,66 0,03 Body 
LDB2 4 16575323 cg08262002 0,0017 0,18 0,0030 0,11 0,77 0,07 0,66 0,06 Body 
CYP4V2 4 187126073 cg09526685 0,0047 -0,22 0,0047 -0,12 0,77 0,09 0,89 0,03 Body 
FLJ44606 5 126409061 cg18710053 0,0002 -0,12 0,0002 -0,12 0,23 0,05 0,35 0,03 5'UTR 
CCNI2 5 132083532 cg08957484 0,0017 -0,12 0,0030 -0,13 0,18 0,09 0,31 0,03 1stExon 
KCTD16 5 143847362 cg18991165 0,0017 0,17 0,0017 0,11 0,91 0,02 0,81 0,06 Body 
  6 33128923 cg16604233 0,0002 0,16 0,0002 0,15 0,73 0,06 0,58 0,04  
  6 75459158 cg22322277 0,0075 0,16 0,0075 0,11 0,67 0,07 0,56 0,07  
  6 158097037 cg10525394 0,0002 -0,16 0,0002 -0,12 0,64 0,07 0,76 0,03  
PNLDC1 6 160241556 cg15829665 0,0030 -0,15 0,0075 -0,11 0,47 0,10 0,57 0,04 3'UTR 
PARK2 6 161836525 cg10735454 0,0005 -0,19 0,0002 -0,14 0,43 0,06 0,57 0,04 Body 
  7 117323381 cg26310285 0,0002 0,16 0,0002 0,11 0,72 0,04 0,62 0,05  
  7 120414717 cg18264932 0,0075 -0,15 0,0075 -0,12 0,66 0,12 0,79 0,03  
STMN4 8 27115956 cg11688949 0,0030 -0,14 0,0010 -0,14 0,43 0,11 0,57 0,02 TSS200 
C9orf167 9 140175679 cg13416866 0,0017 -0,15 0,0017 -0,16 0,39 0,10 0,54 0,04 3'UTR 
PRKG1 10 53287690 cg08751451 0,0075 0,20 0,0075 0,15 0,81 0,05 0,67 0,13 Body 
C10orf120 10 124459681 cg15840151 0,0010 -0,17 0,0010 -0,10 0,58 0,07 0,68 0,05 TSS1500 
YPEL4 11 57417949 cg03773647 0,0005 -0,16 0,0002 -0,10 0,55 0,08 0,66 0,01 TSS1500 
SHANK2 11 70484490 cg00447817 0,0017 -0,13 0,0017 -0,13 0,68 0,06 0,81 0,05 Body 
SHANK2 11 70560211 cg07192048 0,0030 -0,25 0,0030 -0,21 0,41 0,09 0,62 0,10 Body 
SHANK2 11 70673256 cg04262428 0,0017 0,11 0,0005 0,10 0,28 0,04 0,18 0,03 Body 
SHANK2 11 70760166 cg25885280 0,0047 -0,13 0,0075 -0,11 0,53 0,06 0,64 0,05 Body 
ODZ4 11 78761473 cg20831648 0,0047 -0,12 0,0047 -0,10 0,66 0,08 0,76 0,04 Body 
  11 116328665 cg11921539 0,0028 -0,12 0,0002 -0,11 0,46 0,07 0,57 0,01  
	92	
  11 119662882 cg09938664 0,0002 -0,11 0,0002 -0,11 0,40 0,04 0,51 0,03  
PRDM10 11 129793108 cg16983588 0,0005 0,26 0,0005 0,17 0,64 0,09 0,47 0,04 Body 
NTF3 12 5543269 cg27423216 0,0002 -0,25 0,0002 -0,26 0,40 0,12 0,66 0,04 Body 
FBRSL1 12 133135463 cg20454518 0,0010 -0,10 0,0017 -0,11 0,32 0,04 0,43 0,05 Body 
  13 27498239 cg23681440 0,0002 0,13 0,0002 0,14 0,58 0,05 0,44 0,03  
C13orf33 13 31481184 cg13251181 0,0030 0,13 0,0075 0,14 0,58 0,10 0,44 0,02 Body 
  13 33455187 cg10288525 0,0040 0,21 0,0017 0,13 0,80 0,07 0,67 0,04  
BMP4 14 54419614 cg08046044 0,0005 -0,12 0,0010 -0,12 0,18 0,05 0,30 0,03 5'UTR 
  14 101175970 cg18089426 0,0010 0,14 0,0017 0,14 0,73 0,09 0,59 0,06  
ARNT2 15 80853140 cg13148921 0,0005 -0,23 0,0017 -0,21 0,39 0,11 0,60 0,13 Body 
CPEB1 15 83317526 cg17453840 0,0030 -0,13 0,0075 -0,14 0,70 0,16 0,84 0,03 TSS1500 
FLYWCH1 16 2975552 cg01215511 0,0047 -0,23 0,0047 -0,16 0,64 0,16 0,80 0,03 5'UTR 
ABAT 16 8806531 cg01881182 0,0017 -0,20 0,0047 -0,15 0,42 0,07 0,57 0,08 5'UTR 
ABAT 16 8806569 cg16586594 0,0005 -0,18 0,0005 -0,19 0,34 0,08 0,53 0,08 5'UTR 
ABAT 16 8806690 cg08834902 0,0047 -0,23 0,0047 -0,16 0,53 0,10 0,70 0,06 5'UTR 
TEPP 16 58019866 cg04370442 0,0047 -0,15 0,0075 -0,16 0,71 0,21 0,88 0,02 Body 
TEPP 16 58019893 cg12499872 0,0005 -0,31 0,0005 -0,15 0,73 0,17 0,88 0,01 Body 
KCNAB3 17 7832680 cg15951188 0,0047 -0,18 0,0047 -0,19 0,58 0,14 0,77 0,05 1stExon 
CNTNAP1 17 40838983 cg16308533 0,0005 -0,17 0,0010 -0,19 0,66 0,15 0,86 0,04 Body 
CNTNAP1 17 40839022 cg11629889 0,0002 -0,14 0,0010 -0,16 0,71 0,13 0,88 0,03 Body 
QRICH2 17 74270190 cg09812376 0,0056 0,19 0,0047 0,20 0,51 0,10 0,31 0,13 3'UTR 
  19 7934807 cg23995446 0,0075 0,12 0,0047 0,11 0,23 0,11 0,11 0,03  
SLC1A6 19 15121333 cg12695707 0,0002 -0,27 0,0005 -0,16 0,65 0,08 0,81 0,06 TSS1500 
SLC1A6 19 15121509 cg09470638 0,0010 -0,25 0,0048 -0,14 0,67 0,11 0,81 0,04 TSS200 
SLC1A6 19 15121531 cg02489552 0,0002 -0,14 0,0002 -0,21 0,47 0,13 0,68 0,08 TSS200 
LRFN1 19 39799037 cg26910511 0,0047 -0,14 0,0030 -0,16 0,69 0,14 0,85 0,05 Body 
R3HDML 20 42965025 cg25779645 0,0075 -0,16 0,0075 -0,10 0,55 0,08 0,65 0,03 TSS1500 
SOX18 20 62679635 cg02231404 0,0010 -0,20 0,0010 -0,21 0,32 0,12 0,53 0,04 Body 
SOX18 20 62679713 cg22138735 0,0005 -0,17 0,0005 -0,17 0,15 0,06 0,33 0,06 Body 
  22 19141030 cg14372705 0,0017 0,21 0,0017 0,14 0,64 0,09 0,50 0,04  
  22 28074071 cg16331674 0,0030 -0,25 0,0017 -0,11 0,76 0,10 0,87 0,01  
  22 28074146 cg16084133 0,0010 -0,17 0,0005 -0,15 0,68 0,12 0,84 0,02  
SELM 22 31500896 cg21361322 0,0047 -0,39 0,0047 -0,13 0,77 0,13 0,90 0,01 3'UTR 
Nucleotide positions accord to NCBI build 37/hg19. Selection is performed after analysis with two pipelines and application of two 
selection criteria: i) absolute β-value difference > 0.10 and ii) P-value < 0.01. β-diff: β-difference; Chr: chromosome; MMC: 
myelomeningocele; SD: standard deviation. These 45 genes were selected for the functional gene enrichment analysis. 
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Validation study in larger MMC and control cohorts  
A validation study was performed with the Sequenom EpiTYPER to quantify DNA 
methylation for loci that contain the CpGs of the 6 highest ranked genes. The 
validation was performed for 83 MMC patients (fully described in Table 1 of Chapter 
3 and previously in [116]) and 30 unrelated healthy controls. All gene loci include 
some specific significantly hypomethylated CpGs in MMC patients compared to 
controls (Figure 5; left panels). However, only for the SOX18 locus, a significant 
overall hypomethylation was found for MMC patients versus controls (-14%; 95% CI 
[-8%, -20%], P-value = 0.0003) (Figure 5; right panels). For the other 5 genes ABAT, 
CNTNAP1, SLC1A6, SNED1, and TEPP, the overall methylation of the studied locus 
was not significantly different between MMC patients and controls.  
As differences in global DNA hypomethylation have previously been described in 
patients with NTDs in association with the MTHFR 677C>T variant, we genotyped 
this variant for our cohorts. Similar to our previous findings for the HOXB7 locus 
[116], we did not find an association between MTHFR 677 CC versus CT+TT 
carriers and changes in SOX18 methylation values (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Validation of the top 6 differentially methylated genes by Sequenom EpiTYPER in MMC patients 
versus controls. Left: methylation pattern for each CpG unit within the amplicons. Multiple t-test was performed 
for each CpG. P-value: *<0.05. Right: boxplot representing methylation pattern with box = 25th and 75th 
percentiles; bars = min and max values. The mean methylation level of each group is shown above the plot. The 
validation study is performed for 83 MMC patients and 30 controls. * CpGs were first identified by HM450k.  
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Chemically-induced demethylation versus gene expression analysis  
Demethylation studies were performed in HEK cells that were treated for 72 hours 
with 5 µM 5-aza-2'-deoxycytidine (AZA). Bisulfite sequencing using primers similar to 
the Sequenom EpiTYPER study confirmed CpG demethylation for all CpGs within 
the top 6 ranked genes (ABAT, CNTNAP1, SLC1A6, SNED1, SOX18, and TEPP) 
after AZA treatment but again with the most pronounced difference detected for the 
SOX18 locus (Figure 6A). Gene expression was measured for ABAT, CNTNAP1, 
SLC1A6, SNED1, SOX18, and TEPP using qRT-PCR but only TEPP and SOX18 
expression was significantly increased after AZA treatment (Figure 6B).  
 
 
Figure 6. Demethylation studies and gene expression analysis. Demethylation studies were performed using 
5 µM 5-aza-2'-deoxycytidine in HEK cell line. A) Sanger sequencing showing demethylation of SOX18 after 5-
aza-2’-deoxycytidine treatment. The CpGs from the SOX18 amplicon are annotated below the sequence. B) 
Gene expression analysis of top 6 genes using qRT-PCR. Standard: standard culture conditions; AZA: 5-aza-2'-
deoxycytidine. P-value: *<0.05, ***<0.001.  
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Gene expression studies in Zebrafish 
Functional genetic studies were performed in zebrafish to study alterations of sox18 
and abat expression during embryogenesis and neural tube formation. Both genes 
are highly conserved between humans and zebrafish (68% for sox18 and 70% for 
abat). We analysed embryos that express high levels of sox18 and abat after 
microinjection of synthetic mRNA. Detailed morphological analysis of neural tube 
formation during embryogenesis was performed using whole mount in situ 
hybridization (WISH) with a probe for the paired box gene 2a (pax2a) gene. Embryos 
injected with abat and sox18 mRNA developed with mild (for abat) to severe (for 
sox18) malformations in about 50% (for abat) to 74% (for sox18) of the embryos at 
24 hours post fertilization (hpf) (Figure 7). Embryos that express high levels of abat 
present with mainly abnormal neural tube structures (Figure 7A) while embryos with 
high sox18 levels are more severely affected having a general developmental delay 
that includes neural tube malformation (Figure 7B). We also investigated if addition 
of 0,1 mM folic acid to the egg water would rescue the phenotype [123] but no 
significant differences would be observed (Figure 7C).  
	98	
 
 
Figure 7. Phenotype analysis of gene overexpression in zebrafish embryos. A) and B) Pax2a staining after 
microinjection of Abat mRNA (A) and Sox18 mRNA (B). Wild type (WT) zebrafish show expression in the 
hindbrain, hindbrain-midbrain boundary, neural tube, mesoderm, optic stalk, otic vesicle, and pronephric duct. 
Spinal cord malformation is indicated with an arrow. C) Phenotype analysis after Pax2a staining at 24 hpf 
resulted in respectively 50% and 74% embryos with an affected phenotype after Abat and Sox18 overexpression. 
Folic acid supplementation after gene overexpression did not significantly influence the phenotype. P-value: 
***<0.001. 
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SOX18 methylation studies in 5 MMC patients and their non-affected siblings 
and parents  
To study the inheritance of the SOX18 methylation changes, we quantified SOX18 
methylation for 5 MMC patients and their non-affected siblings and parents with the 
Sequenom EpiTYPER (Figure 8A). Interestingly, not only the MMC patients but also 
their non-affected healthy siblings presented with similar levels of SOX18 
hypomethylation whereas their parents had methylation values comparable to these 
of the unrelated control cohort (Figure 8A). There were no significant DNA 
methylation differences between the 5 MMC patients, their siblings and the overall 
MMC cohort. The quantification of DNA methylation for the separate CpGs revealed 
higher methylation values for the parents compared to the MMC patient and its 
healthy sibling for all CpGs (Figure 8B). These data would implicate that SOX18 
hypomethylation is not sufficient to cause a NTD.  
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SOX18 methylation studies in the parents of a MMC patient with a paternally 
inherited BMP4 deletion 
To investigate the influence of an underlying genetic factor, SOX18 DNA methylation 
was quantified in a boy with lumbosacral MMC and his parents. The boy has 
paternally inherited microdeletions that comprise 14q22.1q22.2 (14:53,267,987-
54,933,219;NCBI/hg19, February 2009) and 2p11.2 (2:83,380 184-83,915 
440;NCBI/hg19, February 2009). 14q22.1q22.2 covers the genes FERMT2, DDHD1, 
BMP4, DKN3 and CNIH (Figure 1) while the other deletion in the 2p11.2 region does 
not include genes. The father has postaxial polydactyly, severe myopia and pro-
optosis but no spina bifida. His clinical phenotype is compatible with a BMP4 deletion 
syndrome. Interestingly, BMP4 is one of the 45 genes that showed DNA methylation 
changes in our HM450k analysis (Table 5) and is also present in the functional 
enrichment network very closely connected to SOX18 (Figure 4). The BMP4 deletion 
patient but also his mother presented with significantly lower methylation values 
compared to the father and the group of unrelated healthy controls (Figure 8A). Both 
overall as well as the CpG-specific methylation covering the SOX18 locus were 
significantly different between the patient and his mother (Figure 8A and 8B).  
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4.5 Discussion  
Current research supports the hypothesis that abnormal DNA methylation 
contributes to NTDs [32,40]. However, rather than DNA hypomethylation of individual 
candidate loci, a complex combination of environmental and (epi)genetic factors are 
likely causative for NTDs [124,125]. Analysis of HM450k methylation data for 10 
MMC patients and 6 unrelated healthy controls showed no statistically significant 
difference in global DNA methylation as determined via the LINE-1 and LINE-2 
methylation. However, unsupervised hierarchical clustering analysis showed that 
MMC patients are more closely related to one another compared to unrelated 
healthy controls. The DNA methylation values extracted for candidate genes related 
to folic acid and the one carbon metabolism revealed no significant differences 
between MMC patients and controls. Therefore, we next analysed the HM450k data 
using a genome-wide approach. As divergence between the two Infinium assays 
generates two different types of data [126], different correction and normalization 
methods are suggested to make the datasets comparable. Therefore, we have used 
the two analysis pipelines (WateRmelon and IMA) and these resulted in the 
identification of significant hypomethylation for the genes ABAT, CNTNAP1, 
SLC1A6, SNED1, SOX18 and TEPP. Further validation by Sequenom EpiTYPER 
confirmed CpG-specific DNA hypomethylation for these genes. However, only the 
SOX18 locus showed highly significant overall hypomethylation for MMC patients. 
Recessive and dominant mutations in SOX18 in humans are known to cause 
hypotrichosis-lymphedema-telangiectasia syndrome with a combination of hair and 
cardiovascular anomalies, including symptoms of lymphatic dysfunction [127]. More 
recently, SOX18 has also been identified as a novel target of the Hedgehog 
signalling pathway, which plays an important role in neural tube development [128]. 
Most studies available to date have focused on the role of SOX18 depletion or loss 
of function mutants while our study points to a potential role of SOX18 
hypomethylation leading to increased SOX18 expression. Knowledge on the biology 
of SOX18 overexpression is sparse but evidence for a role in neural tube formation 
is at least supported by our zebrafish studies that showed strongly malformed tails 
with abnormal neural tube development in embryos with high levels of sox18 after 
injection of its mRNA.  
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As periconceptional folate is important for NTD prevention, we compared our 
findings with a large dataset that examined the association between maternal 
plasma folate during pregnancy and genome-wide DNA methylation in newborn cord 
blood [118]. Interestingly, one of the top differentially methylated CpGs of this study 
(cg12695707 within the SLC1A6 gene locus) was also detected as a hypomethylated 
CpG in our study (Table 4). Therefore, SLC1A6 seems to be sensitive to maternal 
plasma folate in both healthy controls as in MMC patients. In addition, multiple 
developmental processes seem to be influenced by maternal folate, including neural 
tube development. Recently, we described the importance of HOX gene methylation 
in neurulation [116], which is also influenced by maternal plasma folate [117]. In 
addition, we checked if our candidate genes are also represented in another large-
scale meta-analysis that investigated the influence of maternal smoking on DNA 
methylation in newborns [129]. Five of our 75 candidate loci with abnormal 
methylation being BMP4, ENAH, GALNT2, NRP2 and one CpG in a locus without an 
annotated gene seem to be highly significantly influenced by maternal smoking. 
Bone morphogenetic protein 4 (BMP4) is of special interest as it is involved in 
craniofacial development and an important candidate gene for cleft palate defects 
[130]. However, BMP4 has not yet been implicated directly in lumbosacral MMC. 
Based on the meta-analysis, BMP4 is associated with increased methylation after 
maternal smoking [129].  
 
In addition to dietary and environmental factors, DNA sequence variability 
influences DNA methylation. The influence of DNA sequence variability on DNA 
methylation is estimated to differ between 22-80% [131]. In order to investigate how 
genetic factors might influence DNA methylation, we first genotyped the MTHFR 
677C>T variant as this variant is known to lead to hyperhomocysteinemia and global 
DNA hypomethylation especially under low folate conditions [88]. We did not find an 
additive effect of the MTHFR variant on SOX18 methylation. To investigate whether 
candidate genes from literature might be differentially methylated, we compared the 
findings of our top 45 significantly differentially methylated genes with the gene list 
from a recent NTD wiki database that provides an online up-to-date list of genes 
implicated in neural tube closure (http://ntdwiki.wikispaces.com). Only one gene of 
our top genes, ENAH, was present in the candidate gene list. However, the interplay 
between genetics and epigenetics in driving a disease phenotype is not well 
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understood and is completely unknown for NTD etiology. As we hypothesized that 
there may be a maternal factor that contributes to a disturbed DNA methylation 
cycle, we performed SOX18 methylation studies for 5 families including the MMC 
patient and their non-affected parents and sibling. Both parents had methylation 
levels comparable to these of the control cohort while the MMC patients and their 
healthy siblings had significantly lower SOX18 methylation. These findings are 
suggestive of an epigenetic change induced by the mother. In addition, we report 
here the first MMC case with a combined genetic and epigenetic defect involving a 
paternally inherited chromosomal deletion that includes BMP4 and a maternally 
inherited defect in SOX18 methylation. The MMC child, born from Caucasian non-
related parents, was diagnosed with a lumbosacral NTD and carries a paternally 
inherited 14q22.1-2 deletion that involves FERMT2, DDHD1, BMP4, DKN3 and 
CNIH. BMP4 deletions have been associated with variable defects of the eyes, 
palate, limbs and brain and with developmental and growth delay but not with NTDs 
[132,133]. Mutations in DDHD1 are found in patients with hereditary spastic 
paraplegia [134], CDKN3 is linked with different cancers while for FERMT2 and 
CNIH no human diseases have been described. The father with the same 
chromosomal deletion has postaxial polydactyly, severe myopia and pro-optosis but 
no NTD. Interestingly, SOX18 methylation studies in the parents and patient showed 
pronounced hypomethylation in the mother and patient. Though further biological 
studies are needed to support any functional interplay between BMP4 and SOX18,, 
this pedigree illustrates the inheritance of genetic and epigenetic factors that could 
cause a NTD. It is worth to notice that both SOX18 [135-137] and BMP4 [138,139] 
have been described as regulators of angiogenesis and this could explain an old 
concept that there might be a vascular basis for NTDs [140]. The vascular 
hypothesis states that NTDs result from a disturbance in the timely development of 
the vasculature. A constant nutrition supply is essential for normal embryonic 
development. The transition from an avascular to a vascular organism is normally 
accomplished during the fourth postconceptional week. The neural system has a 
very prolific growth during the prevascular stage and is therefore the first to outgrow 
its nutrient supply. As both SOX18 and BMP4 are implicated in the establishment of 
a vascular network, there might be a vascular basis for NTDs [136,137]. 
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An important shortcoming of our study is the fact that we only had access to 
leukocyte DNA for assessment of methylation. We do not know whether differential 
methylation of the same gene set would be observed in brain or spinal cord tissue of 
MMC patients. But concordant methylation alterations in brain and blood suggest 
that blood methylation might be representative for brain methylation 
[112,113,141,142]. It is known that DNA methylation in blood is significantly more 
variable than DNA methylation in brain tissues [141]. Horvath et al. [142] and Farré 
et al. [141] identified an epigenetic signature of age that is not related to cell type 
composition and that does not require a correction for cellular heterogeneity. This is 
an interesting finding, as until now there was still no clear evidence that epigenetic 
marks of different cell types respond in a similar way to environmental influences. 
The sample size of our genome-wide study was small, but the reproducibility of 
significant hypomethylation of the top CpGs in a much larger cohort suggests that 
the application of two pipelines to analyse the HM450k dataset was a good strategy.  
 
4.6 Conclusion 
This is the first study that investigates genome-wide DNA methylation in leukocytes 
in patients with NTDs. We report SOX18 as novel risk gene for NTDs but our 
findings also suggest that SOX18 hypomethylation and increased expression must 
interplay with other environmental and (epi)genetic factors that are causative for 
NTDs. Therefore further studies should focus on a gene discovery design for MMC 
that includes both DNA methylation and next generation sequencing approaches. It 
is possible that gene variants in combination with changes in methylation are more 
prone to result in a multifactorial disease as spina bifida.   
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Context of the study 
Analyzing HM450k data is complex and data processing and interpretation need to 
be given particular consideration and care [83]. In order to acquire knowledge in the 
technical and analytical aspects of the HM450k arrays, I received a Short-Term 
Scientific Mission grant (within the framework of the COST–BM1209 project: 
European Network of congenital imprinting disorders) to visit the lab of Prof. D. Monk 
in the laboratory of Genomic Imprinting and Cancer at IDIBELL in Barcelona, Spain. 
During this research visit, I analyzed the data of the HM450k BeadChip performed to 
study the imprinting disease pseudohypoparathyroidism. Patient samples and their 
clinical data were already available for this study and the array processing of the 
HM450k was performed by the Genome Centre (Bart's and the London School of 
Medicine and Dentistry, Londen, UK). I also did locus-specific validation studies with 
the Sequenom EpiTYPER for this study. Obtained expertise in data analysis and 
filtering was used for this doctoral thesis.  
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5.1 Abstract  
Background: Pseudohypoparathyroidism (PHP) is caused by (epi)genetic 
defects in the imprinted GNAS cluster. Current classification of PHP patients is 
hampered by clinical and molecular diagnostic overlap. The European Consortium 
for the study of PHP designed a genome-wide methylation study to improve 
molecular diagnosis.  
Methods: The HumanMethylation 450K BeadChip was used to analyze 
genome-wide methylation in 24 PHP patients with parathyroid hormone resistance 
and 20 age- and gender-matched controls. Patients were previously diagnosed with 
GNAS-specific differentially methylated regions (DMRs) and include 6 patients with 
known STX16 deletion (PHPΔstx16) and 18 without deletion (PHPneg).  
Results: The array demonstrated that PHP patients do not show DNA methylation 
differences at the whole genome level. Unsupervised clustering of GNAS-specific 
DMRs divides PHPΔstx16 versus PHPneg patients. Interestingly, in contrast to the 
notion that all PHP patients share methylation defects in the A/B DMR while only 
PHPΔstx16 patients have normal NESP, GNAS-AS1 and XL methylation, we found a 
novel DMR (named GNAS-AS2) in the GNAS-AS1 region that is significantly 
different in both PHPΔstx16 and PHPneg, as validated by Sequenom EpiTYPER in a 
larger PHP cohort. The analysis of 58 DMRs revealed that 8/18 PHPneg and 1/6 
PHPΔstx16 patients have multi-locus methylation defects. Validation was performed for 
FANCC and SVOPL DMRs.  
Conclusions: This is the first genome-wide methylation study for PHP patients 
that confirmed that GNAS is the most significant DMR, and the presence of STX16 
deletion divides PHP patients in 2 groups. Moreover, a novel GNAS-AS2 DMR 
affects all PHP patients and PHP patients seem sensitive to multi-locus methylation 
defects.  
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5.2 Introduction 
Genomic imprinting is a parent-of-origin dependent gene expression that is 
essential for mammalian development. A mechanism underlying allele-specific 
expression is DNA methylation. The addition of a methyl group to DNA cytosine 
nucleotides at CpG sites can occur in an allele-specific manner, and allele-specific 
methylation in imprint control regions (referred to as differentially methylated regions, 
DMR) is associated with parent-of-origin dependent gene expression. Imprinting 
disorders are a group of rare diseases affecting growth, development and 
metabolism, that are associated with (epi)genetic disruption of imprinting genes [66]. 
Pseudohypoparathyroidism (PHP) is a rare endocrine disorder that can be caused 
by genetic or epigenetic alterations in the imprinted cluster GNAS localized on 
chromosome 20q13.3 [143]. The human GNAS locus harbors four DMRs 
encompassing the promoters of four alternative transcripts: exon A/B (GNAS-A/B: 
TSS DMR = A/B), GNAS antisense (GNAS-AS1: TSS DMR = AS1), extra-large 
stimulatory G protein (GNAS-XL: Ex1 DMR = XL) and neuroendocrine secretory 
protein 55 (GNAS-NESP: TSS DMR = NESP) (Figure 1A) [144]. PHP type I (PHP1A 
and PHP1B) patients are characterized by end-organ resistance to the action of the 
parathyroid hormone (PTH), which leads to hypocalcemia, hyperphosphatemia and 
elevated levels of PTH in absence of vitamin D deficiency. They often also have 
thyroid stimulating hormone (TSH) resistance [143,144]. PHP1A patients have in 
addition to hormone resistance clinical features collectively referred to as Albright’s 
Hereditary Osteodystrophy (AHO) that include brachydactyly, short stature and 
round face; they may also present with obesity, subcutaneous ossifications, mental 
retardation and behavior problems [145,146]. PHP1A is caused by heterozygous 
maternally inherited inactivating mutations in the coding sequence of Gsα (exons 1 
to 13 of GNAS) [143,144,147]. On the other hand, paternally inherited inactivating 
mutations lead to pseudopseudohypoparathyroidism (PPHP), characterized by AHO 
features but without hormone resistance [143,144,147]. Most patients affected with 
the PHP1B form of the disease exhibit mainly PTH resistance and subclinical TSH 
resistance and do not have AHO features. In some cases however, typical 
brachydactyly, severe obesity [148] and congenital hypothyroidism [149,150] have 
been described in PHP1B patients highlighting the overlap between PHP1A and 
PHP1B. All PHP1B patients have methylation abnormalities in the GNAS cluster with 
loss of imprinting at the A/B DMR [147]. The familial form of PHP1B (often referred to 
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as autosomal dominant AD-PHP1B) is typically associated with microdeletions in the 
STX16 region located upstream of the GNAS cluster [151-154] and less frequently 
with deletion removing the NESP DMR [155]. On the other hand, sporadic PHP1B 
patients have broad GNAS methylation defects that involve all four GNAS DMRs 
without a known underlying genetic cause [143,144,147]. 
However, from recent data, it becomes clear this original PHP classification is no 
longer accurate for the following four reasons: i) broad GNAS methylation defects 
were also found for PHP1B patients with an AHO phenotype [148,156-158], (ii) the 
degree of the methylation defect seems not to correlate with the disease severity 
[159], iii) reduced Gsα activity is no longer exclusive for PHP1A with inactivating 
mutations but recently also was described for PHP patients with epigenetic defects 
[160,161] and iv) partial GNAS methylation defects have been described [162]. 
Moreover, as shown for other imprinting disorders, such as Silver-Russell or 
Beckwith-Wiedemann syndrome, also some PHP1B patients were shown to have 
multi-locus imprinting defects as studied by a targeted approach that comprised 
known imprinted loci [163-165]. Therefore, there is a strong need to improve the 
current classification of PHP patients that might be feasible based on more detailed 
(epi)genetic or clinical data using larger patient cohorts analyzed with more powerful 
techniques. The European Consortium for the study of PHP (EuroPHP) designed the 
present genome-wide methylation study to gain insight in epigenetic profiles that 
might improve an epigenetic-based classification. We have analyzed the 
methylomes of 24 previously diagnosed PHP patients with GNAS epigenetic defects 
recruited from 5 European centers. This sample set includes 6 patients with the 
STX16 3-kb recurrent microdeletion (PHPΔstx16) [152] and 18 without any identified 
deletion within the GNAS locus (PHPneg). The following analyses were performed i) 
changes in DNA methylation at the genome-wide level, ii) unsupervised cluster 
analysis for the GNAS locus and comparisons with previous GNAS methylation data 
used for PHP diagnosis and iii) detailed DNA quantification analysis for other 
imprinted DMRs. DNA methylation data were validated with the Sequenom 
EpiTYPER for additional PHP patients with PTH resistance and proven epigenetic 
defects.  
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Table 1: Clinical and molecular characteristics of the PHP patients enrolled in the genome-wide DNA 
methylation study. From left to right: 1) clinical characteristics; 2) mean methylation values of GNAS studies 
that were performed previously by 5 different European centers as described in figure 1; 3) mean methylation 
values of GNAS investigated with HM450k. Ordering of the patients according to unsupervised hierarchical 
clustering of GNAS methylation investigated with HM450k. Patients* have methylation changes at imprinted 
genes other than GNAS. Methylation values are presented as %. BD: brachydactyly; Ca: calcium; F: female; 
LAB: laboratory of initial diagnostic screening, annotation as shown in figure 1; M: male; OS: heterotopic 
ossifications; P: phosphate; PTH-res: Parathyroid hormone resistance; TSH-res: Thyroid-stimulating hormone 
resistance; ΔSTX16: patients with underlying STX16 deletion. * methylation < or > than 3SD outside the mean of 
the controls; ** methylation < or > than 3SD outside the mean of the controls and < 0.20 or > 0.80 absolute 
methylation. Mean ± SD of the 20 controls from the HM450k array is shown below the HM450k columns.  
 
 
5.3 Materials and methods 
Patient samples 
A total of 61 PHP patients were enrolled by 5 different endocrinology centers from 
the European PHP Consortium. The molecular diagnosis for PHP was performed by 
each center using the methylation detection assay for the GNAS DMRs as previously 
described with methodologies and the location of the studied amplicons in Figure 1 
and Table 1 [162]. All PHP patients included in this study have PTH resistance and 
were labeled with PHP1A if an obvious AHO phenotype was present (only 
brachydactyly and subcutaneous ossifications were noticed, Table 1). Based on the 
genetic screening for STX16 deletions and GNAS methylation screening, 
laboratories were asked to label the patients with: i) STX16 deletion present or not, 
ii) AB-only or broad methylation defect and iii) full or partial methylation defect [162]. 
This resulted in the use of the following labels (Table 1): PHP1B - A/B only, full 
PHP1B - broad, partial PHP1B - broad and partial PHP1A - broad. These terms are 
based on the original classification used for patients with PHP type I.  
Table 1 presents the patients for the genome-wide study and Table 2 the patients for 
the replication studies. The order of the patients in Table 1 was determined by 
unsupervised cluster analysis of genome-wide data for only the GNAS locus. The 
total number of PHP patients that were enrolled for the HumanMethylation 450K 
(HM450k) array and Sequenom studies are specified in Table 2. Shortly, the 
genome-wide DNA methylation study was performed for 24 PHP patients and 20 
age- and gender-matched healthy controls (Table 1). Validation of NESP-AS2 was 
performed for 42 PHP patients and 20 controls. Validation of the methylation levels 
of FANCC, SVOPL and WDR27 was performed in 26 PHP patients and 12 controls.  
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Table 2: Number of PHP patients enrolled in the genome-wide and Sequenom EpiTYPER validation studies. 
 
  HM450k Sequenom EpiTYPER 
Patients  WDR27 SVOPL FANCC NESP-AS 
STX16 del 6 5 (3) 5 (3) 5 (3) 20 (3) 
no-STX16 del 18 21 (3) 21 (3) 21 (3) 22 (3) 
all 24 26 (6) 26 (6) 26 (6) 42 (6) 
Controls 20 12 (2) 12 (2) 12 (2) 20 (10) 
Patients are divided in two groups based on the presence or absence of STX16 deletion. Patients included in 
both the genome-wide study and the locus-specific validation study with Sequenom EpiTYPER are indicated 
between brackets. 
 
Informed consent for methylation and genetic studies was obtained from all 
participants and/or their legal representatives after approval of these studies by local 
Ethical Committees. 
 
Genome-wide methylation profiling using the HM450k array 
Genomic DNA was extracted from leukocytes using standard techniques and 
bisulfite converted using the EZ DNA methylation kit (Zymo Research, Irvine CA) as 
previously described [116]. The array was performed by the Genome Centre (Bart's 
and the London School of Medicine and Dentistry, Londen, UK) on the 
HumanMethylation 450K BeadChip (Illumina) using manufacturer’s reagents and 
protocols. An identical control sample was assigned to each batch and samples were 
distributed randomly to control for batch effects. The correlation for the internal 
quality control was high (> 0.99). The methylation level (β-value) was calculated 
using the Methylation Module of BeadStudio software. 
 
HM450k data filtering and genome-wide analysis 
After normalization of the data using GenomeStudio software, data were analyzed 
using a pipeline developed within the R statistical analysis environment 
(http://www.r-project.org, Bioconductor, Seattle, USA). Before analyzing the data, we 
excluded possible sources of technical bias. Probes with a high detection value 
(p>0.01) in more than 10% of the samples (644 probes) and probes containing any 
missing values (13194 probes) were removed, as well as non-CpG and gender 
matched probes. Finally, we excluded probes as they contained SNPs present in 
>1% of the population and leukocyte-specific probes [166,167]. In total, we analyzed 
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355105 probes for all DNA samples (73% of probes). No statistical batch control was 
required as all the cases and controls had been processed in the same time and 
correlation for the quality control was high (> 0.99). The mean methylation and 
standard deviation were determined for the control population and individual 
samples. We did not detect any differentially methylated DMRs between the 20 
control samples. DNA samples from imprinting syndrome patients were considered 
epimutated if the methylation value for an imprinted DMR differed was outside 3 
standard deviations from the 20 control samples. Cluster analysis was performed 
within the R statistical analysis environment.   
 
HM450k data filtering for analysis of imprinted genes 
We analyzed 58 imprinted DMRs that also included the DMRs of the GNAS cluster 
(Table 3). The list was based on the known imprinted DMRs from the consensus list 
from the European Network of Human Congenital Imprinting Disorders 
(http://www.imprinting-disorders.eu). In addition, we included novel human imprinted 
DMRs from recent research that combined whole-genome bisulfite sequencing with 
HM450k to generate methylation profiles [168] as well as four novel candidate DMRs 
(GLP2R, JAKMIP1, LOC100130522/PARD6G-AS1, SVOPL) from research using 
genome-wide methylation profiling with HM450k in patients with multilocus 
methylation defects [169]. These regions have not yet been further characterised to 
determine SNP vs parental-origin methylation and tissue profile. Some DMRs of the 
list are secondary DMRs (i.e. DIRAS3:Ex2-DMR, all the SNRPN DMRs).  
 
 
Table 3: Location of 58 human imprinted DMRs investigated in this study.  
 
Imprinted DMR Chr Start End Methylation origin 
Germline 
derived 
Associated 
disease 
PPIEL:Ex1-DMR 1 40024626 40025540 M Oocyte gDMR MLID 
DIRAS3:Ex2-DMR 1 68512505 68513486 M Oocyte gDMR MLID 
DIRAS3:TSS-DMR 1 68515433 68517545 M Oocyte gDMR MLID 
GPR1-AS:TSS-DMR 2 207066967 207069445 M Oocyte gDMR  
ZDBF2/GPR1:IG-DMR 2 207114583 207136544 P Sperm gDMR-secondary DMR  
JAKMIP1 4 6107021 6107339    
NAP1L5:TSS-DMR 4 89618184 89619237 M Oocyte gDMR MLID 
VTRNA2-1:DMR 5 135414802 135416645 M Oocyte gDMR  
FAM50B:TSS-DMR 6 3849082 3850359 M Oocyte gDMR MLID 
PLAGL1:alt-TSS-DMR 6 144328078 144329888 M Oocyte gDMR TNDM; MLID 
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IGF2R:Int2-DMR 6 160426558 160427561 M Oocyte gDMR MLID 
WDR27:Int13-DMR 6 170054504 170055618 M Oocyte gDMR MLID 
GRB10:alt-TSS-DMR 7 50848726 50851312 M Oocyte gDMR MLID 
PEG10:TSS-DMR 7 94285537 94287960 M Oocyte gDMR MLID 
MEST:alt-TSS-DMR 7 130130122 130134388 M Oocyte gDMR MLID 
SVOPL 7 138348774 138349443    
HTR5A:TSS-DMR 7 154862719 154863382 M Oocyte gDMR  
ERLIN2:Int6-DMR 8 37604992 37606088 M Oocyte gDMR MLID 
PEG13:TSS-DMR 8 141108147 141111081 M Oocyte gDMR MLID 
FANCC:Int1-DMR 9 98075400 98075744 M Oocyte gDMR MLID 
INPP5F:Int2-DMR 10 121578046 121578727 M Oocyte gDMR  
H19/IGF2:IG-DMR 11 2018812 2024740 P Sperm gDMR SRS/BWS 
IGF2:Ex9-DMR 11 2153991 2155112 P No-secondary DMR SRS/BWS 
IGF2:alt-TSS-DMR 11 2168333 2169768 P Sperm gDMR SRS/BWS 
KCNQ1OT1:TSS-DMR 11 2719948 2722259 M Oocyte gDMR BWS (rare Sotos syndrome) 
RB1:Int2-DMR 13 48892341 48895763 M Oocyte gDMR  
MEG3/DLK1:IG-DMR 14 101275427 101278058 P Sperm gDMR TS14/KOS14 
MEG3:TSS-DMR 14 101290524 101293978 P No-secondary DMR TS14/KOS14 
MEG8:Int2-DMR 14 101370741 101371419 M No-secondary DMR  
miR 4508/ 15 23807086 23807592    
MKRN3:TSS-DMR 15 23807086 23812495 M Oocyte gDMR-secondary DMR  
MAGEL2:TSS-DMR 15 23892425 23894029 M No-secondary DMR  
NDN:TSS-DMR 15 23931451 23932759 M No-secondary DMR  
SNRPN intragenic CpG32 15 24346736 24347142    
SNRPN intragenic CpG29 15 24671872 24672679    
SNRPN intragenic CpG30 15 24722753 24723071    
SNRPN intragenic CpG40 15 25017924 25018886    
SNRPN:alt-TSS-DMR 15 25068564 25069481 M No-secondary DMR  
SNRPN_2 15 25093008 25093829    
SNRPN_3 15 25123027 25123905    
SNURF:TSS-DMR 15 25200004 25201976 M Oocyte gDMR PWS/AS 
IGF1R:Int2-DMR 15 99408496 99409650 M Oocyte gDMR  
ZNF597:3' DMR 16 3481801 3482388 M Oocyte gDMR  
ZNF597:TSS-DMR 16 3492828 3494463 P No-secondary DMR  
GLP2R 17 9729250 9729424    
LOC100130522/PARD6G-AS1 18 77905355 77905947    
ZNF331:alt-TSS-DMR1 19 54040510 54042212 M Oocyte gDMR MLID 
ZNF331:alt-TSS-DMR2 19 54057086 54058425 M Oocyte gDMR  
PEG3:TSS-DMR 19 57348493 57353271 M Oocyte gDMR MLID 
MCTS2P:TSS-DMR 20 30134663 30135933 M Oocyte gDMR MLID 
NNAT:TSS-DMR 20 36148604 36150528 M Oocyte gDMR  
L3MBTL1:alt-TSS-DMR 20 42142365 42144040 M Oocyte gDMR MLID 
GNAS-NESP:TSS-DMR 20 57414039 57418612 P No-secondary DMR PHP 
GNAS-AS1:TSS-DMR 20 57425649 57428033 M Oocyte gDMR PHP 
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GNAS-XL:Ex1-DMR 20 57428905 57431463 M Oocyte gDMR PHP 
GNAS A/B:TSS-DMR 20 57463265 57465201 M No-secondary DMR PHP 
WRB:alt-TSS-DMR 21 40757510 40758276 M Oocyte gDMR MLID 
NHP2L1:alt-TSS-DMR 22 42077774 42078873 M Oocyte gDMR MLID 
 
Nucleotide positions accord to NCBI build 37/hg19. The list is based on both known and novel imprinted DMRs. 
Novel imprinted DMRs are indicated in bold. DMR: differentially methylated region; M: maternally derived 
methylation; P: paternally derived methylation; gDMR: germline DMR; PHP = Pseudohypoparathyroidism; SRS: 
Silver Russell syndrome; BWS: Beckwith Wiedemann syndrome; AS: Angelman syndrome; PWS: Prader Willi 
syndrome; MLID: Multi-locus imprinting disturbance; TS14: Temple syndrome; KOS14: Kagami-Ogata syndrome; 
TNDM: Transient Neonatal Diabetes. 
 
Validation of NESP-AS2 and FANCC, SVOPL, WDR27 methylation using the 
Sequenom EpiTYPER  
Leukocyte DNA (1 µg) was subjected to bisulfite treatment using the 
MethylDetectorTM bisulfite modification kit (Active Motif, Carlsbad CA, USA) as we 
described [97,98,116,162,168]. The Sequenom MassARRAY (Sequenom, San 
Diego, CA, USA) was used for quantitative DNA methylation analysis of the CpGs 
within the amplicons of FANCC, SVOPL and WDR27 using conditions described. 
Long cycling incubation was applied to further optimize the conversion reaction [99]. 
Primers were designed using the Sequenom EpiDesigner BETA software 
(www.epidesigner.com), taking into account amplicon coverage, number of CpGs, 
fragment size and number of nucleotide repeats in the primer sequence. PCR steps 
were performed in triplicate for each DNA sample and a standard deviation between 
replicates was mostly <10%. When triplicate measurements had a SD >10% or when 
only one of the triplicates was available, data for that sample were excluded. The 
mean of 3 values was used for further analyses. The EpiTYPER analysis method 
reports CpG methylation values as percentage. Statistical analyses to quantify DNA 
methylation differences were performed using the Prism 6 software (GraphPad 
Software Inc., San Diego). DNA samples from PHP patients were considered 
epimutated if the methylation value for an imprinted DMR was outside two and three 
standard deviations determined from the control samples. A two-tailed T-test was 
used to assess differences in mean DNA methylation levels between cohorts for the 
overall amplicon considered as methylation average and for each CpG unit within 
this amplicon separately.  
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GNAS molecular analysis 
Genomic DNA was isolated from leukocytes. Genotype for the GNAS exon 5 SNP 
(rs7121) at codon 131 was determined by PCR with the forward primer 5’-
ttggtagcgccctcccaggc-3’ and the reverse primer 5’- catgttcctatatggacactg-3’. After 
denaturation at 95°C, 40 cycles of DNA amplification were performed using Taq PCR 
Mastermix at 95°C for 30 s, 58°C for 60 s, and 72°C for 60 s. The PCR products 
were digested using the restriction enzyme FokI and analyzed on a 2% agarose gel. 
Only samples heterozygous at FokI polymorphism were selected. One patient and 
one control were heterozygous. Total RNA was extracted from platelets using TRIzol 
(Invitrogen) reagent, according to the manufacturer’s protocol. The GNAS gene was 
amplified from platelet RNA to check expression of XL.  
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5.4 Results 
Genome-wide DNA  methylation analysis for PHP patients 
The Illumina Infinium HumanMethylation 450K BeadChip (HM450k) was used to 
determine genome-wide DNA methylation profiles in 24 PHP patients and 20 age- 
and gender-matched healthy controls. Table 1 presents the clinical characteristics of 
the PHP patients that all have PTH resistance and hypocalcemia. Mild AHO features 
were only present in patients 8, 10, 13, 15 and 20. All 24 PHP patients were 
previously diagnosed with a GNAS epigenetic defect using different methodologies 
(Figure 1B/C) and methylation values for the different GNAS DMRs obtained by 
these assays are shown in Table 1. We have included 6 PHP patients with a deletion 
of the STX16 region upstream of GNAS and hypomethylation of the A/B DMR only 
(referred to as PHPΔstx16) and 18 PHP patients without the deletion and full or partial 
methylation defects in A/B, XL, AS1 and NESP DMRs (referred to as PHPneg) (Table 
1). Hierarchical cluster analysis of all CpGs according to the different subtypes 
PHPΔstx16, PHPneg or control (Figure 2A) and unsupervised hierarchical clustering 
analysis of the data (Figure 2B) showed that the samples are clustered irrespective 
of the subgroup, suggesting that there are no subgroup differences at whole genome 
level. To further exclude a global methylation defect in PHP patients, we also 
analyzed the methylation of DNA repetitive elements (LINE-1 and LINE-2) that again 
showed no differences between patients and controls (data not shown).  
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Figure 3. Unsupervised hierarchical clustering of GNAS methylation in PHP patients. Methylation values of 
the individual CpGs of the 4 GNAS DMRs are extracted from data obtained with the HM450k. Green and red 
represent 0 and 1 methylation, respectively. The arrows show the different GNAS transcripts.  
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GNAS methylation analysis based on HM450k data for PHP patients 
The methylation values for all CpGs located within the GNAS cluster were extracted 
from data obtained from the genome-wide methylation analysis. The HM450k 
contains probes mapping to 4 regions that cover the 4 GNAS DMRs as specified by 
red boxes in Figure 1C (referred to as A/B, XL, AS1 and NESP). These regions are 
larger but overlap with the regions that were previously investigated by 5 European 
centers that have used different technologies including MS-MLPA, Sequenom 
EpiTYPER or pyrosequencing to quantify the methylation of the GNAS DMRs for the 
24 PHP patients (see Figure 1C for the location of the studied regions and 
methodologies and Table 1 for the results for each patient). Unsupervised 
hierarchical cluster analysis of GNAS methylation data obtained from the HM450k for 
the 24 PHP patients divided these patients in 2 groups according to the 
presence/absence of STX16 deletion (PHPΔstx16 versus PHPneg) (Figure 3). As 
known in literature [143,144] and confirming the previous diagnosis that was made 
by the 5 laboratories, PHPΔstx16 only showed hypomethylation of DMR A/B while 
PHPneg patients had abnormal methylation for all 4 GNAS DMRs. However, 2 PHPneg 
patients (23 and 24) were clustered closer to the healthy control population having 
normal methylation values for the all GNAS DMRs (Table 1 and Figure 3). These 
patients were previously identified with a ‘partial’ GNAS methylation defect using 
MS-MLPA and pyrosequencing respectively. After analyzing the separate CpGs from 
the HM450k, no significant differences were found compared to the control 
population (separated CpGs are visualized in Figure 3). At the individual probe level 
we noticed that both patients were mosaic and patient 23 was slightly more 
hypomethylated than patient 24.  
Interestingly, a smaller region we referred to as AS2 within the AS1 amplicon had 
significantly lower methylation values for both PHPΔstx16 and PHPneg patients 
compared to the controls (Figure 3 and Table 1). This AS2 region does not overlap 
with amplicons that were previously studied for the AS region by MS-MLPA, 
Sequenom EpiTYPER or pyrosequencing by the different laboratories (Figure 1B/C). 
The AS2 region is separated from XL by a hypermethylated region (Figure 3 and 
Figure 4). To confirm AS2 hypomethylation, a validation study was developed using 
the Sequenom EpiTYPER to quantify methylation in the AS2 region in 42 PHP 
patients with PTH resistance that were previously diagnosed with a GNAS 
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epimutation and 20 age- and gender-matched healthy controls. These 42 PHP 
patients include 20 PHPΔstx16 and 22 PHPneg patients, of which 3 patients in each 
group were also analyzed by HM450k array (Table 2). The 22 PHPneg comprise 20 
PHP1B with full or partial broad GNAS methylation defect and 2 PHP1B patients with 
isolated A/B methylation defect but having no STX16 deletion. Significant AS2 
hypomethylation (P-value < 0.0001) was detected for both PHPΔstx16 and PHPneg 
patient groups compared to controls (Figure 5). No significant difference in AS2 
methylation was found between PHPΔstx16 and  PHPneg patients with mean 
methylation values of 10% (95% CI: 7-13%) vs. 8% (95% CI: 5-11%), respectively. 
This suggests that the imprinting defect for this interval is not determined by the 
STX16 deletion and is specific for PHP1B. To investigate if AS2 hypomethylation 
changed XL expression, we performed GNAS versus XL mRNA expression studies 
using total blood mRNA from a PHPneg patient and control heterozygous for GNAS 
SNP (rs7121), but we could not detect XL expression in blood cells.  
 
 
Figure 4. Detailed schematic representation of the human GNAS-AS region. Bars indicate the different 
GNAS-AS methylation studies that were performed in this study using the 450K BeadChip (GNAS-AS1) and 
Sequenom EpiTYPER (GNAS-AS2) and previously, by the different European centers (black bars). Nucleotide 
positions accord to NCBI build 37/hg19.		
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Figure 5. Scatter plot of NESP-AS2 methylation in PHP patients and controls. Methylation values are 
obtained with the Sequenom EpiTYPER. Horizontal bars indicate the mean and SD of the group. PHP patients 
are separated according to underlying STX16 deletion.  
 
Methylation studies of other imprinted genes for PHP patients  
As multi-locus abnormalities have also been described for PHP1B patients [164], we 
analysed the methylation values for all CpGs located within 58 imprinted DMRs for 
humans that are covered by the HM450k (Table 3). In addition to methylation 
abnormalities for the 4 GNAS DMRs, we found multi-locus methylation defects in 8 
PHPneg and 1 PHPΔstx16 patients (Figure 6). Abnormal methylation was found for 19 
of the 58 human imprinted DMRs and this included significant hypomethylation for 
PPIEL:Ex1-DMR, DIRAS3:Ex2-DMR, DIRAS3:TSS-DMR, JAKMIP1, NAP1L5:TSS-
DMR, FAM50B:TSS-DMR, SVOPL, FANCC:Int1-DMR, SNRPN:alt-TSS-DMR, 
IGF1R:Int2-DMR, LOC100130522/PARD6G-AS1, WRB:alt-TSS-DMR, and 
NHP2L1:alt-TSS-DMR and significant hypermethylation for ZBDF2/GPR1:IG-DMR, 
PEG13:TSS-DMR, RB1:Int2-DMR, SNRPN intragenic CpG40, SNRPN_2 and 
SNRPN_3. ZBDF2/GPR1:IG-DMR hypermethylation is likely due to GPR1-AS:TSS-
DMR hypomethylation. The GPR1-AS:TSS-DMR is not included in our screening, as 
it acquires immediate biparental methylation following implantation, therefore we can 
only infer loss of methylation due to hypermethylation of ZBDF2 [170]. The clinical 
phenotype of the patients with multi-locus methylation abnormalities was not different 
from the PHP patients with GNAS specific epimutations (Table 1).  
 
	 127	
 
Figure 6. Heatmap showing methylation of known imprinted genes in PHP patients. Methylation 
values of the genes are extracted from data obtained with the HM450k. Dark green and red respresent -
3SD and +3SD, respectively, of the mean as determined in 20 controls. Lighter green and red represent 
additional cut-offs for absolute methylation < 0.20 and > 0.80. Patients* have multi-locus methylation 
abnormalities. PHPΔSTX16: patients with underlying STX16 deletion. 
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To confirm the findings of multi-locus abnormalities, we performed a validation study 
using the Sequenom EpiTYPER for 26 PHP patients and 12 healthy controls. We 
have selected FANCC and SVOPL as hypomethylation was seen in 3 and 7 PHP 
patients, respectively. We also validated the methylation of WDR27 amplicon as 
negative control. The 26 PHP patients included 5 PHPΔstx16 and 21 PHPneg patients, 
3 patients of each group were also analyzed by HM450k (Table 2). Eight patients 
had multi-locus methylation abnormalities (Figure 7). The most significant 
methylation difference was found for SVOPL in three PHPneg patients.  
 
 
 
Figure 7. Scatter plot of FANCC and SVOPL methylation in PHP patients and controls. Methylation values 
are obtained with the Sequenom EpiTYPER. Bar indicates the mean of the group. PHP patients are separated 
according to underlying STX16 deletion. Patients that were investigated with the HM450k are indicated in blue. 
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5.5 Discussion 
Genome-wide studies to identify genetic alterations have successfully entered 
the field of rare diseases [171]. Similar attempts to elucidate the epigenome are 
expected to improve our limited knowledge about imprinting disorders (IDs). There 
has been a revolution in DNA methylation analysis technology over the past decade 
as genome-wide and entire methylomes can be characterized at single-base-pair 
resolution [172]. Their implementation to study IDs has only just started. A custom 
Illumina GoldenGate array targeting 27 imprinted DMRs has been used to study 65 
patients with an ID (that include Beckwith-Wiedemann syndrome (BWS), transient 
neonatal diabetes mellitus (TNDM), PHP1B, Silver-Russell (SRS), Angelman 
syndrome (AS) and Prader-Willi syndrome (PWS)) and found multi-locus 
hypomethylation in patients with BWS, SRS, TNDM, and PHP1B, but not in AS and 
PWS [163]. Two studies have used the HM450k array to quantify genome-wide DNA 
methylation for BWS and TNDM [169] or SRS patients [173] and concluded that 
multiple and even novel imprinted genes were abnormally methylated in IDs.   
Here, we have studied DNA methylation at about 485.000 CpGs genome-
wide in 24 PHP patients with proven but different types of GNAS epimutations. The 
methylomes analyzed for 58 imprinted DMRs revealed in addition to the expected 
GNAS methylation defect, also a multi-locus methylation abnormality in 9 of the 24 
patients for 19 other imprinted DMRs that were not previously known for these PHP 
cases. However, patients did not share a common pattern for these multi-locus 
methylation abnormalities and there was a high variability in the degree of 
methylation difference and the number of amplicons per patient that were abnormally 
methylated. A validation study with the EpiTYPER for the most common abnormally 
methylated DMRs FANCC and SVOPL indeed showed significant methylation 
differences in a replication cohort of PHP patients. The FANCC and SVOPL DMRs 
are not well studied and further studies are needed to define the functional relevance 
of these methylation changes. Though larger cohorts are needed to be conclusive, 
based on results from both the HM450k and the EpiTYPER study, it seems that 
PHPneg patients are more sensitive to these multi-locus defects compared to 
PHPΔstx16 patients. Other studies that have used targeted approaches with a limited 
number of known imprinted DMRs have also reported multi-locus defects in PHP 
patients. Perez-Nanclares et al reported the first two PHP patients with multi-locus 
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hypomethylation; one patient at PEG1/MEST and the other at GTL2 [165]. Court et 
al identified five PHP patients with hypomethylation at other imprinted loci: 
PEG1/MEST, MCTS2, IGF2R, ZNF331, L3MTBL1 and MEG3 [163]. Maupetit-
Méhouas et al studied a larger cohort of 63 PHP patients for the methylation pattern 
at eight imprinted loci and found multi-locus imprinting defects for 4 PHP patients at 
PEG1/MEST, L3MBTL1 and DLK1/GTL2 [164]. Though in our PHP cohort we 
observe a higher rate of multi-locus methylation defects (38% of all patients), this is 
probably due to the fact that more DMRs were studied but remarkably, most of these 
previously reported abnormal DMRs are also abnormal in our study. Docherty et al 
identified novel candidate imprinted genes in patients with imprinting disorders and 
multi-locus methylation defects [169]; we identified hypomethylation of three 
candidate regions (PPIEL:Ex1-DMR, WRB:alt-TSS-DMR and NHP2L1:alt-TSS-
DMR) from this study in our patients with PHP1B. The clinical relevance of these 
regions has not yet been determined. It is possible that these genes are common in 
most imprinting disorders. Interestingly, we identified two patients with methylation 
changes in the SNRPN DMRs. These two patients also have hypomethylation of the 
novel candidate DMR LOC100130522/PARD6G-AS1 [169]. Methylation changes in 
SNRPN DMRs are associated with PWS and AS, but these patients are very 
infrequent and moreover loss of methylation of the SNRPN DMR is rarely described 
in other imprinting disordes with multilocus methylation disturbances. It has only 
been observed in two patients with SRS [174], two patients with BWS [163,169] and 
one patient with TNDM [169]. In accordance with previous studies, our PHP patients 
with multi-locus methylation defects do not show evidence for phenotype differences 
with patients having only a GNAS methylation defect. Further studies including 
biochemical analyses are necessary to confirm these findings. The patient with the 
highest number of genes presenting with a methylation defect has severe 
hypertension with organ damage but a link with the methylation defect is not obvious. 
The other patients with multi-locus methylation defects have no additional clinical or 
molecular features. We identified five patients with simultaneous hypo- and 
hypermethylation. This finding is consistent with the report of Maupetit-Méhouas 
[164]. The epidominance hypothesis suggests that the phenotype is determined by 
the most strongly affected imprinted locus [164]. Patients with hypomethylation of 
multiple imprinted loci have been associated with increased frequency of 
developmental delay and congenital anomalies [175] but based on our current study, 
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we have no evidence for a clinical impact. Of particular interest is the fact that 
methylation disturbances at multiple imprinted loci are now described in a subset of 
patients affected with different IDs and this could point to a common pathogenic 
mechanism for IDs [176].  
 
According to the original classification for PHP, we have included PHP1B 
patients with A/B only and partial or full broad methylation defects and PHP1A 
patients with a broad partial methylation defect. During the last years, it became 
clear for reasons specified in the introduction that this classification is no longer 
accurate. All CpGs from the genome-wide data within the GNAS cluster were 
analyzed using unsupervised hierarchical cluster analysis.  This analysis divided our 
patients in two groups seemingly only dependent on having the STX16 deletion or 
not (referred to as PHPΔstx16 and PHPneg). The studied intervals cover the 4 DMRs in 
GNAS but these loci are much larger compared to the amplicons that were 
previously studied by the different labs that have used MS-MLPA, Sequenom 
EpiTYPER or pyrosequencing (for details see Figure 1). PHP1B patients 23 and 24 
that were diagnosed by MS-MLPA and pyrosequencing having a partial broad GNAS 
methylation defect are now clustered more closer to the control group. The most 
intriguing finding is however the discovery of a novel previously not described DMR 
(named GNAS-AS2) in the GNAS cluster that was found hypomethylated for both 
PHPΔstx16 and PHPneg patients. GNAS-AS2 is located within the large GNAS-AS1 
region and is actually located in the promoter region of the XL exon 1 (Figure 4), but 
is separated from XL by a hypermethylated region. Many studies have described that 
PHP1B patients with STX16 deletion only have hypomethylation of the A/B DMR 
while the DMRs XL, GNAS-AS1 and NESP are normal [151-154]. This is also the 
case for the present HM450k data except for the CpGs that are located in the GNAS-
AS2 region. GNAS-AS2 hypomethylation for both PHPΔstx16 and PHPneg patients was 
validated with the EpiTYPER. Only 1/24 (1 with partial PHP1B - broad) and 4/42 
PHP (3 with PHP1B - A/B only and 1 with partial PHP1B - broad) patients had a 
normal GNAS-AS2 methylation based on HM450k and EpiTYPER data, respectively. 
Methylation defects affecting the maternal A/B DMR lead to the loss of Gsα 
expression in renal proximal tubules and renal PTH resistance. It is however not 
clear at this moment whether hypomethylation of the GNAS-AS2 DMR has a 
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phenotype impact or whether methylation studies of this region can be useful for a 
better characterization of PHP patients. Further experiments are also needed to 
determine if loss of methylation of DMR GNAS-AS2 influences the expression of 
GNAS-XL.  
 
5.6 Conclusion 
We here present the first genome-wide methylation study in different types of 
PHP. It seems that only the presence of the STX16 deletion is of significant 
importance to divide PHP in 2 groups of patients with significantly different 
methylation profiles. Methylation changes in other imprinted DMRs seem to be 
enriched in especially PHPneg patients. We identified a novel GNAS-AS2 DMR in the 
GNAS locus that is hypomethylated in all PHP patients, independently from STX16 
deletion. Further studies must be undertaken to unravel the function and clinical 
impact of methylation changes in the GNAS-AS2 region that in addition to the A/B 
DMR can also be hypomethylation in PHP patients with STX16 deletion.  
	 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is good to have an end to journey toward;  
but it is the journey that matters, in the end. 
 Ernest Hemingway (1899-1961)
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Despite the high incidence and severity of neural tube defects (NTDs), the exact 
underlying mechanism is still unknown. Multiple candidate genes and pathways are 
known to be involved, but growing evidence is also available for an important role of 
epigenetics and DNA methylation in the origin of NTDs.  
 
The aim of this doctoral thesis was to determine which DNA regions and signaling 
pathways are more sensitive to DNA methylation changes during embryogenesis 
and lead to NTDs. Therefore, in addition to the core study of genome-wide DNA 
methylation, we designed locus-specific and functional validation studies to identify 
the most interesting candidate genes and in order to unravel the impact of DNA 
methylation in neural tube development and disease.  
 
Starting with a literature review in Chapter 2 on “Folate, DNA methylation and neural 
tube defects” we noticed that human studies investigating DNA methylation in 
patients with NTDs vary widely in study design. These studies investigated 
heterogeneous study populations and types of tissues and use different methylation 
quantification assays. Although findings of global DNA hypomethylation and LINE-1 
hypomethylation suggest that disruption of genomic stability may play a role in neural 
tube closure, it is still unclear how specific regions of the genome are prone to folic 
acid and DNA methylation changes during embryonic development. Therefore we 
designed a genome-wide DNA methylation study in patients with lumbosacral MMC 
using leukocyte DNA.  
 
Genome-wide data can be analyzed using both a candidate-gene specific approach 
whereby single gene information is extracted from the genome-wide analysis 
(Chapter 3 and 5) or a ‘true’ genome-wide approach to identify differentially 
methylated regions between patients and controls (Chapter 4 and 5). As analyzing 
HM450k data is complex and data processing needs particular care [83], I visited the 
lab of Prof. D. Monk to obtain expertise in data analysis and filtering. During this 
research stay we developed bioinformatics tools for both a candidate-gene specific 
as a genome-wide analysis. This study was performed on patients with the imprinting 
disease pseudohypoparathyroidism and results are presented in Chapter 5. 
Imprinting disorders include a broad spectrum of growth and development defects 
that are dependent on (epi)genetic disruption of imprinted genes. Recently, it 
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became clear that the original PHP classification was no longer accurate due to 
(epi)genetic overlap and moreover some patients with PHP were identified to have 
broader methylation defects involving more than one imprinted gene, a phenomenon 
called “multi-locus imprinting defects”. Differences in DNA methylation were 
investigated for the GNAS locus, all known imprinted genes and DNA repetitive 
elements (LINE-1 and LINE-2). In addition, different normalization methods were 
compared for the genome-wide DNA methylation analysis. Validation studies using 
Sequenom EpiTYPER were also performed for this study. Obtained expertise in data 
analysis and filtering was used for this doctoral thesis.  
 
In Chapter 3 we used a candidate-gene specific approach to analyze the genome-
wide DNA methylation data of the patients with lumbosacral MMC. As Homeobox 
(HOX) genes play a central role in spinal cord development, and are tightly regulated 
in a spatiotemporal and collinear manner, partly by epigenetic modifications, we 
studied changes in DNA methylation for the different HOX genes. Interestingly, 
almost all CpGs were hypomethylated for the MMC patients with HOXB7 as the most 
significant locus. We confirmed HOXB7 hypomethylation in a larger cohort but also 
in 12 unaffected siblings each related to a MMC patient. The validation study 
confirmed a significant association between MMC and HOXB7 hypomethylation (-
14,4%; 95% CI [11,9%, 16,9%]; P-value < 0.0001). Biological validation using a 
zebrafish model showed that Hoxb7a overexpression but not depletion results in 
dysmorphic neural tube formation. Interestingly, HOXB7 hypomethylation was also 
present in 12 unaffected siblings, each related to a MMC patient. This could confirm 
the hypothesis that children born from mothers with folic acid resistance and a 
disturbed one-carbon metabolism, can present with alterations in DNA methylation 
with high risk for abnormal embryonic development. Moreover, this finding is 
suggestive of a multifactorial etiology of NTDs. No association was found between 
the MTHFR genotype and HOXB7 methylation, which suggests that an intrinsic 
defect in the folic acid pathway related to MTHFR activity is not involved.  
 
To investigate whether genome-wide DNA methylation analysis without focusing on 
candidate pathways could reveal novel genes associated with NTDs; we 
subsequently used a genome-wide approach in Chapter 4 to identify differentially 
methylated regions between patients with lumbosacral MMC and controls. We 
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analyzed the HM450k data using two pipelines (IMA and WateRmelon) and found 
that 75 CpGs (mapping to 45 genes) were significantly differentially methylated in 
patients with MMC. The HOX genes were not included in this list, but HOXB7 could 
be retrieved when only one filter was relieved. HOXB7 was significantly 
hypomethylated in MMC patients with significant p-values of 0.007 for both pipelines 
but with a mean difference in methylation of -0.24 for IMA and -0.06 for the 
WateRmelon pipeline. Gene enrichment analysis showed multiple gene ontology 
classes related to neurodevelopmental processes. Moreover, genes are often 
involved in multiple gene ontology classes and seem to act together through various 
biological pathways. Validation studies were subsequently applied for the top genes 
selected from the genome-wide analysis: ABAT, CNTNAP1, SLC1A6, SNED1, 
SOX18 and TEPP. For each locus, CpG specific methylation differences could be 
replicated, but the only significant overall methylation difference was found for 
SOX18 (- 14%; 95% CI [-8%, -20%], P-value = 0.0003). No additive effect was found 
for the MTHFR C/T variant. Based on the findings between the siblings, we 
performed an additional analysis to study the inheritance of SOX18 methylation 
changes in 5 families of patients with NTDs. Interestingly, the unaffected siblings 
showed SOX18 hypomethylation in the same range as the MMC patients while the 
parents had normal methylation values comparable to the values found for the 
unrelated healthy controls. To further investigate the influence of an underlying 
genetic factor, we quantified SOX18 methylation in a boy with MMC and a paternally 
inherited BMP4 deletion and his parents. Interestingly, the patient with the BMP4 
deletion had very low methylation values that were also present in his healthy mother 
while his father had normal methylation. Though further studies are essential to 
support a role for BMP4 deletion and SOX18 overexpression, this family illustrates 
that the inheritance of genetic and epigenetic factors could co-act in neural tube 
development. Notable, regulators of angiogenesis are found for both SOX18 [135] 
and BMP4 [138] what could clarify an old concept that there might be a vascular 
basis for NTDs [140]. Biological validation of SOX18 using chemically induced DNA 
demethylation in HEK cells resulted in SOX18 hypomethylation and increased 
expression. Furthermore, overexpression in zebrafish embryos resulted in a 
dysmorphic neural tube that could not be rescued by addition of folic acid. As it might 
be informative in which pathways maternal folate impacts neural tube development, 
we replicated the top findings of our study with data from a recent meta-analysis that 
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examined the relation between maternal plasma folate and newborn DNA 
methylation. This study showed that DNA methylation of genes involved in multiple 
developmental processes, including neural tube development, are influenced by 
maternal folate. Interestingly, we share one of the top differentially methylated CpGs 
that is located within SLC1A6. SLC1A6 (High Affinity Aspartate/Glutamate 
Transporter, Member 6) is a member of the family of excitatory amino acid 
transporters, which are widely distributed throughout the brain and spinal cord [177]. 
Transporter dysfunction is linked to excitotoxic concentrations of glutamate that 
could be a mechanism of neurodegeneration and cell death [178]. SLC1A6 seems to 
be sensitive to maternal plasma folate influences in both healthy controls as in 
patients with MMC.  
 
STUDY LIMITATIONS 
Some limitations need to be taken into account when interpreting our data.  
 
First of all, although the HM450k represents so far the most standardized 
methodology to assess DNA methylation at genome-wide level, it has some inherent 
limitations. Some probes can generate artifactual data as some probes co-hybridize 
at additional locations on the genome than the targeted CpGs, some probes contain 
common SNPs and probes with a high average intensity are more prone to 
inconsistent measurements. In addition, divergence between the two Infinium assays 
generates two different types of data [126]. Different correction and normalization 
methods are suggested to make the two data sets comparable. Therefore, careful 
preprocessing and normalization of HM450k data is important to remove any source 
of variation that is related to technical limitations [83]. The HM450k relies also on 
traditional bisulfite treatment that cannot discriminate between 5-methylcytosine and 
5-hydroxymethylcytosine. As recently became clear that DNA methylation is highly 
dynamic during brain development, it would also be interesting to investigate 5-
hydroxymethylation in patients with NTDs [179].  
 
Secondly, the sample size of our genome-wide DNA methylation study is relatively 
small. Therefore, after filtering out problematic probes, we applied two different 
pipelines using different data normalization methods. In a larger cohort of patients 
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and controls, we subsequently performed validation studies using another 
methodology to quantify DNA methylation (EpiTYPER). 
 
Thirdly, leukocyte blood was used as surrogate tissue. The ideal tissue would be to 
use brain or spinal cord, which can only be obtained post-mortem. But various other 
studies report concordant methylation profiles in brain and blood what suggests that 
DNA methylation in blood might reflect brain DNA methylation [112-114,142]. DNA 
methylation in blood is significantly more variable than DNA methylation in brain 
tissues [141]. Studies in brain tissue of patients with NTDs are essential to 
investigate the presence of more stable gene expression levels in brain versus 
blood. Farré et al [141] also identified an epigenetic signature of age that is not 
related to cell type composition and that did not require a correction for cellular 
heterogeneity. This is an interesting finding, as until now there was still no clear 
evidence that epigenetic marks of different cell types respond in a similar way to 
environmental influences.  
 
Finally, in the current study we were not able to control for genotype. It is estimated 
that DNA methylation variability differs between 22-80% upon DNA sequence 
variability [131]. We did not find an association with the MTHFR genotype, but we 
illustrated a possible interaction of (epi)genetic variants in the family of the patient 
with the BMP4 deletion. Further studies combining (epi)genetics and environmental 
modulators are essential to unravel NTD etiology.  
 
CLINICAL AND SCIENTIFIC RELEVANCE OF THE THESIS 
 
A. Clinical relevance 
NTDs arise from a complex combination of genetic and environmental interactions. 
Although we are only beginning to understand their etiology, two major advances 
have been made in their prevention and treatment. First periconceptional folate 
supplements prevent both NTD occurrence as recurrence [180] and second, recent 
surgical advances demonstrate that prenatal surgery improves patient outcomes [4].  
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Despite these advances, NTDs still represent the second most common group of 
human birth defects and result in enormous clinical, emotional, financial and societal 
costs [181]. Each year, 300 000 to 400 000 infants worldwide are born with a NTD. 
Patients suffer from hydrocephalus, neurogenic bladder, kidney disease, orthopedic 
complications and psychosocial problems. Treatment includes surgery, medication 
and physiotherapy. Recent advances resulted in an increased life expectancy and 
improved quality of life, but no treatment exists that completely eliminates the serious 
disability or premature mortality. The weighted average lifetime cost for a child with a 
NTD in the Netherlands is calculated to be €242 948, the quality of life and the life 
expectancy are included in the weighted average [182]. Furthermore this study 
recommends folic acid food fortification in the Netherlands, being still cost-effective 
even if only one case is averted. In Belgium, prenatal diagnosis of NTDs leads to 
termination of pregnancy in 61% of cases. For a full evaluation of quality-adjusted life 
years (QALYs) and the economical signature of NTDs, associated costs should be 
taken into account. Such analysis has not yet been performed in Belgium or other 
European countries.  
 
For all these reasons, identifying (epi)genetic predictors of NTDs is of great 
importance for the counseling of women of childbearing age. An understanding of 
(epi)genetic risk factors would also have implications for identifying potential 
protective treatments. The key challenge is to understand the developing neural 
tube, to help generate new intervention strategies to tackle the clinical challenges 
and to alleviate the economical and societal burdens that accompany these defects. 
 
B. Scientific biological relevance 
As already pointed out, both genetic and non-genetic factors are implicated in the 
causes of NTDs. The genomics revolution provides methods to investigate candidate 
genes for NTD causation. Numerous mouse NTD models aid to understand the 
process of neurulation and point to several candidate pathways for the study in 
human NTDs [16,22]. The impact of maternal folic acid supplementation highlights 
the importance of environmental factors in human NTD etiology [31,55]. Mouse 
mutants show a more diverse range of responses to folic acid supplementation, 
suggesting that the response to folic acid fortification may be more complex than 
previously suggested and that the length of folic acid exposure and the individual 
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genetic background plays a central role for a phenotypic response [183]. Mutations 
in genes that affect DNA methylation, histone modification or chromatin remodeling, 
result in NTDs in mice [16,22]. The MTHFR 677C>T genotype reduces global DNA 
methylation and is a risk factor for NTDs. Methyl-donor enriched diets can induce 
alterations in gene expression, and long-term generational exposure can result in 
increasing variation in DNA methylation. 
 
Epigenetic studies bring new insights in how folic acid may affect transcriptional 
programs during neural tube closure and identify genes and pathways that are 
differentially regulated in this way. 
 
C. Advantages of this study 
The first important advantage of these studies is the use of the genome-wide DNA 
methylation approach. The HM450k is highly accurate and reproducible for genome-
wide DNA methylation profiling. It covers almost half a million cytosines in 99% of 
RefSeq genes and 96% of CpG islands, as well as multiple CGI shores and isolated 
CpGs. The interrogated CpGs cross promoter regions, 5’ and 3’ UTRs, gene bodies 
and intergenic regions. The HM450k allows a precise quantification of the 
methylation level and generates data more quickly and easily analyzable than 
sequencing data. Therefore this technology represents so far the most standardized 
high-throughput methodology for quantification of DNA methylation [82,126].  
 
High-throughput technology is inherently imprecise and noisy, and the complexity of 
the data requests careful consideration in separating signal from noise. Therefore, 
the second important advantage of our study is that we performed locus-specific 
validation studies in a large cohort of patients with MMC. Of note is the advantage of 
the use of a different technique to validate the findings, as technical problems or 
inadequate statistical analysis might introduce bias [82]. In addition, the population 
for the locus-specific validation study was carefully selected based on the same 
phenotype: all patients had an open lumbosacral MMC. Gender- and age matched 
controls were selected, as aging affects DNA methylation [142,184]. 
 
The last advantage is the use of a zebrafish model for functional validation of the 
findings from our DNA methylation studies. The similarity between zebrafish and 
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vertebrate neurulation in combination with the practical advantages of working with 
zebrafish, renders it as a viable and useful model to investigate human neurulation in 
health and disease.   
 
D. Future research perspectives 
Neural tube defects are suggested to have a highly multifactorial and polygenic 
inheritance pattern. Therefore, it would be interesting to combine next-generation 
sequencing approaches and epigenetic studies in large families with both affected 
and unaffected individuals and to investigate the influence of environmental factors 
in these studies.  
 
First of all, we are contributing to a large international study entitled “An investigation 
of genetic factors predisposing to valproic acid-associated neural tube defects” (Prof. 
Frank Vajda, The Royal Melbourne Hospital, Melbourne, Australia). In this study, 
whole-exome sequencing and genome-wide DNA methylation studies will be 
combined to investigate whether highly penetrant maternal, paternal or de novo 
genetic variants influence NTD occurrence and whether there is a link with altered 
DNA methylation patterns.  
It is known that prenatal exposure to the anti-epileptic drug valproic acid is 
associated with a 10- to 20-fold increased risk of spina bifida [185]. Although the 
underlying teratogenic mechanism remains unknown, it has been proposed that 
histone deacetylase inhibition, folate antagonism and competition for the folate 
receptor binding are included [186]. However, folate does not seem to be effective in 
preventing NTDs associated with valproic acid exposure [187]. Epigenetic 
modifications have been postulated to play a role in valproic acid-induced 
teratogenesis [188]. A study of valproic acid teratogenicity in mice resulted in many 
homeotic malformations and altered expression of HOX genes, in addition they 
found that genetic susceptibility for valproic acid induced malformations could reside 
in both the fetal and the parental genomes [189]. We found that HOXB7 
hypomethylation is a potential risk factor for NTDs and also that (epi)genetic 
susceptibility might interplay as a cause for NTDs.  
 
Secondly, work with inducible pluripotent stem (iPS) cells would be interesting for the 
development of alternative preventive or curative therapies. After the identification of 
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the key players in neurulation and NTDs, iPS cells allow direct study of basic 
biological processes in cells derived from human patients. Stem cell research 
provides abundant material and a relatively fast time frame to analysis, which 
provides the possibility to screen small molecules for therapeutic or preventive 
potential. Mesenchymal stem cells occur naturally in the amniotic fluid and are good 
candidates for tissue engineering strategies for the repair of neural tube defects 
[190,191]. These new treatment modalities with iPS cells have to be confirmed in 
rigorous animal experimental studies before the use in human clinical trials. 
 
Thirdly, not all NTDs are preventable with folic acid treatment in human or in animal 
models. Spina bifida is reduced in the Axd mutant by methionine and in Curly tail by 
inositol [22]. The mouse models suggested that genetic heterogeneity could explain 
this differential response to folic acid action. More studies including additional 
micronutrients carry the possibility of defining which genetic risk factors may be best 
targeted by therapies beyond folic acid, in order to develop alternative preventive 
therapies.  
 
GENERAL CONCLUSION 
This doctoral thesis investigated the relation between DNA methylation and 
NTDs. We believe that our data support the multifactorial polygenic inheritance 
pattern of NTDs and the importance of epigenetic changes in neural tube 
development and disease. To our knowledge this is the first study investigating 
genome-wide DNA methylation in leukocyte DNA of patients with NTDs including a 
large locus-specific validation study and functional validation in a zebrafish model. 
Further combined (epi)genetic studies are essential to unravel the complex etiology 
of NTDs and to alleviate the clinical, economical and psychological burdens for 
patients with NTDs.  
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SCIENTIFIC SUMMARY 
 
Neural tube defects, affecting 1-2 per 1000 pregnancies, are severe congenital 
malformations that arise during early embryonic development due to failure of 
neurulation. Neural tube closure is influenced by a complex multifactorial etiology 
including both genetic and environmental factors. Although more than 250 mice 
models are known for NTDs and many candidate genes have been investigated in 
patient cohorts, the molecular basis underlying most human NTDs has still to be 
unravelled. Obesity, diabetes and anti-epileptic drugs give a higher risk for NTDs. On 
the other hand, folic acid prevents up to 70% of NTDs. However, most maternal folic 
acid levels in NTD-affected pregnancies are normal and despite optimal 
supplementation, the incidence of NTDs remains high. These environmental factors 
are linked to DNA methylation, an epigenetic modification that changes gene 
expression. The methylation hypothesis suggests that folate prevents NTDs by 
stimulating cellular methylation reactions and that a disturbed one-carbon 
metabolism may underlie NTDs. This brings us to the main question of this thesis: 
Can folate affect neural tube closure via changes in DNA methylation? 
 
In this doctoral thesis, we wanted to investigate which DNA regions are more 
sensitive to methylation changes during embryogenesis and can lead to NTDs. 
Therefore; we performed a genome-wide DNA methylation analysis in patients with a 
myelomeningocele.  
 
In Chapter 1 we go back to the embryological background of NTDs and we give an 
overview of the genetic and environmental factors that are known to be involved in 
NTDs. As we suppose that epigenetics and DNA methylation might fill the gap of 
knowledge in the search for the pathogenesis of NTDs, Chapter 2 gives an overview 
of studies that have been investigating the link between folate, DNA methylation and 
NTDs.  
In Chapter 3 and 4 we discuss the results of the genome-wide DNA methylation 
study in patients with a myelomeningocele (MMC). In Chapter 3 we first investigated 
DNA methylation of the Homeobox genes in patients with a MMC. Homeobox genes 
play a central role in neural tube development for the establishment of the anterior-
posterior body axis and are tightly regulated in a spatiotemporal and collinear 
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manner, partly by chromatin structure and epigenetic modifications. This study 
identified HOXB7 hypomethylation as a potential risk factor for NTDs. In addition, 
HOXB7 hypomethylation was also present in unaffected siblings of patients with a 
MMC. These findings are suggestive for additional (epi)genetic factors underlying 
NTDs. Therefore, we further analysed the genome-wide DNA methylation data 
without prioritizing for candidate genes in Chapter 4. Forty-five genes were 
significantly differentially methylated, and functional enrichment analysis revealed 
multiple neurodevelopmentally important gene ontology classes. Validation of the top 
6 genes (ABAT, CNTNAP1, SLC1A6, SNED1, SOX18 and TEPP) showed that 
SOX18 hypomethylation is a potential risk factor for NTDs. DNA methylation 
analyses in families of patients with MMC revealed that parents had a significantly 
higher methylation than both patients with MMC and their unaffected siblings. These 
findings might suggest a maternal contribution for a disturbed one-carbon 
metabolism. DNA methylation analysis in a family of a patient with a paternally 
inherited BMP4 deletion showed that genetic and epigenetic factors might interplay 
in the development of NTDs.  
In Chapter 5 we present the study of genome-wide DNA methylation in patients with 
pseudohypoparathyroidism, that was performed to obtain expertise in data analysis 
and filtering, subsequently used for this thesis.  
 
In conclusion, this doctoral thesis investigated the relation between DNA methylation 
and NTDs. We believe that our data support the multifactorial polygenic inheritance 
pattern of NTDs and the importance of epigenetic changes in neural tube 
development and disease. Further combined (epi)genetic studies are essential to 
unravel the complex etiology of NTDs and to alleviate the clinical, economical and 
psychological burdens for patients with NTDs.  
 
 
 
 
	 161	
NEDERLANDSTALIGE SAMENVATTING 
 
Een open rug, of spina bifida, is het gevolg van een onvolledige sluiting van de 
primitieve neurale buis en de daarboven gelegen wervelbogen en huid. De term 
spina bifida is immers afgeleid vanuit het Latijn en betekent letterlijk “gespleten 
ruggengraat”. Neurale buis defecten (NBD) ontstaan binnen de eerste vier weken 
van de zwangerschap. Wereldwijd vormen NBD de tweede meest voorkomende 
congenitale aandoening met een incidentie van 0.5-2 per 1000 zwangerschappen. 
Ondanks de hoge prevalentie en de traumatische gevolgen voor patiënten met NBD, 
blijft het exacte ontstaansmechanisme nauwelijks begrepen. Zowel het hoge 
recurrentie- en occurentie- risico, als de hogere prevalentie in bepaalde etnische 
groepen, wijzen op het belang van genetische factoren. Daarnaast spelen 
verschillende omgevingsfactoren een belangrijke rol in het voorkomen van NBD. 
Maternele foliumzuur suppletie leidde tot 75% reductie van de incidentie, maar het 
blijft echter onduidelijk hoe foliumzuur neurale buisdefecten voorkomt. De maternele 
foliumzuurspiegel is in de meeste zwangerschappen met NBD immers normaal. 
Recent onderzoek verlegt de focus naar epigenetische mechanismen die door 
deregulatie van genexpressie tot NBD kunnen leiden. Wijzigingen in DNA-methylatie 
is één van de hoofdmechanismen van de epigenetica. Foliumzuur staat centraal in 
het één-koolstof-metabolisme dat noodzakelijk is voor DNA-synthese en de 
productie van s-adenosyl-methionine, de universele methyl groep donor voor alle 
macromolecules. Kan foliumzuur bijgevolg neurale buis sluiting beïnvloeden door 
veranderingen in DNA methylatie? 
 
In deze doctorale thesis hebben we onderzocht welke DNA-regio’s meer gevoelig 
zijn aan veranderingen in DNA methylatie tijdens de vroege embryonale ontwikkeling 
en zouden kunnen leiden tot NBD. Hiervoor hebben we een genoom-wijde DNA 
methylatie analyse uitgevoerd in patiënten met spina bifida aperta ofwel 
myelomeningocele (MMC).  
 
In de introductie van deze thesis gaan we terug naar de embryologie van NBD en 
geven we een overzicht van de genetische en omgevingsfactoren die een 
belangrijke rol spelen in de pathogenese. Aangezien we veronderstellen dat 
epigenetica en DNA methylatie de kenniskloof zouden kunnen sluiten, geven we in 
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hoofdstuk 2 een overzicht van de studies die al naar verbanden tussen foliumzuur, 
DNA methylatie en NBD hebben gezocht.  
 
In hoofdstukken 3 en 4 bespreken we vervolgens de resultaten van de genoom-wijde 
DNA methylatie studie in patiënten met spina bifida. Aangezien Homeobox genen 
embryologisch een belangrijke rol spelen in de vorming van de neurale buis, en 
aangezien deze genen epigenetisch gereguleerd zijn, hebben we in hoofdstuk 3 
eerst DNA methylatie voor de Homeobox genen onderzocht. Deze studie toont aan 
dat HOXB7 hypomethylatie een potentiële risicofactor voor spina bifida is. Aangezien 
HOXB7 hypomethylatie ook voorkomt bij niet-aangetaste broers en zussen van 
patiënten, spelen vermoedelijk bijkomende (epi)genetische factoren eveneens een 
rol. Daarom hebben we vervolgens in hoofdstuk 4 de genoom-wijde data zonder 
voorkennis geanalyseerd. Hierbij hebben we 45 genen gevonden, die betrokken zijn 
in meerdere neurologische ontwikkelingsprocessen. Na verdere validatie van de top 
6 genen (ABAT, CNTNAP1, SLC1A6, SNED1, SOX18 en TEPP) blijkt dat SOX18 
een bijkomende potentiële risicofactor voor spina bifida is. Op basis van de 
bevindingen bij de broers en zussen, hebben we SOX18 methylatie verder 
onderzocht in 5 families van patiënten met spina bifida. Hierbij stellen we vast dat de 
beide ouders een significant hogere methylatie hebben, vergelijkbaar aan de 
gezonde controles, dan de beide kinderen. Zowel de patiënt als zijn gezonde broer 
of zus heeft een lagere methylatie dan beide ouders, vergelijkbaar aan de patiënten 
met spina bifida. Bijkomende analyse in de familie van een patiënt met een paterneel 
overgeërfde BMP4 deletie, geeft aanwijzing voor een potentieel samenspel van 
zowel genetische als epigenetische factoren onderliggend aan spina bifida.  
 
In hoofdstuk 5 beschrijven we de studie van genoom-wijde DNA methylatie in 
patiënten met pseudohypoparathyroïdie, die werd uitgevoerd om expertise te 
verwerven in de analyse en filtering van genoom-wijde data.  
 
Tot slot kunnen we stellen dat onze studie de relatie tussen DNA methylatie en NBD 
heeft onderzocht. Onze data ondersteunen het multifactoriële polygenische 
overervingspatroon dat aan de oorzaak van NBD ligt en geven aanwijzingen voor de 
belangrijke rol die DNA methylatie hierin speelt. Bijkomende gecombineerde 
genetische en epigenetische studies zijn essentieel om de complexe etiologie van 
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NBD verder te ontrafelen en om de klinische, economische en psychologische last 
voor patiënten te verlichten. Aangezien het duidelijk is dat foliumzuur een belangrijke 
rol speelt in het ontstaan van neurale buisdefecten, ondersteunen we de 
internationale richtlijnen die de dagelijkse inname van 400 microgram foliumzuur 
vanaf drie maanden voor tot minstens drie maanden na de conceptie adviseren.  
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instantie de kans te geven de opleiding pediatrie te volgen en om deze vervolgens te 
verrijken in de wereld van de wetenschappen. Al hoorde het onderwerp van mijn 
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